U.S. patent application number 11/436554 was filed with the patent office on 2006-09-14 for il-i7 homologous polypeptides and therapeutic uses thereof.
This patent application is currently assigned to GENENTECH, INC. Invention is credited to Jian Chen, Ellen Fivaroff, Audrey Goddard, Austin Gurney, Hanzhong Li, William I. Wood.
Application Number | 20060205038 11/436554 |
Document ID | / |
Family ID | 26772882 |
Filed Date | 2006-09-14 |
United States Patent
Application |
20060205038 |
Kind Code |
A1 |
Chen; Jian ; et al. |
September 14, 2006 |
IL-I7 homologous polypeptides and therapeutic uses thereof
Abstract
The present invention is directed to novel polypeptides having
sequence identity with IL-17 and to nucleic acid molecules encoding
those polypeptides. Also provided herein are vectors and host cells
comprising those nucleic acid sequences, chimeric polypeptide
molecules comprising the polypeptides of the present invention
fused to heterologous polypeptide sequences, antibodies which bind
to the polypeptides of the present invention and to methods for
producing the polypeptides of the present invention. Further
provided herein are methods for treating degenerative cartilaginous
disorders.
Inventors: |
Chen; Jian; (Princeton,
NJ) ; Fivaroff; Ellen; (San Francisco, CA) ;
Goddard; Audrey; (San Francisco, CA) ; Gurney;
Austin; (Belmont, CA) ; Li; Hanzhong; (San
Mateo, CA) ; Wood; William I.; (Hillsborough,
CA) |
Correspondence
Address: |
SIDLEY AUSTIN LLP;ATTN: DC PATENT DOCKETING
1501 K STREET, NW
WASHINGTON
DC
20005
US
|
Assignee: |
GENENTECH, INC
|
Family ID: |
26772882 |
Appl. No.: |
11/436554 |
Filed: |
May 19, 2006 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
09854280 |
May 10, 2001 |
|
|
|
11436554 |
May 19, 2006 |
|
|
|
09311832 |
May 14, 1999 |
|
|
|
09854280 |
May 10, 2001 |
|
|
|
60085579 |
May 15, 1998 |
|
|
|
60113621 |
Dec 23, 1998 |
|
|
|
Current U.S.
Class: |
435/69.52 ;
435/320.1; 435/325; 530/351; 536/23.5 |
Current CPC
Class: |
A61P 19/00 20180101;
C07K 2319/30 20130101; C07K 14/52 20130101; C12N 2799/026 20130101;
A61K 38/00 20130101; C07K 2319/00 20130101; A61P 19/02 20180101;
C07K 14/54 20130101; C07K 14/47 20130101 |
Class at
Publication: |
435/069.52 ;
435/320.1; 435/325; 530/351; 536/023.5 |
International
Class: |
C07K 14/54 20060101
C07K014/54; C07H 21/04 20060101 C07H021/04; C12P 21/04 20060101
C12P021/04; C12N 15/63 20060101 C12N015/63 |
Claims
1-42. (canceled)
43. An isolated antibody that binds the polypeptide of SEQ ID
NO:3.
44. The isolated antibody of claim 43 that binds the polypeptide of
SEQ ID NO:3 lacking its associated signal peptide.
45. The isolated antibody of claim 43 which is a monoclonal
antibody.
46. The isolated antibody of claim 43 which is a humanized
antibody.
47. The isolated antibody of claim 43 which is a human
antibody.
48. The isolated antibody of claim 43 which is a chimeric
antibody.
49. The isolated antibody of claim 43 which is a single chain
antibody.
50. The isolated antibody of claim 43 which is an antibody
fragment.
51. The isolated antibody of claim 43 which is labeled with a
detectable moiety capable of directly or indirectly producing a
signal.
52. A pharmaceutical composition comprising the isolated antibody
of claim 43 and a pharmaceutically acceptable carrier.
53. An isolated antibody that binds the mature polypeptide of SEQ
ID NO:3 consisting of amino acid residues 19-197 of SEQ ID
NO:3.
54. The isolated antibody of claim 53 which is a monoclonal
antibody.
55. The isolated antibody of claim 53 which is a humanized
antibody.
56. The isolated antibody of claim 53 which is a human
antibody.
57. The isolated antibody of claim 53 which is a chimeric
antibody.
58. The isolated antibody of claim 53 which is a single chain
antibody.
59. The isolated antibody of claim 53 which is an antibody
fragment.
60. The isolated antibody of claim 53 which is labeled with a
detectable moiety capable of directly or indirectly producing a
signal.
61. A pharmaceutical composition comprising the isolated antibody
of claim 53 and a pharmaceutically acceptable carrier.
62. An isolated antibody that binds the polypeptide encoded by the
cDNA clone deposited as ATCC deposit number 203552.
63. The isolated antibody of claim 62 which is a monoclonal
antibody.
64. The isolated antibody of claim 62 which is a humanized
antibody.
65. The isolated antibody of claim 62 which is a human
antibody.
66. The isolated antibody of claim 62 which is a chimeric
antibody.
67. The isolated antibody of claim 62 which is a single chain
antibody.
68. The isolated antibody of claim 62 which is an antibody
fragment.
69. The isolated antibody of claim 62 which is labeled with a
detectable moiety capable of directly or indirectly producing a
signal.
70. A pharmaceutical composition comprising the isolated antibody
of claim 62 and a pharmaceutically acceptable carrier.
Description
FIELD OF THE INVENTION
[0001] The present invention relates generally to the
identification and isolation of novel DNA, therapeutic uses and the
recombinant production of novel polypeptides having sequence
identity with the cytokine IL-17, and cytotoxic
T-lymphocyte-associated antigen 8 (CTLA-8) designated herein as
PRO1031 and PRO1122 polypeptides.
BACKGROUND OF THE INVENTION
[0002] It has been reported that the cytokine interleukin 17
(IL-17) stimulates epithelial, endothelial, and fibroblastic cells
to secrete cytokines such as IL-6, IL-8, and
granulocyte-colony-stimulating factor, as well as prostaglandin E2.
While expression of IL-17 is restricted to activated T cells, the
IL-17 receptor is widely expressed, a property consistent with the
pleiotropic activities of IL-17. Moreover, it has been shown that
when cultured in the presence of IL-17, fibroblasts could sustain
proliferation of CD34+ preferential maturation into neutrophils. As
a result, IL-17 could be an early potentiator or even maintainer of
T cell-dependent inflammatory reaction and/or an element of the
cytokine network that bridges the immune system to hematopoiesis.
See, Yao, et al., J. Immunol., 155(12):5483-5486 (1995); Fossiez,
et al., J. Exp. Med., 183(6):2593-2603 (1996); Kennedy, et al., J.
Interferon Cytokine Res., 16(8):611-617(1996).
[0003] More generally, all novel proteins are of interest.
Extracellular proteins play an important role in the formation,
differentiation and maintenance of multicellular organisms. The
fate of many individual cells, e.g., proliferation, migration,
differentiation, or interaction with other cells, is typically
governed by information received from other cells and/or the
immediate environment. This information is often transmitted by
secreted polypeptides (for instance, mitogenic factors, survival
factors, cytotoxic factors, differentiation factors, neuropeptides,
and hormones) which are, in turn received and interpreted by
diverse cell receptors or membrane-bound proteins. These secreted
polypeptides or signaling molecules normally pass through the
cellular secretory pathway to reach their site of action in the
extracellular environment.
[0004] Secreted proteins have various industrial applications,
including pharmaceuticals, diagnostics, biosensors and bioreactors.
Most protein drugs available at present, such as thrombolytic
agents, interferons, interleukins, erythropoietins, colony
stimulating factors, and various other cytokines, are secretory
proteins. Their receptors, which are membrane proteins, also have
potential as therapeutic or diagnostic agents.
[0005] Efforts are being undertaken by both industry and academia
to identify new, native secreted proteins. Many efforts are focused
on the screening of mammalian recombinant DNA libraries to identify
the coding sequences for novel secreted proteins. Examples of
screening methods and techniques are described in the literature
[see, for example, Klein et al., Proc. Natl. Acad. Sci,
93:7108-7113 (1996); U.S. Pat. No. 5,536,637)]. The results of such
efforts are presented herein.
[0006] Interleukin-17 is a recently described, T cell-derived
cytokine, the biological functions of which are only beginning to
be understood. Spriggs et al., J. Clin. Immunol. 17: 366 (1997);
Broxmeyer, H. E., J. Exp. Med. 183: 2411 (1996). When IL-17 was
initially identified as a cDNA clone from a rodent T-cell lymphoma,
it was recognized as having a sequence similar to an open reading
frame from a primate herpesvirus, Herpervirus saimiri Rouvier et
al., J. Immunol. 150: 5445 (1993), Yao et al., Immunity 3: 811
(1995) [Yao-1], Fossiez et al., J. Exp. Med. 183: 2593 (1996).
Subsequently, it has been confirmed that this viral protein has
many if not all of the immunostimulatory activities found for the
host IL-17. Fleckenstein and Desrosiers, "Herpesvirus saimiri and
herpesvirus ateles," In The Herpesviruses, I. B. Roizman, ed,
Plenum Publishing Press, New York, p. 253 (1982), Biesinger, B. I.
et al., Procl Natl Acad. Sci. USA 89: 3116 (1992).
[0007] Human IL-17 is a 20-30 kDa, disulfide linked, homodimeric
protein with variable glycosylation. Yao-1, supra; Fossier et al,
supra. It is encoded by a 155 amino acid open reading frame that
includes an N-terminal secretion signal sequence of 19-23 amino
acids. The amino acid sequence of IL-17 is only similar to the
Herpesvirus protein described above and does not show significant
identity with the sequences of other cytokines or other known
proteins. Additionally, the IL-17 encoding mRNA has been detected
has only been detected in activated CD4.sup.+ memory T cells and
PMA/ionomycin stimulated PBMC cells.
[0008] Despite its restricted tissue distribution, IL-17 exhibits
pleiotropic biological activities on various types of cells, such
as fibroblasts, endothelial cells and epithelial cells. Spriggs, M.
K., supra.; Broxmeyer, H. E., supra. IL-17 has been found to
stimulate the production of many cytokines: TNF-.alpha. and
IL-1.beta. from macrophages [Jovanovic et al., J. Immunol 160: 3513
(1998)]; IL-6, IL-8 and the intracellular adhesion molecule
(ICAM-1) from human fibroblasts. Fossiez et al., supra, Yao et al.,
J. Immunol. 155: 5483 (1995) [Yao-2];
granulocyte-colony-stimulating factor (G-CSM) and prostaglandin
(PGE-2) form synoviocytes, Fossiez et al., supra. Through the
induction of a number of cytokines, IL-17 is able to mediate a
wide-range of response, mostly proinflammatory and hematopoietic.
This has led to the suggestion that IL-17 may play a pivotal role
in initiating or sustaining an inflammatory response. Jovanovic et
al., supra.
[0009] Consistent with IL-17's wide-range of effects, the cell
surface receptor for IL-17 has been found to be widely expressed in
many tissues and cell types Yao et al., Cytokine 9: 794 (1997)
[Yao-3]. While the amino acid sequence of the hIL-17 receptor (866
a.a.) predicts a protein with a single transmembrane domain and a
long, 525 amino acid intracellular domain, the receptor sequence is
unique and is not similar to that of any of the receptor from the
cytokine/growth factor receptor family. This coupled with the lack
of similarity of IL-17 itself to other known proteins indicates
that IL-17 and its receptor may be part of a novel family of
signaling proteins and receptors.
[0010] IL-17 has further been shown, by intracellular signaling, to
stimulate transient Ca.sup.2+ influx and a reduction in
[cAMP].sub.i in human macrophages. Jovanovic et al., supra.
Fibroblasts and macrophages treated with IL-17 induce the
activation of NF-.kappa.B, Yao-1, supra, Jovanovic et al, supra.,
while macrophages treated with it activate NF-.kappa.B and
mitogen-activated protein kinases. Shalom-Barek et al., J. Biol.
Chem. 273: 27467 (1998).
[0011] The present invention describes the cloning and
characterization of two novel proteins, termed PRO1031 (IL-17B) and
PRO1122 (IL-17C), and active variants thereof, that are similar in
amino acid sequence to IL-17.
SUMMARY OF THE INVENTION
[0012] Applicants have identified a cDNA clone that encodes a novel
polypeptide having sequence identity with IL-17, wherein the
polypeptide is designated in the present application as "PRO1031"
or "PRO1122".
[0013] In one embodiment, the invention provides an isolated
nucleic acid molecule comprising DNA encoding a PRO1031 or PRO1122
polypeptide.
[0014] In one aspect, the isolated nucleic acid comprises DNA
encoding the PRO1031 or PRO1122 polypeptide having amino acid
residues: from about 21 through 180 of FIG. 1 (SEQ ID NO:1), or
from about 19 through 197 of FIG. 3 (SEQ ID NO:3), respectively, or
is complementary to such encoding nucleic acid sequence, and
remains stably bound to it under at least moderate, and optionally,
under high stringency conditions.
[0015] In another embodiment, the isolated nucleic acid comprises
DNA having at least about 80% sequence identity, preferably at
least about 81% sequence identity, more preferably at least about
82% sequence identity, yet more preferably at least about 83%
sequence identity, yet more preferably at least about 84% sequence
identity, yet more preferably at least about 85% sequence identity,
yet more preferably at least about 86% sequence identity, yet more
preferably at least about 87% sequence identity, yet more
preferably at least about 88% sequence identity, yet more
preferably at least about 89% sequence identity, yet more
preferably at least about 90% sequence identity, yet more
preferably at least about 91% sequence identity, yet more
preferably at least about 92% sequence identity, yet more
preferably at least about 93% sequence identity, yet more
preferably at least about 94% sequence identity, yet more
preferably at least about 95% sequence identity, yet more
preferably at least about 96% sequence identity, yet more
preferably at least about 97% sequence identity, yet more
preferably at least about 98% sequence identity, yet more
preferably at least about 99% sequence identity to (a) a DNA
molecule encoding a PRO1031 or PRO1122 polypeptide comprising the
sequence of amino acid residues from 1 or about 21 to 180,
inclusive, of FIG. 1 (SEQ ID NO:1) or from 1 or about 19 to 197,
inclusive, of FIG. 3 (SEQ ID NO:3), or the (b) the complement of
the DNA molecule of (a). Alternatively, the isolated nucleic acid
comprises DNA encoding the PRO1031 polypeptide having amino acid
residues 1 through 180, inclusive, of FIG. 3 (SEQ ID NO:3).
Alternatively, the isolated nucleic acid comprises DNA encoding a
1122 polypeptide having the sequence of amino acid residues from
about 1 to about 197, inclusive of FIG. 1 (SEQ ID NO:1).
[0016] In another aspect, the invention concerns an isolated
nucleic acid molecule encoding a PRO1031 or PRO1122 polypeptide
comprising DNA hybridizing to the complement of the nucleic acid
between about residues: (a) 42 to about 581, inclusive, of FIG. 2
(SEQ ID NO:2), or (b) 49 to about 640, inclusive, or FIG. 4 (SEQ ID
NO:4), respectively. Preferably, the hybridization range extends
from about nucleic acid residue (a) about 102 to about 581,
inclusive, of FIG. 2 (SEQ ID NO:2), or (b) about 104 to about 640,
inclusive, of FIG. 4 (SEQ ID NO:4), respectively. Preferably,
hybridization occurs under stringent hybridization and wash
conditions.
[0017] In another aspect, the invention concerns an isolated
nucleic acid molecule encoding an active PRO1031 or PRO1122
polypeptide comprising a nucleotide sequence that hybridizes to the
complement of a nucleic acid sequence that encodes amino acids (a)
1 or about 21 to about 180, inclusive, of FIG. 1 (SEQ ID NO:1), or
(b) 1 or about 19 to about 197, inclusive, of FIG. 3 (SEQ ID NO:3).
Preferably, hybridization occurs under stringent hybridization and
wash conditions.
[0018] In a further aspect, the invention concerns an isolated
nucleic acid molecule comprising DNA having at least about 80%
sequence identity, preferably at least about 81% sequence identity,
more preferably at least about 82% sequence identity, yet more
preferably at least about 83% sequence identity, yet more
preferably at least about 84% sequence identity, yet more
preferably at least about 85% sequence identity, yet more
preferably at least about 86% sequence identity, yet more
preferably at least about 87% sequence identity, yet more
preferably at least about 88% sequence identity, yet more
preferably at least about 89% sequence identity, yet more
preferably at least about 90% sequence identity, yet more
preferably at least about 91% sequence identity, yet more
preferably at least about 92% sequence identity, yet more
preferably at least about 93% sequence identity, yet more
preferably at least about 94% sequence identity, yet more
preferably at least about 95% sequence identity, yet more
preferably at least about 96% sequence identity, yet more
preferably at least about 97% sequence identity, yet more
preferably at least about 98% sequence identity, yet more
preferably at least about 99% sequence identity to (a) a DNA
molecule encoding the same mature polypeptide encoded by the human
protein cDNA in ATCC deposit No. 209866 (DNA59294-1381) or 203552
(DNA62377-1381-1). In a preferred embodiment, the nucleic acid
comprises DNA encoding the same mature polypeptide encoded by the
human protein cDNA in ATCC deposit number 209866 (DNA59294-1381) or
203553 (DNA62377-1381-1), deposited on 14 May 1998 and 23 Dec.
1998, respectively. In a more preferred embodiment, the nucleic
acid comprises the cDNA insert of ATCC deposit DNA59294-1381 (ATCC
209866) deposited on 14 May 1998 or DNA62377-1381-1 (ATCC 203552),
deposited on 22 Dec. 1998, respectively.
[0019] In another aspect, the invention concerns an isolated
nucleic acid molecule comprising a nucleotide sequence encoding a
protein having at least about 80% sequence identity, preferably at
least about 81% sequence identity, more preferably at least about
82% sequence identity, yet more preferably at least about 83%
sequence identity, yet more preferably at least about 84% sequence
identity, yet more preferably at least about 85% sequence identity,
yet more preferably at least about 86% sequence identity, yet more
preferably at least about 87% sequence identity, yet more
preferably at least about 88% sequence identity, yet more
preferably at least about 89% sequence identity, yet more
preferably at least about 90% sequence identity, yet more
preferably at least about 91% sequence identity, yet more
preferably at least about 92% sequence identity, yet more
preferably at least about 93% sequence identity, yet more
preferably at least about 94% sequence identity, yet more
preferably at least about 95% sequence identity, yet more
preferably at least about 96% sequence identity, yet more
preferably at least about 97% sequence identity, yet more
preferably at least about 98% sequence identity, yet more
preferably at least about 99% sequence identity to (a) the
full-length polypeptide encoded by the cDNA deposited with the ATCC
on (1) 14 May 1998 under ATCC Deposit No.: 209866 (DNA59294-1381)
or (2) 23 Dec. 1998 under ATCC Deposit No.: 203553
(DNA62377-1381-1), or (b) the complement of the nucleotide sequence
of (a). In a preferred embodiment, the isolated nucleic acid
molecule encodes the same full length polypeptide as the cDNA
deposit of ATCC Deposit No.: 209866 or 203553, respectively.
[0020] In a further aspect, the isolated nucleic acid molecule
comprises a nucleotide sequence having at least about 80% sequence
identity, preferably at least about 81% sequence identity, more
preferably at least about 82% sequence identity, yet more
preferably at least about 83% sequence identity, yet more
preferably at least about 84% sequence identity, yet more
preferably at least about 85% sequence identity, yet more
preferably at least about 86% sequence identity, yet more
preferably at least about 87% sequence identity, yet more
preferably at least about 88% sequence identity, yet more
preferably at least about 89% sequence identity, yet more
preferably at least about 90% sequence identity, yet more
preferably at least about 91% sequence identity, yet more
preferably at least about 92% sequence identity, yet more
preferably at least about 92% sequence identity, yet more
preferably at least about 93% sequence identity, yet more
preferably at least about 94% sequence identity, yet more
preferably at least about 95% sequence identity, yet more
preferably at least about 96% sequence identity, yet more
preferably at least about 97% sequence identity, yet more
preferably at least about 98% sequence identity, yet more
preferably at least about 99% sequence identity, to: (a) DNA
molecule comprising the sequence of nucleotides from about 42 or
about 102 to about 581, inclusive, of FIG. 2 (SEQ ID NO:2) or from
about 49 or about 104 to about 640, inclusive, of FIG. 4 (SEQ ID
NO:4); or (b) the complement of the DNA molecule of (a).
[0021] In another aspect, the isolated nucleic acid molecule
comprises: (a) the nucleotide sequence from about 42 or about 102
to about 581, inclusive, of FIG. 2 (SEQ ID NO:2) or from about 49
or about 104 to about 640, inclusive, of FIG. 4 (SEQ ID NO:4); or
(b) the complement of the DNA molecule of (a).
[0022] In a further aspect, the invention concerns an isolated
nucleic acid molecule produced by hybridizing a test DNA molecule
under stringent conditions with: (a) a DNA molecule encoding (i) a
PRO1031 polypeptide having the sequence of amino acid residues from
about 1 or about 21 to about 180, inclusive, of FIG. 1 (SEQ ID
NO:1), or (ii) a PRO1122 polypeptide having the sequence of amino
acid residues from about 1 or about 19 to about 197, inclusive, of
FIG. 3 (SEQ ID NO:3); or (b) the complement of the DNA molecule of
(a), and if the DNA molecule has at least about an 80% sequence
identity, preferably at least about an 81% sequence identity, more
preferably at least about a 82% sequence identity, yet more
preferably at least about a 83% sequence identity, yet more
preferably at least about 84% sequence identity, yet more
preferably at least about 85% sequence identity, yet more
preferably at least about 86% sequence identity, yet more
preferably at least about 87% sequence identity, yet more
preferably at least about 88% sequence identity, yet more
preferably at least about 89% sequence identity, yet more
preferably at least about 90% sequence identity, yet more
preferably at least about 91% sequence identity, yet more
preferably at least about 92% sequence identity, yet more
preferably at least about 93% sequence identity, yet more
preferably at least about 94% sequence identity, yet more
preferably at least about 95% sequence identity, yet more
preferably at least about 96% sequence identity, yet more
preferably at least about 97% sequence identity, yet more
preferably at least about 98% sequence identity, yet more
preferably at least about 99% sequence identity to (a) or (b),
isolating the test DNA molecule.
[0023] In yet a further aspect, the invention concerns an isolated
nucleic acid molecule comprising: (a) DNA encoding a polypeptide
scoring at least about 80% positives, preferably at least about 81%
positives, more preferably at least about 82% positives, yet more
preferably at least about 83% positives, yet more preferably at
least about 84% positives, yet more preferably at least about 85%
positives, yet more preferably at least about 86% positives, yet
more preferably at least about 87% positives, yet more preferably
at least about 88% positives, yet more preferably at least about
89% positives, yet more preferably at least about 90% positives,
yet more preferably at least about 91% positives, yet more
preferably at least about 92% positives, yet more preferably at
least about 93% positives, yet more preferably at least about 94%
positives, yet more preferably at least about 95% positives, yet
more preferably at least about 96% positives, yet more preferably
at least about 97% positives, yet more preferably at least about
98% positives, yet more preferably at least about 99% positives,
when compared with the amino acid sequence of residues about (i) 21
to about 180, inclusive, of FIG. 1 (SEQ ID NO:1), or (ii) 19 to
about 197, inclusive, of FIG. 3 (SEQ ID NO:3), or (b) the
complement of the DNA of (a).
[0024] In a specific aspect, the invention provides an isolated
nucleic acid molecule comprising DNA encoding a PRO1032 or PRO1122
polypeptide without the N-terminal signal sequence and/or
initiating methionine, or is complementary to such encoding nucleic
acid molecule. The signal peptide has been tentatively identified
as extending from about amino acid residue (a) 1 to about amino
acid residue 20, inclusive, in the sequence of FIG. 1 (SEQ ID
NO:1), or (b) 1 to about amino acid residue 18, inclusive, in the
sequence of FIG. 3 (SEQ ID NO:3). It is noted, however, that the
C-terminal boundary of the signal peptide may vary, but most likely
by no more than about 5 amino acids on either side of the signal
peptide C-terminal boundary as initially identified herein, wherein
the C-terminal boundary of the signal peptide may be identified
pursuant to criteria routinely employed in the art. Nielsen et al.,
Prot. Engin. 10: 1-6 (1997), von Heinje et al., Nucl. Acids Res.
14: 4683-4690 (1986). Moreover, it is also recognized that, in some
cases, cleavage of the signal sequence form a secreted polypeptide
is not entirely uniform, resulting in more than one secreted
species. These polypeptides, and the polynucleotides encoding them,
are contemplated by the present invention. A such, for purposed of
the present application, the signal peptide of the PRO1032 or
PRO1122 polypeptide shown in FIG. 1 (SEQ ID NO:1) or FIG. 3 (SEQ ID
NO:3), respectively, extends from amino acids 1 to X, wherein X is
any amino acid from (a) 15 to 25 of FIG. 1 (SEQ ID NO:1), or (b) 13
to 23 of FIG. 3 (SEQ ID NO:3), respectively of FIG. 3.
[0025] Another embodiment is directed to fragments of a PRO1031- or
PRO1122-encoding sequence that may find use as, for example,
hybridization probes or for encoding fragments of a PRO1031 or
PRO1122 polypeptide that may optionally encode a polypeptide
comprising a binding site for an anti-PRO1031 or anti-PRO1122
antibody. Such nucleic acids fragments are usually at least about
20 nucleotides in length, preferably at least about 30 nucleotides
in length, more preferable at least about 40 nucleotides in length,
yet more preferably at least about 50 nucleotides in length, yet
more preferably at least about 60 nucleotides in length, yet more
preferably at least about 70 nucleotides in length, yet more
preferably at least about 80 nucleotides in length, yet more
preferably at least about 90 nucleotides in length, yet more
preferably at least about 100 nucleotides in length, yet more
preferably at least about 110 nucleotides in length, yet more
preferably at least about 120 nucleotides in length, yet more
preferably at least about 130 nucleotides in length, yet more
preferably at least about 140 nucleotides in length, yet more
preferably at least about 150 nucleotides in length, yet more
preferably at least about 160 nucleotides in length, yet more
preferably at least about 170 nucleotides in length, yet more
preferably at least about 180 nucleotides in length, yet more
preferably at least about 190 nucleotides in length, yet more
preferably at least about 200 nucleotides in length, yet more
preferably at least about 250 nucleotides in length, yet more
preferably at least about 300 nucleotides in length, yet more
preferably at least about 350 nucleotides in length, yet more
preferably at least about 400 nucleotides in length, yet more
preferably at least about 450 nucleotides in length, yet more
preferably at least about 500 nucleotides in length, yet more
preferably at least about 600 nucleotides in length, yet more
preferably at least about 700 nucleotides in length, yet more
preferably at least about 800 nucleotides in length, yet more
preferably at least about 900 nucleotides in length, yet more
preferably at least about 100 nucleotides in length, wherein in
this context "about" means the referenced nucleotide sequence
length plus or minus 10% of that referenced length. In a preferred
embodiment, the nucleotide sequence fragment is derived from any
coding region of the nucleotide sequence shown in FIG. 2 (SEQ ID
NO:2) or FIG. 4 (SEQ ID NO:4). In a more preferred embodiment, the
nucleotide sequence fragment is derived from nucleotides about 50
to about 390 and about 621 through about 640, inclusive, of FIG. 4
(SEQ ID NO:4). Alternatively, the nucleotide sequence fragment can
be derived from a fragment within the region between 391 and 620,
inclusive, provided at least one nucleotide is included outside of
the region (i.e., 50-390, 621-640).
[0026] In another embodiment, the invention provides a vector
comprising DNA encoding a PRO1031 or PRO1122 or its variants. The
vector may comprise any of the isolated nucleic acid molecules
hereinabove defined.
[0027] In another embodiment, the invention provides a host cell
comprising the above vector. By way of example, the host cells may
be CHO cells, E. coli, or yeast. A process for producing PRO1031 or
PRO1122 polypeptides is further provided and comprises culturing
host cells under conditions suitable for expression of PRO1031 or
PRO1122, respectively, and recovering PRO1031 or PRO1122,
respectively, from the cell culture.
[0028] In another embodiment, the invention provides isolated
PRO1031 or PRO1122 polypeptides encoded by any of the isolated
nucleic acid sequences hereinabove defined.
[0029] In another aspect, the invention concerns an isolated
PRO1031 or PRO1122 polypeptide, comprising an amino acid sequence
having at least about 80% sequence identity, preferably at least
about 81% sequence identity, more preferably about 82% sequence
identity, yet more preferably at least about 83% sequence identity,
yet more preferably at least about 84% sequence identity, yet more
preferably at least about 85% sequence identity, yet more
preferably at least about 86% sequence identity, yet more
preferably at least about 87% sequence identity, yet more
preferably at least about 88% sequence identity, yet more
preferably at least about 89% sequence identity, yet more
preferably at least about 90% sequence identity, yet more
preferably at least about 91% sequence identity, yet more
preferably at least about 92% sequence identity, yet more
preferably at least about 93% sequence identity, yet more
preferably at least about 94% sequence identity, yet more
preferably at least about 95% sequence identity, yet more
preferably at least about 96% sequence identity, yet more
preferably at least about 97% sequence identity, yet more
preferably at least about 98% sequence identity, yet more
preferably at least about 99% sequence identity to the sequence of
amino acid residues about (a) 1 or about 21 to about 180,
inclusive, of FIG. 1 (SEQ ID NO:1), or (b) 1 or about 19 to about
197, inclusive, of FIG. 3 (SEQ ID NO:3), respectively. In a
preferred aspect, the polypeptide comprises amino acid residues
about (a) 1 or about 21 to about 180, inclusive, of FIG. 1 (SEQ ID
NO:1) or (b) 1 or about 19 to about 197, inclusive, of FIG. 3 (SEQ
ID NO:3), respectively.
[0030] In a further aspect, the invention concerns an isolated
PRO1031 or PRO1122 polypeptide comprising an amino acid sequence
having at least about 80% sequence identity, preferably at least
about 81% sequence identity, more preferably at least about 82%
sequence identity, yet more preferably at least about 83% sequence
identity, yet more preferably at least about 84% sequence identity,
yet more preferably at least about 85% sequence identity, yet more
preferably at least about 86% sequence identity, yet more
preferably at least about 87% sequence identity, yet more
preferably at least about 88% sequence identity, yet more
preferably at least about 89% sequence identity, yet more
preferably at least about 90% sequence identity, yet more
preferably at least about 91% sequence identity, yet more
preferably at least about 92% sequence identity, yet more
preferably at least about 93% sequence identity, yet more
preferably at least about 94% sequence identity, yet more
preferably at least about 95% sequence identity, yet more
preferably at least about 96% sequence identity, yet more
preferably at least about 97% sequence identity, yet more
preferably at least about 98% sequence identity, yet more
preferably at least about 99% sequence identity to the amino acid
encoded by the human protein cDNA deposited with the ATCC on (1) 14
May 1999 under ATCC Deposit No. 209866 (DNA59294-1381) or (2) 22
Dec. 1998 under ATCC Deposit No. 203552, respectively.
[0031] In a preferred embodiment, the PRO1031 or PRO1122
polypeptide is obtained or obtainable by expressing the polypeptide
encoded by the cDNA insert of the vector deposited on (a) 14 May
1998 under ATCC deposit number 209866 (DNA59294-1381), or (b) 22
Dec. 1998 under ATCC deposit number 203552 (DNA62377-1381-1).
[0032] In a further aspect, the invention concerns an isolated
PRO1031 or PRO1122 polypeptide comprising an amino acid sequence
scoring at least about 80% positives, preferably at least about 81%
positives, more preferably at least about 82% positives, yet more
preferably at least about 83% positive, yet more preferably at
least about 84% positives, yet more preferably at least about 85%
positives, yet more preferably at least about 86% positives, yet
more preferably at least about 87% positives, yet more preferably
at least about 88% positives, yet more preferably at least about
89% positives, yet more preferably at least about 90% positives,
yet more preferably at least about 91% positives, yet more
preferably at least about 92% positives, yet more preferably at
least about 93% positives, yet more preferably at least about 94%
positives, yet more preferably at least about 95% positives, yet
more preferably at least about 96% positives, yet more preferably
at least about 97% positives, yet more preferably at least about
98% positives, yet more preferably at least about 99% positives,
when compared with the amino acid sequence of residues from about
(1) 1 or about 21 to about 180, inclusive, of FIG. 1 (SEQ ID NO:1),
or (2) 1 or about 19 to about 197, inclusive, of FIG. 3 (SEQ ID
NO:3).
[0033] In a specific aspect, the invention provides an isolated
PRO1031 or PRO1122 polypeptide without the N-terminal signal
sequence and/or initiating methionine and is encoded by a
nucleotide sequence that encodes such an amino acid sequence as
hereinbefore described. Processes for producing the same are also
herein described, wherein those processes comprise culturing a host
cell comprising a vector which comprises the appropriate encoding
nucleic acid molecule under conditions suitable for expression of
the PRO1031 or PRO1122 polypeptide and recovering the PRO1031 or
PRO1122 polypeptide, respectively, from the cell culture.
[0034] In still a further aspect, the invention provides a
polypeptide produced by: (1) hybridizing a test DNA molecule under
stringent conditions with (a) a DNA molecule encoding a (i) PRO1031
polypeptide having the sequence of amino acid residues from about
21 to about 180, inclusive, of FIG. 1 (SEQ ID NO:1), or (ii)
PRO1122 polypeptide having the sequence of amino acid residues from
about 19 to about 197, inclusive, of FIG. 3 (SEQ ID NO:3), or (b)
the complement of the DNA molecule of (a); and if the test DNA
molecule has at least about an 80% sequence identity, preferably at
least about an 81% sequence identity, more preferably at least
about an 82% sequence identity, yet more preferably at least about
an 83% sequence identity, yet more preferably at least about an 84%
sequence identity, yet more preferably at least about an 85%
sequence identity, yet more preferably at least about an 86%
sequence identity, yet more preferably at least about an 87%
sequence identity, yet more preferably at least about an 88%
sequence identity, yet more preferably at least about an 89%
sequence identity, yet more preferably at least about a 90%
sequence identity, yet more preferably at least about a 91%
sequence identity, yet more preferably at least about a 92%
sequence identity, yet more preferably at least about a 93%
sequence identity, yet more preferably at least about a 94%
sequence identity, yet more preferably at least about a 95%
sequence identity, yet more preferably at least about a 96%
sequence identity, yet more preferably at least about a 97%
sequence identity, yet more preferably at least about 98% sequence
identity, yet more preferably at least about a 99% sequence
identity to (a) or (b); (2) culturing a host cell comprising the
test DNA molecule under conditions suitable for expression of the
polypeptide, and (3) recovering the polypeptide from the cell
culture.
[0035] In yet another aspect, the invention concerns an isolated
PRO1031 or PRO1122 polypeptide comprising the sequence of amino
acid residues from about (1) 1 or about 21 to about 180, inclusive,
of FIG. 1 (SEQ ID NO:1), or (2) 1 or about 19 to about 197,
inclusive, of FIG. 3 (SEQ ID NO:3), respectively, or a fragment
thereof which is biologically active or sufficient to provide a
binding site for an anti-PRO1031 or anti-PRO1122 antibody,
respectively, wherein the identification of PRO1031 or PRO1122
polypeptide fragments, respectively, that possess biological
activity or provide a binding site for an anti-PRO1031 or
anti-PRO1122 antibody, respectively, may be accomplished in a
routine manner using techniques which are well known in the
art.
[0036] In another embodiment, the invention provides chimeric
molecules comprising a PRO1031 or PRO1122 polypeptide fused to a
heterologous polypeptide or amino acid sequence. An example of such
a chimeric molecule comprises a PRO1031 or PRO1122 polypeptide,
respectively, fused to an epitope tag sequence or a Fc region of an
immunoglobulin.
[0037] In another embodiment, the invention provides an antibody
which specifically binds to a PRO1031 or PRO1122 polypeptide.
Optionally, the antibody is a monoclonal antibody, an antibody
fragment or a single chain antibody.
[0038] In yet another embodiment, the invention concerns agonists
and antagonists of a native PRO1031 or PRO1122 polypeptide. In a
particular aspect, the agonist or antagonist is an anti-PRO1031 or
anti-PRO1122 antibody, or a small molecule.
[0039] In yet another embodiment, the invention concerns a method
of identifying agonists or antagonists of a native PRO1031 or
native PRO1122 polypeptide, by contacting the native PRO1031 or
PRO1122 polypeptide with a candidate molecule and monitoring a
biological activity mediated by said polypeptide.
[0040] In still a further embodiment, the invention concerns a
composition comprising a PRO1031 or PRO1122 polypeptide, or an
agonist or antagonist as hereinabove defined, in combination with a
carrier. Preferably, the carrier is pharmaceutically
acceptable.
[0041] In still a further embodiment, the invention concerns the
use of a PRO1031 or PRO1122 polypeptide, or an agonist or
antagonist thereof as hereinbefore described, or an anti-PRO1031 or
anti-PRO1122 antibody, for the preparation of a medicament useful
in the treatment of a condition which is responsive to the PRO1031
or PRO1122 polypeptide or an agonist or antagonist thereof (e.g.,
anti-PRO1031 or PRO1122). In a particular aspect, the invention
concerns the use of a PRO1031 or PRO1122 polypeptide, or an agonist
or antagonist thereof in a method for treating a degenerative
cartilaginous disorder.
[0042] In still a further embodiment, the invention relates to a
method of treating a degenerative cartilaginous disorder by
administration of a therapeutically effective amount of a PRO1031
or PRO1122 polypeptide, agonist, or antagonist thereof to a mammal
suffering from said disorder.
[0043] In still a further embodiment, the invention relates to a
method of diagnosing a degenerative cartilaginous disorder by (1)
culturing test cells or tissues expressing PRO1031 or PRO1122; (2)
administering a compound which can inhibit PRO1031 or PRO1122
modulated signaling; and (3) measuring the PRO1031 or PRO1122
mediated phenotypic effects in the test cells.
[0044] In still a further embodiment, the invention relates to
PRO1031 or PRO1122 antagonists and/or agonist molecules. In one
aspect, the inventions provides a method of screening compounds
which mimic PRO1031 or PRO1122 (agonists) or diminish the effect of
the PRO1031 or PRO1122 (antagonists).
[0045] In still a further embodiment, the invention relates to a
therapeutic composition comprising a therapeutically effective
amount of PRO1031, PRO1122, antagonist or agonist thereof in
combination with a pharmaceutically-acceptable carrier.
[0046] In still a further embodiment, the invention relates to an
article of manufacture comprising a container, label and
therapeutically effective amount of PRO1031, PRO1122, antagonist or
agonist thereof in combination with a pharmaceutically-acceptable
carrier.
BRIEF DESCRIPTION OF THE DRAWINGS
[0047] FIG. 1 shows the amino acid sequence (SEQ ID NO:1) derived
from nucleotides 42-581 of SEQ ID NO:2. Also shown in FIG. 1 are
the signal peptide, an N-glycosylation site, a region having
sequence identity with IL-17, the molecular weight, and approximate
pI.
[0048] FIG. 2 shows a nucleotide sequence (SEQ ID NO:2) containing
the nucleotide sequence of a native sequence PRO1031 cDNA
(nucleotides 42-581 of SEQ ID NO:2), wherein the nucleotide
sequence (SEQ ID NO:2) is a clone designated herein as "UNQ516"
and/or "DNA59294-1381".
[0049] FIG. 3 shows the amino acid sequence (SEQ ID NO:3) derived
from nucleotides 50-640 of SEQ ID NO:4. Also shown are the
approximate locations of the signal peptide, a leucine zipper
pattern in a region having sequence identity with IL-17. The
approximate weight in daltons, and approximate pI are also
shown.
[0050] FIG. 4 shows a nucleotide sequence (SEQ ID NO:4) containing
the nucleotide sequence of a native sequence PRO1122 cDNA
(nucleotides 50-640 of SEQ ID NO:1), wherein the nucleotide
sequence (SEQ ID NO:4) is a clone designated herein as "UNQ561"
and/or "DNA62377-1381-1". The complementary sequence and deduced
amino acid sequences are also shown.
[0051] FIG. 5 shows DNA47332 (SEQ ID NO:5), a virtual DNA fragments
used in the isolation of DNA59294 (SEQ ID NO:2).
[0052] FIG. 6 shows DNA49665 (Incyte EST 1347523) (SEQ ID NO:7), a
virtual fragment used in the isolation of DNA62377 (SEQ ID
NO:4).
[0053] FIG. 7A shows an alignment between the protein sequences
encoded by DNA59624 (IL17-B) (SEQ ID NO:1), DNA62377 (IL17-C) (SEQ
ID NO:3) and IL-17 (SEQ ID NO:11). The putative signal sequences
are underlined, potential N-linked glycosylation sites are double
underlined, and conserved tryptophan and cysteine residues are
marked with asterisks. IL-17, IL-17B and IL-17C share 26-28% amino
acid identity with each other. FIG. 7B shows an alignment between
just the encoded protein from DNA59624 (SEQ ID NO:1) and DNA62377
(SEQ ID NO:3).
[0054] FIG. 8 is an RNA blot analysis of IL-17B (UNQ516) (SEQ ID
NO:1). The northern blot depicts mRNA from human tissues (Clontech)
hybridized to a human IL17B specific radiolabeled probe as
described in Example 8. RNA size markers are shown on the left. A
rehybridization of the same blot with a human .beta.-actin cDNA
probe is shown at the bottom.
[0055] FIGS. 9A-9B depict bar graphs representing the biological
activities of IL17 (SEQ ID NO:11), IL17B (UNQ516) (SEQ ID NO:1) and
IL17C (UNQ561) (SEQ ID NO:3). FIG. 9A shows human foreskin
fibroblast (HFF) cells cultured with control Fc fusion protein,
IL-17, IL-17B.Fc (SEQ ID NO:12) or IL-17C.Fc (SEQ ID NO:13) at 100
ng/ml for 18 hours and the conditioned media were assayed for IL-6
(SEQ ID NO:14) as described in Example 10. FIG. 9B shows the human
leukemic cell line, THP1, which was treated with the same cytokines
(100 ng/ml) as above under the same conditions wherein the
supernatants were assayed for the level of TNF-.alpha. release.
Results are expressed as the mean+/-SE of triplicate determinations
from one representative experiment.
[0056] FIG. 10 is a time course representing the dependence of
IL17B and IL17C activated TNF-.alpha. release from THP1 cells. In
FIG. 10A, THP1 cells were incubated with 100 ng/ml (2.2 nM) of
IL17B.Fc (SEQ ID NO:12) or IL17C.Fc (SEQ ID NO:13) for 0.5 to 32
hours, the conditioned media harvested, and the TNF-.alpha.
concentration quantitated as described in Example 10. In FIG. 10B,
THP1 cells were treated with the IL-17B.Fc and IL-17C.Fc at a
concentration range from 0 to 120 nM for 18 hours and the
TNF-.alpha. release determined.
[0057] FIG. 11 is an immunoprecipitation of IL-17R ECD (SEQ ID
NO:15) with IL-17 (SEQ ID NO:11), IL17B (SEQ ID NO:1) and IL-17C
(SEQ ID NO:3). His-tagged IL-17 receptor ECD was expressed in 293
cells and metabolically labeled with .sup.35S as described in
Example 11. The supernatant was recovered and Ni--NTA beads were
used to affinity precipitate the his-tagged IL-17R ECD (SEQ ID
NO:15) in the supernatant (lane 1). In FIG. 11A, IL-17 (SEQ ID
NO:11), IL-17B.Fc (SEQ ID NO:12) and IL-17C.Fc (SEQ ID NO:13), or
control Fc fusion proteins were incubated with the supernatant and
protein-A-agarose beads were added to precipitate the Fc fusion
proteins. For the IL-17 immunoprecipitation reaction, anti-IL-17
antibodies were included. FIG. 11B shows the results of a
competitive binding experiment, wherein immunoprecipitation of
IL-17R ECD (SEQ ID NO:22) by IL-17 (SEQ ID NO:11) was performed in
the presence of a five-fold excess of IL-17B.his (SEQ ID NO:23) and
control his-tagged proteins. Precipitates in both FIG. 11A and FIG.
11B were analyzed by electrophoresis on NuPAGE (4-12% Bis-Tris)
gels. Molecular weight markers are indicated on the left of each
panel.
[0058] FIG. 12 shows FACS analysis of the binding of IL-17B.Fc (SEQ
ID NO:12) and IL-17C.Fc (SEQ ID NO:13) to THP-1 cells. THP-1 cells
were incubated with IL-17B.Fc (A) or IL-17C.Fc (B) or control Fc
fusion proteins in PBS (5% horse serum) and followed by addition of
FITC conjugated anti-Fc secondary antibodies.
[0059] FIG. 13 shows the effect of IL-17 (SEQ ID NO:11) on
articular cartilage. Cartilage explants were cultured with the
indicated concentration of IL-17 alone (solid) or in the presence
of IL-1.alpha. at the indicated concentration (hatched) (SEQ ID
NO:25) or IL1ra (IL-1 receptor antagonist, R&D Systems, 1
.mu.g/ml) (SEQ ID NO:26) for 72 hours. Release of proteolycans (PG)
into the media (top panel) indicates matrix breakdown. Matrix
synthesis was determined by incorporation of .sup.35S-sulphate into
the tissue (bottom panel).
[0060] FIG. 14 shows the effect of IL-17 (SEQ ID NO:11) on the
release of nitric oxide. Explants were treated with IL-17 (10
ng/ml) alone (left columns) or in the presence of IL-1.alpha. (10
ng/ml) (SEQ ID NO:25) (right columns). After 48 hours, media was
assayed for nitrite concentration.
[0061] FIG. 15 shows the effect of NO on IL-17 induced changes in
matrix metabolism. Explants were treated with IL-17 (5 ng/ml) (SEQ
ID NO:11) alone (+) or with an irreversible inhibitor of nitric
oxide synthase, NOS (L-NIO, Caymen Chemical, 0.5 mM). After 72
hours of treatment, media was assayed for (A) nitrite and (B)
proteoglycans (PGs). (C) Proteoglycan synthesis was determined by
incorporation of .sup.35S-sulphate into the tissue.
[0062] FIG. 16 shows the effect of the inhibition of NO on
IL-1.alpha.-induced changes in proteoglycan (PG) metabolism.
Articular cartilage explants were treated with IL-1.alpha. (5
ng/ml) (SEQ ID NO:25) alone (+) or with inhibitors of NOS (L-NIO or
L-NIL) (L-NIL, reversible NOS inhibitor, Caymen Chemical) or IL-1ra
(IL-1 receptor antagonist, R&D Systems, 1 .XI.g/ml) (SEQ ID
NO:26). After 72 hours or treatment, media as assayed for (A)
nitrite concentration and (B) amount of proteoglycans. (C) Matrix
synthesis was determined by incorporation of .sup.35S-sulphate into
the tissue.
[0063] FIG. 17 shows the effect of UNQ516 (SEQ ID NO:1) on
articular cartilage. Explants were treated with UNQ561 at 1% or
0.1% in the absence (leftmost 3 columns) or presence (rightmost
three columns) of IL-1.alpha. (SEQ ID NO:25) at 10 ng/ml, and
proteoglycan (PG) synthesis and nitrite production were determined
as described in Example 16.
[0064] FIG. 18 shows the effect of UNQ561 (SEQ ID NO:3) on
articular cartilage. Explants were treated with UNQ561 at 1% or
0.1% in the absence (leftmost three columns) or presence (rightmost
three columns) of IL-1.alpha. (+) (10 ng/ml) (SEQ ID NO:25).
Proteoglycan (PG) release and synthesis are shown as amount above
control.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
I. Definitions
[0065] The terms "PRO1031 polypeptide", or "PRO1122 polypeptide"
and "PRO1031", or "PRO1122" when used herein encompass native
sequence PRO1031, native sequence PRO1122, respectively and
polypeptide variants thereof (which are further defined herein).
The PRO1031 or PRO1122 polypeptides may be isolated from a variety
of sources, such as from human tissue types or from another source,
or prepared by recombinant or synthetic methods.
[0066] A "native sequence PRO1031 polypeptide" or "native sequence
PRO1122 polypeptide" comprise a polypeptide having the same amino
acid sequence as a PRO1031 or PRO1122 polypeptide, respectively,
derived from nature. Such native sequence PRO1031 or PRO1122
polypeptide can be isolated from nature or can be produced by
recombinant or synthetic means. The term "native sequence PRO1031
polypeptide" or "native sequence PRO1122 polypeptide" specifically
encompasses naturally-occurring truncated or secreted forms of a
PRO1031 polypeptide or PRO1122 polypeptide, respectively, (e.g.,
soluble forms containing for instance, an extracellular domain
sequence), naturally-occurring variant forms (e.g., alternatively
spliced forms) and naturally-occurring allelic variants of a
PRO1031 or PRO1122 polypeptide, respectively.
[0067] In one embodiment of the invention, the native sequence
PRO1031 polypeptide or PRO1122 polypeptide is a full-length or
mature native sequence (a) PRO1031 polypeptide comprising amino
acids 1 or 21 through 180 of FIG. 1 (SEQ ID NO:1) or (b) PRO1122
polypeptide comprising amino acids 1 or 19 through 197 of FIG. 3
(SEQ ID NO:3), respectively. Also, while the PRO1031 or PRO1122
polypeptides disclosed in FIGS. 1 and 3, respectively, (i.e.,
UNQ516 and UNQ561), are shown to begin with a methionine residue
designated as amino acid position 1, it is conceivable and possible
that another methionine residue located either upstream or
downstream from amino acid position 1 in FIG. 1 or FIG. 3 may be
employed as the starting amino acid residue.
[0068] The term "UNQ516" or "UNQ561" refer to the specific native
sequence PRO1031 or PRO1122 protein, respectively, depicted in FIG.
1 or 3, respectively. Optionally, the PRO1031 or PRO1122
polypeptide is obtained or obtainable by expressing the polypeptide
encoded by the cDNA insert of the vector DNA59294-1381 or
DNA62377-1381-1, under ATCC deposit number 209866 or 203552,
respectively.
[0069] "PRO1031 variant" or "PRO1122 variant" means an "active"
PRO1031 polypeptide or PRO1122 polypeptide, respectively, as
defined below having at least about 80% amino acid sequence
identity with the PRO1031 polypeptide or PRO1122 polypeptide,
respectively, having the deduced amino acid sequence of residues
(1) 1 or about 21 to about 180 shown in FIG. 1 (SEQ ID NO:1), or
(2) 1 or about 19 to 197 shown in FIG. 3 (SEQ ID NO:3),
respectively, for a full-length or mature native sequence PRO1031
or PRO1122 polypeptide, respectively. Such PRO1031 or PRO1122
polypeptide variants include, for instance, PRO1031 polypeptides or
PRO1122 polypeptides, respectively, wherein one or more amino acid
residues are added, substituted or deleted, at the N- or C-terminus
or within the sequence of FIG. 1 (SEQ ID NO:1) or FIG. 3 (SEQ ID
NO:3), respectively. Ordinarily, a PRO1031 or PRO1122 polypeptide
variant will have at least about 80% amino acid sequence identity,
preferably at least about 81% amino acid sequence identity, more
preferably at least about 82% amino acid sequence identity, yet
more preferably at least about 83% sequence identity, yet more
preferably at least about 84% sequence identity, yet more
preferably at least about 85% sequence identity, yet more
preferably at least about 86% sequence identity, yet more
preferably at least about 87% sequence identity, yet more
preferably at least about 88% sequence identity, yet more
preferably at least about 89% sequence identity, yet more
preferably at least about 90% sequence identity, yet more
preferably at least about 91% sequence identity, yet more
preferably at least about 92% sequence identity, yet more
preferably at least about 96% sequence identity, yet more
preferably at least about 97% sequence identity, yet more
preferably at least about 98% sequence identity, yet more
preferably at least about 99% amino acid sequence identity with the
amino acid sequence of FIG. 1 (SEQ ID NO:1) or FIG. 3 (SEQ ID
NO:3), with or without the signal peptide (E.g., with signal
peptide amino acid residues 1 to 180 of SEQ ID NO:1, 1 to 197 of
SEQ ID NO:3, without signal peptide about 21 to 180 of SEQ ID NO:1,
about 19 to 197 of SEQ ID NO:3). The variants provided herein
exclude native sequence PRO1031 and PRO1122 sequences as well the
polypeptides and nucleic acids described herein with which the
PRO1031 and PRO1122 polypeptides share 100% identity and/or which
are already known in the art.
[0070] "Percent (%) amino acid sequence identity" with respect to
the PRO1031 amino acid sequences identified herein is defined as
the percentage of amino acid residues in a candidate sequence that
are identical with the amino acid residues in a PRO1031 polypeptide
sequence, after aligning the sequences and introducing gaps, if
necessary, to achieve the maximum percent sequence identity, and
not considering any conservative substitutions as part of the
sequence identity. Alignment for purposes of determining percent
amino acid sequence identity can be achieved in various ways that
are within the skill in the art, for instance, using publicly
available computer software such as ALIGN, ALIGN-2, Megalign
(DNASTAR) or BLAST (e.g., Blast, Blast-2, WU-Blast-2) software.
Those skilled in the art can determine appropriate parameters for
measuring alignment, including any algorithms needed to achieve
maximal alignment over the full length of the sequences being
compared. For example, the % identity values used herein are
generated using WU-BLAST-2 (Altschul et al., Methods in Enzymology
266: 460-480 (1996). Most of the WU-BLAST-2 search parameters are
set to the default values. Those not set to default values, i.e.,
the adjustable parameters, are set with the following values:
overlap span=1, overlap fraction=0.125, word threshold (T)=11, and
scoring matrix=BLOSUM 62. For purposes herein, a % amino acid
sequence identity value is determined by divided (a) the number of
matching identical amino acid residues between the amino acid
sequence of the PRO1031 or PRO1122 polypeptide of interest and the
comparison amino acid sequence of interest (i.e., the sequence
against which the PRO1031 or PRO1122 polypeptide of interest is
being compared) as determined by WU-BLAST-2 by (b) the total number
of amino acid residues of the PRO1031 or PRO1122 polypeptide of
interest, respectively.
[0071] A "PRO1031 or PRO1122 variant polynucleotide" or PRO1031 or
PRO1122 variant nucleic acid sequence" means an active PRO1031 or
PRO1122 polypeptide-encoding nucleic acid molecule as defined below
having at least about 65% nucleic acid sequence identity with the
nucleotide acid sequence of nucleotides: (1) about 42 or about 102
to about 589 or about 687 of the PRO1031-encoding nucleotide
sequence shown in FIG. 2 (SEQ ID NO:2); or (2) about 59 or about
104 to about 640 or about 1043 of the PRO1122-encoding nucleotide
sequence shown in FIG. 4 (SEQ ID NO:4), respectively. Ordinarily, a
PRO1031 or PRO1122 polypeptide will have at least about 65% nucleic
acid sequence identity, more preferably at least about 70% nucleic
acid sequence identity, yet more preferably at least about 75%
nucleic acid sequence identity, yet more preferably at least about
80% nucleic acid sequence identity, yet more preferably at least
about 81% nucleic acid sequence identity, yet more preferably at
least about 82% nucleic acid sequence identity, yet more preferably
at least about 83% nucleic acid sequence identity, yet more
preferably at least about 84% nucleic acid sequence identity, yet
more preferably at least about 85% nucleic acid sequence identity,
yet more preferably at least about 86% nucleic acid sequence
identity, yet more preferably at least about 87% nucleic acid
sequence identity, yet more preferably at least about 88% nucleic
acid sequence identity, yet more preferably at least about 89%
nucleic acid sequence identity, yet more preferably at least about
90% nucleic acid sequence identity, yet more preferably at least
about 91% nucleic acid sequence identity, yet more preferably at
least about 92% nucleic acid sequence identity, yet more preferably
at least about 93% nucleic acid sequence identity, yet more
preferably at least about 94% nucleic acid sequence identity, yet
more preferably at least about 95% nucleic acid sequence identity,
yet more preferably at least about 96% nucleic acid sequence
identity, yet more preferably at least about 97% nucleic acid
sequence identity, yet more preferably at least about 98% nucleic
acid sequence identity, yet more preferably at least about 99%
nucleic acid sequence identity with the nucleic acid sequence of
nucleotides: 1) about 42 or about 102 to about 589 of the
PRO1031-encoding nucleotide sequence shown in FIG. 2 (SEQ ID NO:2);
or (2) about 59 or about 104 to about 640 of the PRO1122-encoding
nucleotide sequence shown in FIG. 4 (SEQ ID NO:4), respectively.
Variants specifically exclude or do not encompass the native
nucleotide sequence, as well as those prior art sequences which
share 100% identity with the nucleotide sequences of the
invention.
[0072] "Percent (%) nucleic acid sequence identity" with respect to
the PRO1031 or PRO1122 sequences identified herein is defined as
the percentage of nucleotides in a candidate sequence that are
identical with the nucleotides in the PRO1031 sequence or PRO1122
sequence, respectively, after aligning the sequences and
introducing gaps, if necessary, to achieve the maximum percent
sequence identity. Alignment for purposes of determining percent
nucleic acid sequence identity can be achieved in various ways that
are within the skill in the art, for instance, using publicly
available computer software such as ALIGN, Align-2, Megalign
(DNASTAR), or BLAST (e.g., Blast, Blast-2) software. Those skilled
in the art can determine appropriate parameters for measuring
alignment, including any algorithms needed to achieve maximal
alignment over the full length of the sequences being compared. For
purposes herein, however, % nucleic acid identity values are
generated using the WU-BLAST-2 (BlastN module) computer program
(Altschul et al., Methods in Enzymology 266: 460-480 (1996). Most
of the WU-BLAST-2 search parameters are set to the default values.
Those not set default values, i.e., the adjustable parameters, are
set with the following values: overlap span=1, overlap
fraction=0.125, word threshold (T)=11 and scoring matrix=BLOSUM62.
For purposes herein, a % nucleic acid sequence identity value is
determined by dividing (a) the number of matching identical
nucleotides between the nucleic acid sequence of the PRO
polypeptide-encoding nucleic acid molecule of interest and the
comparison nucleic acid molecule of interest (i.e., the sequence
against which the PRO polypeptide-encoding nucleic acid molecule of
interest is being compared) as determined by WU-BLAST-2 by (b) the
total number of nucleotides of the PRO polypeptide-encoding nucleic
acid molecule of interest.
[0073] In other embodiments, the PRO1031 or PRO1122 variant
polypeptides are nucleic acid molecules that encode an active
PRO1031 or PRO1122 polypeptide and which are capable of
hybridizing, preferably under stringent hybridization and wash
conditions, to nucleotide sequences encoding the full-length
PRO1031 or PRO1122 polypeptide shown in FIG. 2 (SEQ ID NO:2) or
FIG. 4 (SEQ ID NO:4), respectively. This scope of variant
polynucleotides specifically excludes those sequences which are
known as of the filing and/or priority dates of the present
application. Furthermore, PRO1031 or PRO1122 variant polypeptides
may also be those that are encoded by a PRO1031 or PRO1122 variant
polynucleotide, respectively.
[0074] The term "positives", in the context of sequence comparison
performed as described above, includes residues in the sequences
compared that are not identical but have similar properties (e.g.,
as a result of conservative substitutions). The % identity value of
positives is determined by the fraction of residues scoring a
positive value in the BLOSUM 62 matrix. This value is determined by
dividing (a) the number of amino acid residues scoring a positive
value in the BLOSUM62 matrix of WU-BLAST-2 between the PRO1031 or
PRO1122 polypeptide amino acid sequence of interest and the
comparison amino acid sequence (i.e., the amino acid sequence
against which the PRO1031 or PRO1122 polypeptide sequence is being
compared) as determined by WU-BLAST-2 by (b) the total number of
amino acid residues of the PRO1031 or PRO1122 polypeptide of
interest.
[0075] "Isolated," when used to describe the various polypeptides
disclosed herein, means polypeptide that has been identified and
separated and/or recovered from a component of its natural
environment. Preferably, the isolated polypeptide is free of
association with all components with which it is naturally
associated. Contaminant components of its natural environment are
materials that would typically interfere with diagnostic or
therapeutic uses for the polypeptide, and may include enzymes,
hormones, and other proteinaceous or non-proteinaceous solutes. In
preferred embodiments, the polypeptide will be purified (1) to a
degree sufficient to obtain at least 15 residues of N-terminal or
internal amino acid sequence by use of a spinning cup sequenator,
or (2) to homogeneity by SDS-PAGE under non-reducing or reducing
conditions using Coomassie blue or, preferably, silver stain.
Isolated polypeptide includes polypeptide in situ within
recombinant cells, since at least one component of the PRO1031 or
PRO1122 polypeptide natural environment will not be present.
Ordinarily, however, isolated polypeptide will be prepared by at
least one purification step.
[0076] An "isolated" PRO1031 or PRO1122 polypeptide-encoding
nucleic acid molecule is a nucleic acid molecule that is identified
and separated from at least one contaminant nucleic acid molecule
with which it is ordinarily associated in the natural source of the
PRO1031 polypeptide- or PRO1122 polypeptide-encoding nucleic acid.
An isolated PRO1031 polypeptide- or PRO1122 polypeptide-encoding
nucleic acid molecule is other than in the form or setting in which
it is found in nature. Isolated PRO1031 polypeptide- or PRO1122
polypeptide-encoding nucleic acid molecules therefore are
distinguished from the PRO1031 polypeptide- or PRO1122
polypeptide-, respectively, encoding nucleic acid molecule as it
exists in natural cells. However, an isolated PRO1031 polypeptide-
or PRO1122 polypeptide-encoding nucleic acid molecule includes
PRO1031 polypeptide- or PRO1122 polypeptide-, respectively,
encoding nucleic acid molecules contained in cells that ordinarily
express PRO1031 polypeptide or PRO1122 polypeptide, where, for
example, the nucleic acid molecule is in a chromosomal location
different from that of natural cells.
[0077] The term "control sequences" refers to DNA sequences
necessary for the expression of an operably linked coding sequence
in a particular host organism. The control sequences that are
suitable for prokaryotes, for example, include a promoter,
optionally an operator sequence, and a ribosome binding site.
Eukaryotic cells are known to utilize promoters, polyadenylation
signals, and enhancers.
[0078] Nucleic acid is "operably linked" when it is placed into a
functional relationship with another nucleic acid sequence. For
example, DNA for a presequence or secretory leader is operably
linked to DNA for a polypeptide if it is expressed as a preprotein
that participates in the secretion of the polypeptide; a promoter
or enhancer is operably linked to a coding sequence if it affects
the transcription of the sequence; or a ribosome binding site is
operably linked to a coding sequence if it is positioned so as to
facilitate translation. Generally, "operably linked" means that the
DNA sequences being linked are contiguous, and, in the case of a
secretory leader, contiguous and in reading phase. However,
enhancers do not have to be contiguous. Linking is accomplished by
ligation at convenient restriction sites. If such sites do not
exist, the synthetic oligonucleotide adaptors or linkers are used
in accordance with conventional practice.
[0079] "Stringency" of hybridization reactions is readily
determinable by one of ordinary skill in the art, and generally is
an empirical calculation dependent upon probe length, washing
temperature, and salt concentration. In general, longer probes
required higher temperatures for proper annealing, while short
probes need lower temperatures. Hybridization generally depends on
the ability of denatured DNA to reanneal when complementary strands
are present in an environment below their melting temperature. The
higher the degree of desired homology between the probe and
hybridizable sequence, the higher the relative temperature that can
be used. As a result, it follows that higher relative temperatures
would tend to make the reactions more stringent, while lower
temperatures less so. For additional details and explanation of
stringency of hybridization reactions, see Ausubel et al., Current
Protocols in Molecular Biology, Wiley Interscience Publishers,
(1995).
[0080] "Stringent conditions" or "high stringency conditions", as
defined herein, may be identified by those that" (1) employ low
ionic strength and high temperature for washing, for example 0.015
M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl
sulfate at 50.degree. C.; (2) employ during hybridization a
denaturing agent, such as formamide, for example, 50% (v/v)
formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1%
polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with
750 mM sodium chloride, 75 mM sodium citrate at 42.degree. C.; or
(3) employ 50% formamide, 5.times.SSC (0.75 M NaCl, 0.075 M sodium
citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium
pyrophosphate, 5.times. Denhardt's solution, sonicated salmon sperm
DNA (50 .mu.g/ml), 0.1% SDS, and 10% dextran sulfate at 42.degree.
C., with washes at 42.degree. C. in 0.2.times.SSC (sodium
chloride/sodium citrate) and 50% formamide at 55.degree. C.,
followed by a high-stringency wash consisting of 0.1.times.SSC
containing EDTA at 55.degree. C.
[0081] "Moderately stringent conditions" may be identified as
described by Sambrook et al., Molecular Cloning. A Laboratory
Manual, New York: Cold Spring Harbor Press, 1989, and include the
use of washing solution and hybridization conditions (e.g.,
temperature, ionic strength and % SDS) less stringent than those
described above. An example of moderately stringent conditions is
overnight incubation at 37.degree. C. in a solution comprising: 20%
formamide, 5.times.SSC (150 mM NaCl, 15 mM trisodium citrate), 50
mM sodium phosphate (pH 7.6), 5.times. Denhardt's solution, 10%
dextran sulfate, and 20 mg/mL denatured sheared salmon sperm DNA,
followed by washing the filters in 1.times.SSC at about
37-50.degree. C. The skilled artisan will recognize how to adjust
the temperature, ionic strength, etc. as necessary to accommodate
factors such as probe length and the like.
[0082] The term "epitope tagged" where used herein refers to a
chimeric polypeptide comprising a PRO1031 or PRO1122 polypeptide,
or domain sequence thereof, fused to a "tag polypeptide". The tag
polypeptide has enough residues to provide an epitope against which
an antibody may be made, or which can be identified by some other
agent, yet is short enough such that it does not interfere with the
activity of the PRO1031 or PRO1122 polypeptide. The tag polypeptide
preferably is also fairly unique so that the antibody does not
substantially cross-react with other epitopes. Suitable tag
polypeptides generally have at least six amino acid residues and
usually between about 8 to about 50 amino acid residues
(preferably, between about 10 to about 20 residues).
[0083] As used herein, the term "immunoadhesin" designates
antibody-like molecules which combine the binding specificity of a
heterologous protein (an "adhesion") with the effector functions of
immunoglobulin constant domains. Structurally, the immunoadhesins
comprise a fusion of an amino acid sequence with the desired
binding specificity which is other than the antigen recognition and
binding site of an antibody (i.e., is "heterologous"), and an
immunoglobulin constant domain sequence. The adhesin part of an
immunoadhesin molecule typically is a contiguous amino acid
sequence comprising at least the binding site of a receptor or a
ligand. The immunoglobulin constant domain sequence in the
immunoadhesin may be obtained from any immunoglobulin, such as
IgG-1, IgG-2, IgG-3 or IgG-4 subtypes, IgA (including IgG-1 and
IgA-2), IgE, IgD or IgM.
[0084] The term "antibody" is used in the broadest sense and
specifically covers single anti-PRO1031 or anti-PRO1122 polypeptide
monoclonal antibodies (including agonist, antagonist, and
neutralizing antibodies), anti-PRO1031 or anti-PRO1122,
respectively, antibody compositions with polyepitopic specificity,
single-chain anti-PRO1031 or anti-PRO1122 antibodies, and fragments
of anti-PRO1031 or anti-PRO1122 antibodies. The term "monoclonal
antibody" as used herein refers to an antibody obtained from a
population of substantially homogeneous antibodies, i.e., the
individual antibodies comprising the population are identical
except for possible naturally-occurring mutations that may be
present in minor amounts.
[0085] "Active" or "activity" for the purposes herein refers to
form(s) of PRO1031 or PRO1122 which retain the biologic and/or
immunologic activities of native or naturally-occurring PRO1031 or
PRO1122, respectively, polypeptide. Elaborating further,
"biological" activity refers to a biological function (either
inhibitory or stimulatory) caused by a native or
naturally-occurring PRO1031 or PRO1122 other than the ability to
induce the production of an antibody against an antigenic epitope
possessed by a native or naturally-occurring PRO1031 or PRO1122 and
an "immunological" activity refers only to the ability to induce
the production of an antibody against an antigenic epitope
possessed by a native or naturally-occurring PRO1031 or PRO1122. A
preferred biological activity includes, for example, the release of
TNF-.alpha. from THP1 cells. An alternative activity is the
reduction in IL-1.alpha. induced NO (nitric oxide) production from
articular cartilage.
[0086] "Degenerative cartilagenous disorder" describes a host of
disorders that is characterized principally by the destruction of
the cartilage matrix. Additional pathologies includes nitric oxide
production, and elevated proteoglycan breakdown. Exemplary
disorders encompassed within this definition, include, for example,
arthritis (e.g., osteoarthritis, rheumatoid arthritis, psoriatic
arthritis), sepsis, ulcerative colitis, psoriasis, multiple
sclerosis, type I diabetes, giant cell arthritis, systemic lupus
erythematosus and Sjogren's syndrome.
[0087] The term "antagonist" is used in the broadest sense, and
includes any molecule that partially or fully blocks, inhibits, or
neutralizes a biological activity of a native PRO1031 or PRO1122
polypeptide disclosed herein. In a similar manner, the term
"agonist" is used in the broadest sense and includes any molecule
that mimics a biological activity of a native PRO1031 or PRO1122
polypeptide disclosed herein. Suitable agonist or antagonist
molecules specifically include agonist or antagonist antibodies or
antibody fragments, fragments or amino acid sequence variants of
native PRO1031 or PRO1122 polypeptides, peptides, small organic
molecules, etc. Method for identifying agonists or antagonists of a
PRO1031 or PRO1122 polypeptide may comprise contacting a PRO1031 or
PRO1122 polypeptide with a candidate agonist or antagonist molecule
and measuring a detectable change in one or more biological
activities normally associated with the PRO1031 or PRO1122
polypeptide.
[0088] "Antibodies" (Abs) and "immunoglobulins" (Igs) are
glycoproteins having the same structural characteristics. While
antibodies exhibit binding specificity to a specific antigen,
immunoglobulins include both antibodies and other antibody-like
molecules which lack antigen specificity. Polypeptides of the
latter kind are, for example, produced at low levels by the lymph
system and at increased levels by myelomas. The term "antibody" is
used in the broadest sense and specifically covers, without
limitation, intact monoclonal antibodies, polyclonal antibodies,
multispecific antibodies (e.g. bispecific antibodies) formed from
at least two intact antibodies, and antibody fragments so long as
they exhibit the desired biological activity.
[0089] The terms "treating", "treatment" and "therapy" as used
herein refer to curative therapy, prophylactic therapy, and
preventative therapy. An example of "preventative therapy" is the
prevention or lessened targeted pathological condition or disorder.
Those in need of treatment include those already with the disorder
as well as those prone to have the disorder or those in whom the
disorder is to be prevented.
[0090] "Chronic" administration refers to administration of the
agent(s) in a continuous mode as opposed to an acute mode, so as to
maintain the initial therapeutic effect (activity) for an extended
period of time. "Intermittent" administration is treatment that is
not consecutively done without interruption, but rather is cyclic
in nature.
[0091] The term "mammal" as used herein refers to any mammal
classified as a mammal, including humans, domestic and farm
animals, and zoo, sports or pet animals, such as cattle (e.g.
cows), horses, dogs, sheep, pigs, rabbits, goats, cats, etc. In a
preferred embodiment of the invention, the mammal is a human.
[0092] Administration "in combination with" one or more further
therapeutic agents includes simultaneous (concurrent) and
consecutive administration in any order.
[0093] A "therapeutically-effective amount" is the minimal amount
of active agent (e.g., PRO1031, PRO1122, antagonist or agonist
thereof) which is necessary to impart therapeutic benefit to a
mammal. For example a "therapeutically-effective amount" to a
mammal suffering or prone to suffering or to prevent it from
suffering from a degenerative cartilagenous disorder is such an
amount which induces, ameliorates or otherwise causes an
improvement in the pathological symptoms, disease progression,
physiological conditions associated with or resistance to
succumbing to a disorder principally characterized by the
destruction of the cartilage matrix.
[0094] "Carriers" as used herein include
pharmaceutically-acceptable carriers, excipients, or stabilizers
which are nontoxic to the cell or mammal being exposed thereto at
the dosages and concentrations employed. Often the
physiologically-acceptable carrier is an aqueous pH buffered
solution. Examples of physiologically acceptable carriers include
buffers such as phosphate, citrate, and other organic acids;
antioxidants including ascorbic acid; low molecule weight (less
than about 10 residues) polypeptides; proteins, such as serum
albumin, gelatin, or immunoglobulins; hydrophilic polymers such as
polyvinylpyrrolidone; amino acids such as glycine, glutamine,
asparagine, arginine or lysine; monosaccharides, disaccharides, and
other carbohydrates including glucose, mannose, or dextrins;
chelating agents such as EDTA; sugar alcohols such as mannitol or
sorbitol; salt-forming counterions such as sodium; and/or nonionic
surfactants such as TWEEN.RTM., polyethylene glycol (PEG), and
PLURONICS.TM..
[0095] "Antibody fragments" comprise a portion of an intact
antibody, preferably the antigen binding or variable region of the
intact antibody. Examples of antibody fragments include Fab, Fab',
F(ab').sub.2 and Fv fragments; diabodies; linear antibodies (Zapata
et al., Protein Engin. 8(10): 1057-1062 [1995]); single-chain
antibody molecules; and multispecific antibodies formed from
antibody fragments.
[0096] Papain digestion of antibodies produces two identical
antigen-binding fragments, called "Fab" fragments, each with a
single antigen-binding site, and a residual "Fc" fragment, a
designation reflecting the ability to crystallize readily. Pepsin
treatment yields an F(ab').sub.2 fragment that has two
antigen-combining sites and is still capable of cross-linking
antigen.
[0097] "Fv" is the minimum antibody fragment which contains a
complete antigen-recognition and -binding site. This region
consists of a dimer of one heavy- and one light-chain variable
domain in tight, non-covalent association. It is in this
configuration that the three CDRs of each variable domain interact
to define an antigen-binding site on the surface of the VH-VL
dimer. Collectively, the six CDRs confer antigen-binding
specificity to the antibody. However, even a single variable domain
(or half of an Fv comprising only three CDR specific for an
antigen) has the ability to recognize and bind antigen, although at
a lower affinity than the entire binding site.
[0098] The Fab fragment also contains the constant domain of the
light chain and the first constant domain (CH1) of the heavy chain.
Fab fragments differ from Fv fragments by the addition of a few
residues at the carboxy terminus of the heavy chain CH1 domain
including one or more cysteines from the antibody hinge region.
Fab'-SH is the designation herein for Fab' in which the cysteine
residue(s) of the constant domains bear a free thiol group.
F(ab').sub.2 antibody fragments originally were produced as pairs
of Fab' fragments which have hinge cysteines between them. Other
chemical couplings of antibody fragments are also known.
[0099] The "light chains" of antibodies (immunoglobulins) from any
vertebrate species can be assigned to one of two clearly distinct
types, called kappa and lambda, based on the amino acid sequences
of their constant domains.
[0100] Depending on the amino acid sequence of the constant domain
of their heavy chains, immunoglobulins can be assigned to different
classes. There are five major classes of immunoglobulins: IgA, IgD,
IgE, IgG, and IgM, and several of these may be further divided into
subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA and
IgA2.
[0101] "Single-chain Fv" or "sFv" antibody fragments comprise the
VH and VL domains of antibody, wherein these domains are present in
a single polypeptide chain. Preferably, the Fv polypeptide further
comprises a polypeptide linker between the VH and VL domain which
enables the sFv to form the desired structure for antigen binding.
For a review of sFv, see Pluckthun in The Pharmacology of
Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds.,
Springer-Verlag, New York, pp. 269-315 (1994).
[0102] The term "diabodies" refers to small antibody fragments with
two antigen-binding sites, which fragments comprise a heavy-chain
variable domain (VH) connected to a light-chain variable domain
(VL) in the same polypeptide chain (VH-VL). By using a linker that
is too short to allow pairing between the two domains on the same
chain, the domains are forced to pair with the complementary
domains of another chain and create two antigen-binding sites.
Diabodies are described more fully in, for example, EP 404,097, WO
93/11161; and Hollinger et al., Proc. Natl. Acad. Sci. USA 90:
6444-6448 (1993).
[0103] An "isolated" antibody is one which has been identified and
separated and/or recovered from a component of its natural
environment. Contaminant components of its natural environment are
materials which would interfere with diagnostic or therapeutic uses
for the antibody, and may include enzymes, hormones, and other
proteinaceous or nonproteinaceous solutes. In preferred
embodiments, the antibody will be purified (1) to greater than 95%
by weight of antibody as determined by the Lowry method, and most
preferably more than 99% by weight, (2) to a degree sufficient to
obtain at least 15 residues of N-terminal or internal amino acid
sequence by use of a spinning cup sequenator, or (3) to homogeneity
by SDS-PAGE under reducing or nonreducing conditions using
Coomassie blue, or preferably, silver stain. Isolated antibody
includes the antibody in situ within recombinant cells since at
least one component of the antibody's natural environment will not
be present. Ordinarily, however, isolated antibody will be prepared
by at least one purification step.
[0104] The word "label" when used herein refers to a detectable
compound or composition which is conjugated directly or indirectly
to the antibody so as to generate a "labeled" antibody. The label
may be detectable by itself (e.g., radioisotope labels or
fluorescent labels) or, in the case of an enzymatic label, may
catalyze chemical alternation of a substrate compound or
composition which is detectable.
[0105] "Solid phase" is meant to be a non-aqueous matrix to which
the antibody of the present invention can adhere. Examples of solid
phases encompassed herein include those formed partially or
entirely of glass (e.g., controlled pore glass), polysaccharides
(e.g., agarose), polyacrylamides, polystyrene, polyvinyl alcohol
and silicones. In certain embodiments, depending on the context,
the solid phase can comprise the well of an assay plate; in others
it is a purification column (e.g., an affinity chromotagraphy
column). This term also includes a discontinuous solid phase of
discrete particles, such as those described in U.S. Pat. No.
4,275,149.
[0106] A "liposome" is a small vesicle composed of various types of
lipids, phospholipids and/or surfactant which is useful for
delivery of a drug (such as a PRO1031 or PRO1122 polypeptide or
antibody thereto) to a mammal. The components of the liposome are
commonly arranged in a bilayer formation, similar to the lipid
arrangement of biological membranes.
[0107] A "small molecule" is defined herein to have a molecule
weight below about 500 Daltons.
[0108] The term "modulate" means to affect (e.g., either
upregulate, downregulate or otherwise control) the level of a
signaling pathway. Cellular processes under the control of signal
transduction include, but are not limited to, transcription of
specific genes, normal cellular functions, such as metabolism,
proliferation, differentiation, adhesion, apoptosis and survival,
as well as abnormal processes, such as transformation, blocking of
differentiation and metastasis.
II. Compositions and Methods of the Invention
[0109] A. Full-Length PRO1031 or PRO1122 Polypeptide
[0110] The present invention provides newly identified and isolated
nucleotide sequences encoding polypeptides referred to in the
present application as PRO1031 or PRO1122. In particular,
Applicants have identified and isolated cDNA encoding a PRO1031
(e.g., UNQ516, IL-17B, SEQ ID NO:1) and PRO1122 (e.g., UNQ561,
IL-17C, SEQ ID NO:3) polypeptide, as disclosed in further detail in
the Examples below. Using BLAST and FastA sequence alignment
computer programs, Applicants found that various portions of the
PRO1031 and PRO1122 polypeptide have sequence identity with IL-17.
Accordingly, it is presently believed that PRO1031 and PRO1122
polypeptide disclosed in the present application are newly
identified members of the cytokine family and thus may be involved
in inflammation and/or the immune system function.
[0111] As presented earlier, the term "PRO1031" or "PRO1122" refers
to the native sequence and variants, whereas the terms "UNQ516" or
"UNQ561" refer to the specific amino acid sequences of FIG. 1 (SEQ
ID NO:1) and FIG. 3 (SEQ ID NO:3), respectively, and/or the
proteins encoded by the cDNA deposited with the American Type
Culture Collection, under Deposit numbers 209866 and 203552,
respectively.
[0112] As disclosed in the Examples below, cDNA clone designated
herein as DNA59294-1381 and DNA62377-1381-1 have been deposited
with the ATCC. The actual nucleotide sequence of the clone can be
readily determined by the skilled artisan by sequencing of the
deposited clone using routine methods in the art. The predicted
amino acid sequence can be determined from the nucleotide sequence
using routine skill. For the PRO1031 or PRO1122 polypeptide and
encoding nucleic acid described herein, Applicants have identified
what is believed to be the reading frame best identifiable with the
sequence information available at the time.
[0113] B. PRO1031 and PRO1122 Variants
[0114] In addition to the full-length native sequence PRO1031 or
PRO1122 polypeptide described herein, it is contemplated that
PRO1031 or PRO1122 variants can be prepared. PRO1031 or PRO1122
variants can be prepared by introducing appropriate nucleotide
changes into the PRO1031- or PRO1122-encoding DNA, or by synthesis
of the desired PRO1031 or PRO1122 polypeptide. Those skilled in the
art will appreciate that amino acid changes may alter
post-translational processes of the PRO1031 or PRO1122 polypeptide,
such as changing the number or position of glycosylation sites or
altering the membrane anchoring characteristics.
[0115] Variations in the native full-length sequence PRO1031 or
PRO1122 or in various domains of the PRO1031 or PRO1122 polypeptide
described herein, can be made, for example, using any of the
techniques and guidelines for conservative and non-conservative
mutations set forth, for instance, in U.S. Pat. No. 5,364,934.
Variations may be a substitution, deletion or insertion of one or
more codons encoding the PRO1031 or PRO1122 polypeptide that
results in a change in the amino acid sequence of the PRO1031 or
PRO1122 polypeptide as compared with the native sequence PRO1031 or
PRO1122. Optionally the variation is by substitution of at least
one amino acid with any other amino acid in one or more of the
domains of the PRO1031 or PRO1122 polypeptide. Guidance in
determining which amino acid residue may be inserted, substituted
or deleted without adversely affecting the desired activity may be
found by comparing the sequence of the PRO1031 or PRO1122
polypeptide with that of homologous known protein molecules and
minimizing the number of amino acid sequence changes made in
regions of high homology. Amino acid substitutions can be the
result of replacing one amino acid with another amino acid having
similar structural and/or chemical properties, such as the
replacement of a leucine with a serine, i.e., conservative amino
acid replacements. Insertions or deletions may optionally be in the
range of 1 to 5 amino acids. The variation allowed may be
determined by systematically making insertions, deletions or
substitutions of amino acids in the sequence and testing the
resulting variants for activity (such as in any of the in vitro
assays described in the Examples below) for activity exhibited by
the full-length or mature native sequence.
[0116] PRO1031 or PRO1122 polypeptide fragments are provided
herein. Such fragments may be truncated at the N-terminus or
C-terminus, or may lack internal residues, for example, when
compared with a full length or native protein. Certain fragments
lack amino acid residues that are not essential for a desired
biological activity of the PRO1031 or PRO1122 polypeptide.
[0117] PRO1031 or PRO1122 fragments may be prepared by any of a
number of conventional techniques. Desired peptide fragments may be
chemically synthesized. An alternative approach involves generating
PRO1031 or PRO1122 fragments by enzymatic digestion, e.g., by
treating the protein with an enzyme known to cleave proteins at
sites defined by particular amino aid residues, or by digesting the
DNA with suitable restriction enzymes and isolating the desired
fragment. Yet another suitable technique involves isolating and
amplifying a DNA fragment encoding a desired polypeptide fragment,
by polymerase chain reaction (PCR). Oligonucleotides that define
the desired termini of the DNA fragment are employed at the 5' and
3' primers in the PCR. Preferably, PRO1031 or PRO1122 polypeptide
fragments share at least one biological and/or immunological
activity with the native PRO1031 or PRO1122 polypeptide shown in
FIG. 1 (SEQ ID NO:1) or FIG. 3 (SEQ ID NO:3).
[0118] In particular embodiments, conservative substitutions of
interest are shown in Table 1 under the heading of preferred
substitutions. If such substitutions result in a change in
biological activity, then more substantial changes, denominated
exemplary substitutions in Table 1, or as further described below
in reference to amino acid classes, are introduced and the products
screened. TABLE-US-00001 TABLE 1 Conservative Substitutions
Preferred Original residue Example substitutions substitutions Ala
(A) val, leu, ile val Arg (R) lys, gln, asn lys Asn (N) gln, his,
lys, arg gln Asp (D) glu glu Cys (C) ser ser Gln (Q) asn asn Glu
(E) asp asp Gly (G) pro, ala ala His (H) asn, gln, lys, arg arg Ile
(I) leu, val, met, ala, phe, leu norleucine Leu (L) norleucine,
ile, val, met, ala, ile phe Lys (K) arg, gln, asn arg Met (M) leu,
phe, ile leu Phe (F) leu, val, ile, ala, tyr leu Pro (P) ala ala
Ser (S) thr thr Thr (T) ser ser Trp (W) tyr, phe tyr Tyr (Y) trp,
phe, thr, ser phe Val (V) ile, leu, met, phe, ala, leu
norleucine
[0119] Substantial modifications in function or immunological
identity of the PRO1031 or PRO1122 polypeptide are accomplished by
selecting substitutions that differ significantly in their effect
on maintaining (a) the structure of the polypeptide backbone in the
area of the substitution, for example, as a sheet or helical
conformation, (b) the charge or hydrophobicity of the molecule at
the target site, or (c) the bulk of the side chain. Naturally
occurring residues are divided into groups based on common
side-chain properties:
(1) hydrophobic: sys, ser, thr;
(2) neutral hydrophilic: cys, ser, thr;
(3) acidic: asp, glu;
(4) basic: asn, gln, his, lys, arg;
(5) residues that influence chain orientation: gly, pro; and
(6) aromatic: trp, tyr, phe.
[0120] Non-conservative substitutions will entail exchanging a
member of one of these classes for another class. Such substituted
residues also may be introduced into the conservative substitution
sites, or more preferably, into the remaining (non-conserved)
sites.
[0121] The variations can be made using methods known in the art
such as oligonucleotide-mediated (site-directed) mutagenesis,
alanine scanning, and PCR mutagenesis. Site-directed mutagenesis
[Carter et al., Nucl. Acids Res., 13:4331 (1986); Zoller et al.,
Nucl. Acids Res., 10:6487 (1987)], cassette mutagenesis [Wells et
al., Gene, 34:315 (1985)], restriction selection mutagenesis [Wells
et al., Philos. Trans. R. Soc. London SerA, 317:415 (1986)] or
other known techniques can be performed on the cloned DNA to
produce the PRO1031-encoding variant DNA.
[0122] Scanning amino acid analysis can also be employed to
identify one or more amino acids along a contiguous sequence. Among
the preferred scanning amino acids are relatively small, neutral
amino acids. Such amino acids include alanine, glycine, serine, and
cysteine. Alanine is typically a preferred scanning amino acid
among this group because it eliminates the side-chain beyond the
beta-carbon and is less likely to alter the main-chain conformation
of the variant. Alanine is also typically preferred because it is
the most common amino acid. Further, it is frequently found in both
buried and exposed positions [Creighton, The Proteins, (W.H.
Freeman & Co., N.Y.); Chothia, J. Mol. Biol., 150:1 (1976)]. If
alanine substitution does not yield adequate amounts of variant, an
isoteric amino acid can be used.
[0123] C. Modifications of PRO1031 or PRO1122
[0124] Covalent modifications of PRO1031 or PRO1122 polypeptides
are included within the scope of this invention. One type of
covalent modification includes reacting targeted amino acid
residues of a PRO1031 or PRO1122 polypeptide with an organic
derivatizing agent that is capable of reacting with selected side
chains or the N- or C-terminal residues of a PRO1031 or PRO1122
polypeptide. Derivatization with bifunctional agents is useful, for
instance, for crosslinking PRO1031 or PRO1122 to a water-insoluble
support matrix or surface for use in the method for purifying
anti-PRO1031 or PRO1122 antibodies, and vice-versa. Commonly used
crosslinking agents include, e.g.,
1,1-bis(diazo-acetyl)-2-phenylethane, glutaraldehyde,
N-hydroxy-succinimide esters, for example, esters with
4-azidosalicylic acid, homobifunctional imidoesters, including
disuccinimidyl esters such as
3,3'-dithiobis-(succinimidylproprionate), bifunctional maleimides
such as bis-N-maleimido-1,8-octane and agents such as
methyl-3-[(p-azidophenyl)-dithio]proprioimidate.
[0125] Other modifications include deamidation of glutaminyl and
asparaginyl residues to the corresponding glutamyl and aspartyl
residues, respectively, hydroxylation of proline and lysine,
phosphorylation of hydroxyl groups of seryl or threonyl residues,
methylation of the .alpha.-amino groups of lysine, arginine, and
histidine side chains [T. E. Creighton, Proteins: Structure and
Molecular Properties, W.H. Freeman & Co., San Francisco, pp.
79-86 (1983)], acetylation of the N-terminal amine, and amidation
of any C-terminal carboxyl group.
[0126] Another type of covalent modification of the PRO1031 or
PRO1122 polypeptide included within the scope of this invention
comprises altering the native glycosylation pattern of the
polypeptide. "Altering the native glycosylation pattern" is
intended for purposes herein to mean deleting one or more
carbohydrate moieties found in native sequence PRO1031 or PRO1122
polypeptide, and/or adding one or more glycosylation sites that are
not present in the native sequence PRO1031 or PRO1122 polypeptide.
Additionally, the phrase includes qualitative changes in the
glycosylation of the native proteins, involving a change in the
nature and proportions of the various carbohydrate moieties
present.
[0127] Addition of glycosylation sites to PRO1031 or PRO1122
polypeptides may be accomplished by altering the amino acid
sequence thereof. The alteration may be made, for example, by the
addition of, or substitution by, one or more serine or threonine
residues to the native sequence PRO1031 or PRO1122 polypeptide (for
O-linked glycosylation sites). The PRO1031 or PRO1122 amino acid
sequence may optionally be altered through changes at the DNA
level, particularly by mutating the DNA encoding the PRO1031 or
PRO1122 polypeptide at preselected bases such that codons are
generated that will translate into the desired amino acids.
[0128] Another means of increasing the number of carbohydrate
moieties on the PRO1031 or PRO1122 polypeptide is by chemical or
enzymatic coupling of glycosides to the polypeptide. Such methods
are described in the art, e.g., in WO 87/05330 published 11 Sep.
1987, and in Aplin and Wriston, CRC Crit. Rev. Biochem., pp.
259-306 (1981).
[0129] Removal of carbohydrate moieties present on the PRO1031 or
PRO1122 polypeptide may be accomplished chemically or enzymatically
or by mutational substitution of codons encoding for amino acid
residues that serve as targets for glycosylation. Chemical
deglycosylation techniques are known in the art and described, for
instance, by Hakimuddin, et al., Arch. Biochem. Biophys., 259:52
(1987) and by Edge et al., Anal. Biochem., 118:131 (1981).
Enzymatic cleavage of carbohydrate moieties on polypeptides can be
achieved by the use of a variety of endo- and exo-glycosidases as
described by Thotakura et al., Meth. Enzymol., 138:350 (1987).
[0130] Another type of covalent modification of PRO1031 or PRO1122
comprises linking the PRO1031 or PRO1122 polypeptide, respectively,
to one of a variety of nonproteinaceous polymers, e.g.,
polyethylene glycol, polypropylene glycol, or polyoxyalkylenes, in
the manner set forth in U.S. Pat. Nos. 4,640,835; 4,496,689;
4,301,144; 4,670,417; 4,791,192 or 4,179,337.
[0131] PRO1031 or PRO1122 polypeptides of the present invention may
also be modified in a way to form chimeric molecules comprising a
PRO1031 or PRO1122 polypeptide, respectively, fused to another,
heterologous polypeptide or amino acid sequence. In one embodiment,
such a chimeric molecule comprises a fusion of a PRO1031 or PRO1122
polypeptide with a tag polypeptide which provides an epitope to
which an anti-tag antibody can selectively bind. The epitope tag is
generally placed at the amino- or carboxyl-terminus of the PRO1031
or PRO1122 polypeptide. The presence of such epitope-tagged forms
of a PRO1031 or PRO1122 polypeptide can be detected using an
antibody against the tag polypeptide. Also, provision of the
epitope tag enables the PRO1031 or PRO1122 polypeptide to be
readily purified by affinity purification using an anti-tag
antibody or another type of affinity matrix that binds to the
epitope tag.
[0132] Various tag polypeptides and their respective antibodies are
well known in the art. Examples include poly-histidine (poly-his)
or poly-histidine-glycine (poly-his-gly) tags; the flu HA tag
polypeptide and its antibody 12CA5 [Field et al., Mol. Cell. Biol.,
8:2159-2165 (1988)]; the c-myc tag and the 8F9, 3C7, 6E10, G4, B7
and 9E10 antibodies thereto [Evan et al., Molecular and Cellular
Biology, 5:3610-3616 (1985)]; and the Herpes Simplex virus
glycoprotein D (gD) tag and its antibody [Paborsky et al., Protein
Engineering, 3(6):547-553 (1990)]. Other tag polypeptides include
the Flag-peptide [Hopp et al., BioTechnology, 6:1204-1210 (1988)];
the KT3 epitope peptide [Martin et al., Science, 255:192-194
(1992)]; an .alpha.-tubulin epitope peptide [Skinner et al., J.
Biol. Chem., 266:15163-15166 (1991)]; and the T7 gene 10 protein
peptide tag [Lutz-Freyermuth et al., Proc. Natl. Acad. Sci. USA,
87:6393-6397 (1990)].
[0133] In an alternative embodiment, the chimeric molecule may
comprise a fusion of a PRO1031 or PRO1122 polypeptide with an
immunoglobulin or a particular region of an immunoglobulin. For a
bivalent form of the chimeric molecule, such a fusion could be to
the Fc region of an IgG molecule. The Ig fusions preferably include
the substitution of a soluble transmembrane domain deleted or
inactivated) form of a PRO1031 or PRO1122 polypeptide in place of
at least one variable region within an Ig molecule. In a
particularly preferred embodiment, the immunoglobulin fusion
includes the hinge, CH2 and CH3, or the hinge, CH1, CH2 and CH3
regions of an IgG1 molecule. For the production of immunoglobulin
fusions see also U.S. Pat. No. 5,428,130, issued Jun. 27, 1995.
[0134] In yet a further embodiment, the PRO1031 or PRO1122
polypeptides of the present invention may also be modified in a way
to form a chimeric molecule comprising a PRO1031 or PRO1122
polypeptide fused to a leucine zipper. Various leucine zipper
polypeptides have been described in the art. See, e.g., Landschulz
et al., Science 240:1759 (1988); WO 94/10308; Hoppe et al., FEBS
Letters 344:1991 (1994); Maniatis et al., Nature 341:24 (1989). It
is believed that use of a leucine zipper fused to a PRO1031 or
PRO1122 polypeptide may be desirable to assist in dimerizing or
trimerizing soluble PRO1031 or PRO1122 polypeptide in solution.
Those skilled in the art will appreciate that the leucine zipper
may be fused at either the N- or C-terminal end of the PRO1031 or
PRO1122 molecule.
[0135] D. Preparation of PRO1031 or PRO1122
[0136] The description below relates primarily to production of
PRO1031 or PRO1122 by culturing cells transformed or transfected
with a vector containing PRO1031 or PRO1122 polypeptide encoding
nucleic acid. It is, of course, contemplated that alternative
methods, which are well known in the art, may be employed to
prepare PRO1031 or PRO1122 polypeptides. For instance, the PRO1031
or PRO1122 sequence, or portions thereof, may be produced by direct
peptide synthesis using solid-phase techniques [see, e.g., Stewart
et al., Solid-Phase Peptide Synthesis, W.H. Freeman Co., San
Francisco, Calif. (1969); Merrifield, J. Am. Chem. Soc.,
85:2149-2154 (1963)]. In vitro protein synthesis may be performed
using manual techniques or by automation. Automated synthesis may
be accomplished, for instance, using an Applied Biosystems Peptide
Synthesizer (Foster City, Calif.) using manufacturer's
instructions. Various portions of PRO1031 or PRO1122 polypeptides
may be chemically synthesized separately and combined using
chemical or enzymatic methods to produce a full-length PRO1031 or
PRO1122 polypeptide.
[0137] 1. Isolation of DNA Encoding PRO1031
[0138] DNA encoding a PRO1031 or PRO1122 polypeptide may be
obtained from a cDNA library prepared from tissue believed to
possess the PRO1031 or PRO1122 mRNA and to express it at a
detectable level. Accordingly, human PRO1031- or PRO1122-encoding
DNA can be conveniently obtained from a cDNA library prepared from
human tissue, such as described in the Examples. The PRO1031- or
PRO1122-encoding gene may also be obtained from a genomic library
or by known synthetic procedures (e.g., automated synthetic
procedures, oligonucleotide synthesis).
[0139] Libraries can be screened with probes (such as antibodies to
a PRO1031 or PRO1122 polypeptide or oligonucleotides of at least
about 20-80 bases) designed to identify the gene of interest or the
protein encoded by it. Screening the cDNA or genomic library with
the selected probe may be conducted using standard procedures, such
as described in Sambrook et al., Molecular Cloning. A Laboratory
Manual (New York: Cold Spring Harbor Laboratory Press, 1989). An
alternative means to isolate the gene encoding PRO1031 is to use
PCR methodology [Sambrook et al., supra; Dieffenbach et al., PCR
Primer: A Laboratory Manual (Cold Spring Harbor Laboratory Press,
1995)].
[0140] The Examples below describe techniques for screening a cDNA
library. The oligonucleotide sequences selected as probes should be
of sufficient length and sufficiently unambiguous that false
positives are minimized. The oligonucleotide is preferably labeled
such that it can be detected upon hybridization to DNA in the
library being screened. Methods of labeling are well known in the
art, and include the use of radiolabels like .sup.32P-labeled ATP,
biotinylation or enzyme labeling. Hybridization conditions,
including moderate stringency and high stringency, are provided in
Sambrook et al., supra.
[0141] Sequences identified in such library screening methods can
be compared and aligned to other known sequences deposited and
available in public databases such as GenBank or other private
sequence databases. Sequence identity (at either the amino acid or
nucleotide level) within defined regions of the molecule or across
the full-length sequence can be determined using methods known in
the art and as described herein (e.g., through sequence alignment
using computer software programs such as ALIGN, DNAstar, BLAST,
BLAST-2, INHERIT and ALIGN-2 which employ various algorithms to
measure homology).
[0142] Nucleic acid having protein coding sequence may be obtained
by screening selected cDNA or genomic libraries using the deduced
amino acid sequence disclosed herein for the first time, and, if
necessary, using conventional primer extension procedures as
described in Sambrook et al., supra, to detect precursors and
processing intermediates of mRNA that may not have been
reverse-transcribed into cDNA.
[0143] 2. Selection and Transformation of Host Cells
[0144] Host cells are transfected or transformed with expression or
cloning vectors described herein for PRO1031 or PRO1122 polypeptide
production and cultured in conventional nutrient media modified as
appropriate for inducing promoters, selecting transformants, or
amplifying the genes encoding the desired sequences. The culture
conditions, such as media, temperature, pH and the like, can be
selected by the skilled artisan without undue experimentation. In
general, principles, protocols, and practical techniques for
maximizing the productivity of cell cultures can be found in
Mammalian Cell Biotechnology: A Practical Approach, M. Butler, ed.
(IRL Press, 1991) and Sambrook et al., supra.
[0145] Methods of transfection are known to the ordinarily skilled
artisan, for example, CaPO.sub.4 and electroporation. Depending on
the host cell used, transformation is performed using standard
techniques appropriate to such cells. The calcium treatment
employing calcium chloride, as described in Sambrook et al., supra,
or electroporation is generally used for prokaryotes or other cells
that contain substantial cell-wall barriers. Infection with
Agrobacterium tumefaciens is used for transformation of certain
plant cells, as described by Shaw et al., Gene, 23:315 (1983) and
WO 89/05859 published 29 Jun. 1989. For mammalian cells without
such cell walls, the calcium phosphate precipitation method of
Graham and van der Eb, Virology, 52:456-457 (1978) can be employed.
General aspects of mammalian cell host system transformations have
been described in U.S. Pat. No. 4,399,216. Transformations into
yeast are typically carried out according to the method of Van
Solingen et al., J. Bact., 130:946 (1977) and Hsiao et al., Proc.
Natl. Acad. Sci. (USA), 76:3829 (1979). However, other methods for
introducing DNA into cells, such as by nuclear microinjection,
electroporation, bacterial protoplast fusion with intact cells, or
polycations, e.g., polybrene, polyornithine, may also be used. For
various techniques for transforming mammalian cells, see Keown et
al., Methods in Enzymology, 185:527-537 (1990) and Mansour et al.,
Nature, 336:348-352 (1988).
[0146] Suitable host cells for cloning or expressing the nucleic
acid (e.g., DNA) in the vectors herein include prokaryote, yeast,
or higher eukaryote cells. Suitable prokaryotes include but are not
limited to eubacteria, such as Gram-negative or Gram-positive
organisms, for example, Enterobacteriaceae such as E. coli. Various
E. coli strains are publicly available, such as E. coli K12 strain
MM294 (ATCC 31,446); E. coli X1776 (ATCC 31,537); E. coli strain
W3110 (ATCC 27,325) and K5772 (ATCC 53,635). Other suitable
prokaryotic host cells include Enterobacteriaceae such as
Escherichia, e.g., E. coli, Enterobacter, Erwinia, Klebisella,
Proteus, Salmonella, e.g., Salmonella typhimurium, Serratia, e.g.,
Serratia marcescans, and Shigella, as well as Bacilli such as B.
subtilis and B. licheniformis (e.g., B. licheniformis 41P disclosed
in DD266,710, published 12 Apr. 1989), Pseudomonas such as P.
aeruginosa, and Streptomyces. These examples are illustrative
rather than limiting. Strain W3110 is one particularly preferred
host or parent host because it is a common host strain for
recombinant DNA product fermentations. Preferably, the host cell
secretes minimal amounts of proteolytic enzymes. For example,
strain W3110 may be modified to effect a genetic mutation in the
genes encoding proteins endogenous to the host, with examples of
such hosts including E. coli W3110 strain 1A2, which has the
complete genotype tonA; E. coli W3110 strain 9E4, which has the
complete genotype tonA ptr3; E. coli W3110 strain 27C7 (ATCC
55,244), which has the complete genotype tonA, ptr3 phoA E15
(argF-lac)169 degP ompT kan.sup.r; E. coli W3110 strain 40B4, which
is strain 37D6 with a non-kanamycin resistant degP deletion
mutation; and an E. coli strain having mutant periplasmic protease
disclosed in U.S. Pat. No. 4,946,783 issued 7 Aug. 1990.
Alternatively, in vivo methods of cloning, e.g., PCR or other
nucleic acid polymerase reactions, are suitable.
[0147] In addition to prokaryotes, eukaryotic microbes such as
filamentous fungi or yeast are suitable cloning or expression hosts
for PRO1031- or PRO1122-encoding vectors. Saccharomyces cerevisiae
is a commonly used lower eukaryotic host microorganism. Others
include Schizosaccharomyces pombe (Beach and Nature, Nature 290:
140[1981]; EP 139,383 published 2 May 1995); Kluyveromyces hosts
(U.S. Pat. No. 4,943,529; Fleer et al., Bio/Technology, 9: 968-975
(1991) such as e.g., K. lactis (MW98-8C, CBS683, CBS4574;
Louvencourt et al., J. Bacteriol. 737 [1983]), K. fragilis (ATCC
12,424), K. bulgaricus (ATCC 16,045), K. wickeramii (ATCC 24,178),
K. waltii (ATCC 56,500), K. drosophilarum (ATCC 36,906); Van den
Berg et al., Bio/Technology 8: 135 (1990)); K. thermotolerans, and
K. marxianus; yarrowia (EP 402,226); Pichia pastoris (EP 183,070);
Sreekrishna et al., J. basic Microbiol. 28: 265-278 [1988]);
Candid; Trichoderma reesia (EP 244,234); Neurospora crassa (Case et
al., Proc. Natl. Acad. Sci. USA 76: 5359-5263 [1979]);
Schwanniomyces such as Schwanniomyces occidentalis (EP 394,538
published 31 Oct. 1990); and filamentous fungi such as, e.g.,
Neurospora, Penicillium, Tolypocladium (WO 91/00357 published 10
Jan. 19910, and Aspergillus hosts such as A. nidulans (Balance et
al., Biochem. Biophys. Res. Commun. 112: 284-289 [1983]; Tilburn et
al., Gene 26: 205-221 [1983]; Yelton et al., Proc. Natl. Acad. Sci.
USA 81: 1470-1474 [1984]) and A. niger (Kelly and Hynes, EMBO J. 4:
475-479 [1985]). Methylotropic yeasts are selected from the genera
consisting of Hansenula, Candida, Kloeckera, Pichia, Saccharomyces,
Torulopsis, and Rhodotorula. A list of specific species that are
exemplary of this class of yeast may be found in C. Antony, The
Biochemistry of Methylotrophs 269 (1982).
[0148] Suitable host cells for the expression of glycosylated
PRO1031 or PRO1122 are derived from multicellular organisms.
Examples of invertebrate cells include insect cells such as
Drosophila S2 and Spodoptera Sf9, Spodoptera high5 as well as plant
cells. Examples of useful mammalian host cell lines include Chinese
hamster ovary (CHO) and COS cells. More specific examples include
monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651);
human embryonic kidney line (293 or 293 cells subcloned for growth
in suspension culture, Graham et al., J. Gen Virol., 36:59 (1977));
Chinese hamster ovary cells/-DHFR(CHO, Urlaub and Chasin, Proc.
Natl. Acad. Sci. USA, 77:4216 (1980)); mouse sertoli cells (TM4,
Mather, Biol. Reprod., 23:243-251 (1980)); human lung cells (W138,
ATCC CCL 75); human liver cells (Hep G2, HB 8065); and mouse
mammary tumor (MMT 060562, ATCC CCL51). The selection of the
appropriate host cell is deemed to be within the skill in the
art.
[0149] 3. Selection and Use of a Replicable Vector
[0150] The nucleic acid (e.g., cDNA or genomic DNA) encoding the
desired PRO1031 or PRO1122 polypeptide may be inserted into a
replicable vector for cloning (amplification of the DNA) or for
expression. Various vectors are publicly available. The vector may,
for example, be in the form of a plasmid, cosmid, viral particle,
or phage. The appropriate nucleic acid sequence may be inserted
into the vector by a variety of procedures. In general, DNA is
inserted into an appropriate restriction endonuclease site(s) using
techniques known in the art. Vector components generally include,
but are not limited to, one or more of a signal sequence, an origin
of replication, one or more marker genes, an enhancer element, a
promoter, and a transcription termination sequence. Construction of
suitable vectors containing one or more of these components employs
standard ligation techniques which are known to the skilled
artisan.
[0151] The PRO1031 or PRO1122 polypeptide may be produced
recombinantly not only directly, but also as a fusion polypeptide
with a heterologous polypeptide, which may be a signal sequence or
other polypeptide having a specific cleavage site at the N-terminus
of the mature protein or polypeptide. In general, the signal
sequence may be a component of the vector, or it may be a part of
the PRO1031- or PRO1122-encoding DNA that is inserted into the
vector. The signal sequence may be a prokaryotic signal sequence
selected, for example, from the group of the alkaline phosphatase,
penicillinase, lpp, or heat-stable enterotoxin II leaders. For
yeast secretion the signal sequence may be, e.g., the yeast
invertase leader, alpha factor leader (including Saccharomyces and
Kluyveromyces .alpha.-factor leaders, the latter described in U.S.
Pat. No. 5,010,182), or acid phosphatase leader, the C. albicans
glucoamylase leader (EP 362,179 published 4 Apr. 1990), or the
signal described in WO 90/13646 published 15 Nov. 1990. In
mammalian cell expression, mammalian signal sequences may be used
to direct secretion of the protein, such as signal sequences from
secreted polypeptides of the same or related species, as well as
viral secretory leaders.
[0152] Both expression and cloning vectors contain a nucleic acid
sequence that enables the vector to replicate in one or more
selected host cells. Such sequences are well known for a variety of
bacteria, yeast, and viruses. The origin of replication from the
plasmid pBR322 is suitable for most Gram-negative bacteria, the
2.mu. plasmid origin is suitable for yeast, and various viral
origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for
cloning vectors in mammalian cells.
[0153] Expression and cloning vectors will typically contain a
selection gene, also termed a selectable marker. Typical selection
genes encode proteins that (a) confer resistance to antibiotics or
other toxins, e.g., ampicillin, neomycin, methotrexate, or
tetracycline, (b) complement auxotrophic deficiencies, or (c)
supply critical nutrients not available from complex media, e.g.,
the gene encoding D-alanine racemase for Bacilli.
[0154] An example of suitable selectable markers for mammalian
cells are those that enable the identification of cells competent
to take up the PRO1031-or PRO1122-encoding nucleic acid, such as
DHFR or thymidine kinase. An appropriate host cell when wild-type
DHFR is employed is the CHO cell line deficient in DHFR activity,
prepared and propagated as described by Urlaub et al., Proc. Natl.
Acad. Sci. USA, 77:4216 (1980). A suitable selection gene for use
in yeast is the trp1 gene present in the yeast plasmid YRp7
[Stinchcomb et al., Nature, 282:39 (1979); Kingsman et al., Gene,
7:141 (1979); Tschemper et al., Gene, 10:157 (1980)]. The trp1 gene
provides a selection marker for a mutant strain of yeast lacking
the ability to grow in tryptophan, for example, ATCC No. 44076 or
PEP4-1 [Jones, Genetics, 85:12 (1977)].
[0155] Expression and cloning vectors usually contain a promoter
operably linked to the PRO1031- or PRO1122-encoding nucleic acid
sequence to direct mRNA synthesis. Promoters recognized by a
variety of potential host cells are well known. Promoters suitable
for use with prokaryotic hosts include the .beta.-lactamase and
lactose promoter systems [Chang et al., Nature, 275:615 (1978);
Goeddel et al., Nature, 281:544 (1979)], alkaline phosphatase, a
tryptophan (trp) promoter system [Goeddel, Nucleic Acids Res.,
8:4057 (1980); EP 36,776], and hybrid promoters such as the tac
promoter [deBoer et al., Proc. Natl. Acad. Sci. USA, 80:21-25
(1983)]. Promoters for use in bacterial systems also will contain a
Shine-Dalgarno (S.D.) sequence operably linked to the DNA encoding
the PRO1031 or PRO1122 polypeptide.
[0156] Examples of suitable promoting sequences for use with yeast
hosts include the promoters for 3-phosphoglycerate kinase [Hitzeman
et al., J. Biol. Chem., 255:2073 (1980)] or other glycolytic
enzymes [Hess et al., J. Adv. Enzyme Reg., 7:149 (1968); Holland,
Biochemistry, 17:4900 (1978)], such as enolase,
glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate
decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase,
3-phosphoglycerate mutase, pyruvate kinase, triosephosphate
isomerase, phosphoglucose isomerase, and glucokinase.
[0157] Other yeast promoters, which are inducible promoters having
the additional advantage of transcription controlled by growth
conditions, are the promoter regions for alcohol dehydrogenase 2,
isocytochrome C, acid phosphatase, degradative enzymes associated
with nitrogen metabolism, metallothionein,
glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible
for maltose and galactose utilization. Suitable vectors and
promoters for use in yeast expression are further described in EP
73,657.
[0158] PRO1031 or PRO1122 transcription from vectors in mammalian
host cells is controlled, for example, by promoters obtained from
the genomes of viruses such as polyoma virus, fowlpox virus (UK
2,211,504 published 5 Jul. 1989), adenovirus (such as Adenovirus
2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a
retrovirus, hepatitis-B virus and Simian Virus 40 (SV40), from
heterologous mammalian promoters, e.g., the actin promoter or an
immunoglobulin promoter, and from heat-shock promoters, provided
such promoters are compatible with the host cell systems.
[0159] Transcription of a DNA encoding a PRO1031 or PRO1122
polypeptide by higher eukaryotes may be increased by inserting an
enhancer sequence into the vector. Enhancers are cis-acting
elements of DNA, usually about from 10 to 300 bp, that act on a
promoter to increase its transcription. Many enhancer sequences are
now known from mammalian genes (globin, elastase, albumin,
.alpha.-fetoprotein, and insulin). Typically, however, one will use
an enhancer from a eukaryotic cell virus. Examples include the SV40
enhancer on the late side of the replication origin (bp 100-270),
the cytomegalovirus early promoter enhancer, the polyoma enhancer
on the late side of the replication origin, and adenovirus
enhancers. The enhancer may be spliced into the vector at a
position 5' or 3' to the PRO1031 or PRO1122 coding sequence, but is
preferably located at a site 5' from the promoter.
[0160] Expression vectors used in eukaryotic host cells (yeast,
fungi, insect, plant, animal, human, or nucleated cells from other
multicellular organisms) will also contain sequences necessary for
the termination of transcription and for stabilizing the mRNA. Such
sequences are commonly available from the 5' and, occasionally 3',
untranslated regions of eukaryotic or viral DNAs or cDNAs. These
regions contain nucleotide segments transcribed as polyadenylated
fragments in the untranslated portion of the mRNA encoding PRO1031
or PRO1122.
[0161] Still other methods, vectors, and host cells suitable for
adaptation to the synthesis of PRO1031 or PRO1122 polypeptides in
recombinant vertebrate cell culture are described in Gething et
al., Nature, 293:620-625 (1981); Mantei et al., Nature, 281:40-46
(1979); EP 117,060; and EP 117,058.
[0162] 4. Detecting Gene Amplification/Expression
[0163] Gene amplification and/or expression may be measured in a
sample directly, for example, by conventional Southern blotting,
Northern blotting to quantitate the transcription of mRNA [Thomas,
Proc. Natl. Acad. Sci. USA, 77:5201-5205 (1980)], dot blotting (DNA
analysis), or in situ hybridization, using an appropriately labeled
probe, based on the sequences provided herein. Alternatively,
antibodies may be employed that can recognize specific duplexes,
including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes
or DNA-protein duplexes. The antibodies in turn may be labeled and
the assay may be carried out where the duplex is bound to a
surface, so that upon the formation of duplex on the surface, the
presence of antibody bound to the duplex can be detected.
[0164] Gene expression, alternatively, may be measured by
immunological methods, such as immunohistochemical staining of
cells or tissue sections and assay of cell culture or body fluids,
to quantitate directly the expression of gene product. Antibodies
useful for immunohistochemical staining and/or assay of sample
fluids may be either monoclonal or polyclonal, and may be prepared
in any mammal. Conveniently, the antibodies may be prepared against
a native sequence PRO1031 or PRO1122 polypeptide or against a
synthetic peptide based on the DNA sequences provided herein or
against exogenous sequence fused to PRO1031- or PRO1122-encoding
DNA and encoding a specific antibody epitope.
[0165] 5. Purification of Polypeptide
[0166] Forms of PRO1031 or PRO1122 may be recovered from culture
medium or from host cell lysates. If membrane-bound, it can be
released from the membrane using a suitable detergent solution
(e.g. Triton-X 100) or by enzymatic cleavage. Cells employed in
expression of PRO1031 or PRO1122 polypeptides can be disrupted by
various physical or chemical means, such as freeze-thaw cycling,
sonication, mechanical disruption, or cell lysing agents.
[0167] It may be desired to purify PRO1031 or PRO1122 from
recombinant cell proteins or polypeptides. The following procedures
are exemplary of suitable purification procedures: by fractionation
on an ion-exchange column; ethanol precipitation; reverse phase
HPLC; chromatography on silica or on a cation-exchange resin such
as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate
precipitation; gel filtration using, for example, Sephadex G-75;
protein A Sepharose columns to remove contaminants such as IgG; and
metal chelating columns to bind epitope-tagged forms of the PRO1031
or PRO1122 polypeptide. Various methods of protein purification may
be employed and such methods are known in the art and described for
example in Deutscher, Methods in Enzymology, 182 (1990); Scopes,
Protein Purification: Principles and Practice, Springer-Verlag, New
York (1982). The purification step(s) selected will depend, for
example, on the nature of the production process used and the
particular PRO1031 or PRO1122 polypeptide produced.
[0168] E. Uses for PRO1031
[0169] Nucleotide sequences (or their complement) encoding PRO1031
or PRO1122 polypeptides have various applications in the art of
molecular biology, including uses as hybridization probes, in
chromosome and gene mapping and in the generation of anti-sense RNA
and DNA. PRO1031- or PRO1122-encoding nucleic acid will also be
useful for the preparation of PRO1031 or PRO1122 polypeptides by
the recombinant techniques described herein.
[0170] The full-length DNA59294-1381 nucleotide sequence (SEQ ID
NO:2), full-length DNA62377-1381-1 nucleotide sequence (SEQ ID
NO:4) or the full-length native sequence PRO1031 or PRO1122
nucleotide-encoding sequence, or portions thereof, may be used as
hybridization probes for a cDNA library to isolate the full-length
PRO1031 or PRO1122 gene or to isolate still other genes (for
instance, those encoding naturally-occurring variants of PRO1031,
PRO1122 or the same from other species) which have a desired
sequence identity to the PRO1031 or PRO1122 nucleotide sequence
disclosed in FIG. 2 (SEQ ID NO:2) or FIG. 4 (SEQ ID NO:4),
respectively. Optionally, the length of the probes will be about 20
to about 50 bases. The hybridization probes may be derived from the
DNA59294-1381 or DNA62377-1381-1 nucleotide sequence of SEQ ID NO:2
or SEQ ID NO:4, respectively, as shown in FIG. 2 or FIG. 4,
respectively, or from genomic sequences including promoters,
enhancer elements and introns of native sequence PRO1031- or
PRO1122-encoding DNA. By way of example, a screening method will
comprise isolating the coding region of the PRO1031 or PRO1122 gene
using the known DNA sequence to synthesize a selected probe of
about 40 bases. Hybridization probes may be labeled by a variety of
labels, including radionucleotides such as .sup.32P or .sup.35S, or
enzymatic labels such as alkaline phosphatase coupled to the probe
via avidin/biotin coupling systems. Labeled probes having a
sequence complementary to that of the PRO1031 or PRO1122 gene of
the present invention can be used to screen libraries of human
cDNA, genomic DNA or mRNA to determine which members of such
libraries the probe hybridizes to. Hybridization techniques are
described in further detail in the Examples below.
[0171] Any EST sequence (or fragment thereof) disclosed in the
present application may similarly be employed as probes, using the
methods disclosed herein.
[0172] Other useful fragments of the PRO1031 or PRO1122 nucleic
acids include antisense or sense oligonucleotides comprising a
single-stranded nucleic acid sequence (either RNA or DNA) capable
of binding to target PRO1031 or PRO1122 mRNA (sense) of PRO1031 or
PRO1122 DNA (anti-sense) sequences. Antisense or sense
oligonucleotides, according to the present invention, comprise a
fragment of the coding region of PRO1031 or PRO1122 DNA. Such a
fragment generally comprises at least about 14 nucleotides,
preferably from about 14 to 30 nucleotides. The ability to derive
an antisense or a sense oligonucleotide, based upon a cDNA sequence
encoding a given protein is described in, for example, Stein and
Cohen, Cancer Res. 48:2659 (1988) and van der Krol et al.,
BioTechniques 6: 958 (1988).
[0173] Binding of antisense or sense oligonucleotides to target
nucleic acid sequences results in the formation of duplexes that
block transcription or translation of the target sequence by one of
several means, including enhanced degradation of the duplexes,
premature termination of transcription or translation, or by other
means. The antisense oligonucleotides thus may be used to block
expression of PRO1031 or PRO1122 proteins. Antisense or sense
oligonucleotides further comprise oligonucleotides having modified
sugar-phosphodiester backbones (or other sugar linkages, such as
those described in WO 91/06629) and wherein such sugar linkages are
resistant to endogenous nucleases. Such oligonucleotides with
resistant sugar linkages are stable in vivo (i.e., capable of
resisting enzymatic degradation) but retain sequence specificity to
be able to bind to target nucleotide sequences.
[0174] Other examples of sense or antisense oligonucleotides
include those oligonucleotides which are covalently linked to
organic moieties, such as those described in WO 90/10048, and other
moieties that increase affinity of the oligonucleotide for a target
nucleic acid sequence, such poly-L-lysine. Further still,
intercalating agents, such as ellipticine, and alkylating agents or
metal complexes may be attached to sense or antisense
oligonucleotides to modify binding specificities of the antisense
or sense oligonucleotide for the target nucleotide sequence.
[0175] Antisense or sense oligonucleotides may be introduced into a
cell containing the target nucleic acid sequence by any gene
transfer method, including, for example, CaPO.sub.4-mediated DNA
transfection, electroporation, or by using gene transfer vectors
such as Epstein-Barr virus. In a preferred procedure, an antisense
or sense oligonucleotide is inserted into a suitable retroviral
vector. A cell containing the target nucleic acid sequence is
contacted with the recombinant retroviral vector, either in vivo or
ex vivo. Suitable retroviral vectors include, but are not limited
to, those derived from the murine retrovirus M-MuLV, N2 (a
retrovirus derived from M-MuLV), or the double copy vectors
designated CDT5A, DCT5B and DCT5C (see WO 90/13641).
[0176] Sense of antisense oligonucleotides also may be introduced
into a cell containing the target nucleotide sequence by formation
of a conjugate with a ligand binding molecule, as described in WO
91/04753. Suitable ligand binding molecules include, but are not
limited to, cell surface receptors, growth factors, other
cytokines, or other ligands that bind to cell surface receptors.
Preferably, conjugation of the ligand binding molecule does not
substantially interfere with the ability of the ligand binding
molecule to bind to its corresponding molecule or receptor, or
block entry of the sense or antisense oligonucleotide or its
conjugated version into the cell.
[0177] Alternatively, a sense or an antisense oligonucleotide may
be introduced into a cell containing the target nucleic acid
sequence by formation of an oligonucleotide-lipid complex, as
described in WO 90/10448. The sense or antisense
oligonucleotide-lipid complex is preferably dissociated within the
cell by an endogenous lipase.
[0178] The probes may also be employed in PCR techniques to
generate a pool of sequences for identification of closely related
PRO1031 or PRO1122 sequences.
[0179] Nucleotide sequences encoding a PRO1031 or PRO1122
polypeptide can also be used to construct hybridization probes for
mapping the gene which encodes that PRO1031 or PRO1122 polypeptide
and for the genetic analysis of individuals with genetic disorders.
The nucleotide sequences provided herein may be mapped to a
chromosome and specific regions of a chromosome using known
techniques, such as in situ hybridization, linkage analysis against
known chromosomal markers, and hybridization screening with
libraries.
[0180] When the coding sequences for PRO1031 or PRO1122 encode a
protein which binds to another protein (example, where the PRO1031
or PRO1122 polypeptide, respectively, functions as a receptor), the
PRO1031 or PRO1122 polypeptide, respectively, can be used in assays
to identify the other proteins or molecules involved in the binding
interaction. By such methods, inhibitors of the receptor/ligand
binding interaction can be identified. Proteins involved in such
binding interactions can also be used to screen for peptide or
small molecule inhibitors or agonists of the binding interaction.
Also, the receptor PRO1031 or PRO1122 polypeptide can be used to
isolate correlative ligand(s). Screening assays can be designed to
find lead compounds that mimic the biological activity of a native
PRO1031 or PRO1122 or a receptor for PRO1031 or PRO1122,
respectively. Such screening assays will include assays amenable to
high-throughput screening of chemical libraries, making them
particularly suitable for identifying small molecule drug
candidates. Small molecules contemplated include synthetic organic
or inorganic compounds. The assays can be performed in a variety of
formats, including protein-protein binding assays, biochemical
screening assays, immunoassays and cell based assays, which are
well characterized in the art.
[0181] Nucleic acids which encode PRO1031 or PRO1122 polypeptide or
any of its modified forms can also be used to generate either
transgenic animals or "knock out" animals which, in turn, are
useful in the development and screening of therapeutically useful
reagents. A transgenic animal (e.g., a mouse or rat) is an animal
having cells that contain a transgene, which transgene was
introduced into the animal or an ancestor of the animal at a
prenatal, e.g., an embryonic stage. A transgene is a DNA which is
integrated into the genome of a cell from which a transgenic animal
develops. In one embodiment, cDNA encoding PRO1031 or PRO1122
polypeptide can be used to clone genomic DNA encoding PRO1031 or
PRO1122 in accordance with established techniques and the genomic
sequences used to generate transgenic animals that contain cells
which express DNA encoding PRO1031 or PRO1122. Methods for
generating transgenic animals, particularly animals such as mice or
rats, have become conventional in the art and are described, for
example, in U.S. Pat. Nos. 4,736,866 and 4,870,009. Typically,
particular cells would be targeted for PRO1031 or PRO1122 transgene
incorporation with tissue-specific enhancers. Transgenic animals
that include a copy of a transgene encoding PRO1031 or PRO1122
introduced into the germ line of the animal at an embryonic stage
can be used to examine the effect of increased expression of DNA
encoding PRO1031 or PRO1122. Such animals can be used as tester
animals for reagents thought to confer protection from, for
example, pathological conditions associated with its
overexpression. In accordance with this facet of the invention, an
animal is treated with the reagent and a reduced incidence of the
pathological condition, compared to untreated animals bearing the
transgene, would indicate a potential therapeutic intervention for
the pathological condition.
[0182] Alternatively, non-human homologues of PRO1031 or PRO1122
can be used to construct a PRO1031 or PRO1122, respectively, "knock
out" animal which has a defective or altered gene encoding PRO1031
or PRO1122, respectively, as a result of homologous recombination
between the endogenous gene encoding PRO1031 or PRO1122,
respectively, and altered genomic DNA encoding PRO1031 or PRO1122,
respectively, introduced into an embryonic cell of the animal. For
example, cDNA encoding PRO1031 or PRO1122, respectively, can be
used to clone genomic DNA encoding PRO1031 or PRO1122,
respectively, in accordance with established techniques. A portion
of the genomic DNA encoding PRO1031 or PRO1122, respectively, can
be deleted or replaced with another gene, such as a gene encoding a
selectable marker which can be used to monitor integration.
Typically, several kilobases of unaltered flanking DNA (both at the
5' and 3' ends) are included in the vector [see e.g., Thomas and
Capecchi, Cell, 51:503 (1987) for a description of homologous
recombination vectors]. The vector is introduced into an embryonic
stem cell line (e.g., by electroporation) and cells in which the
introduced DNA has homologously recombined with the endogenous DNA
are selected [see e.g., Li et al., Cell, 69:915 (1992)]. The
selected cells are then injected into a blastocyst of an animal
(e.g., a mouse or rat) to form aggregation chimeras [see e.g.,
Bradley, in Teratocarcinomas and Embryonic Stem Cells. A Practical
Approach, E. J. Robertson, ed. (IRL, Oxford, 1987), pp. 113-152]. A
chimeric embryo can then be implanted into a suitable
pseudopregnant female foster animal and the embryo brought to term
to create a "knock out" animal. Progeny harboring the homologously
recombined DNA in their germ cells can be identified by standard
techniques and used to breed animals in which all cells of the
animal contain the homologously recombined DNA. Knockout animals
can be characterized for instance, for their ability to defend
against certain pathological conditions and for their development
of pathological conditions due to absence of the PRO1031 or PRO1122
polypeptide.
[0183] Nucleic acid encoding the PRO1031 or PRO1122 polypeptides
may also be used in gene therapy. In gene therapy applications,
gene are introduced into cells in order to achieve in vivo
synthesis of a therapeutically effective genetic product, for
example for replacment of a defective gene. "Gene therapy" includes
both conventional gene therapy where a lasting effect is achieved
by a single treatment, and the administration of gene therapeutic
agents, which involves the one time or repeated administration of a
therapeutically effective DNA or mRNA. Antisense RNAs and DNAs can
be used as therapeutic agents for blocking the expression of
certain genes in vivo. It has already been shown that short
antisense oligonucleotides can be imported into cells where act as
inhibitors, despite their low intracellular concentrations caused
by their restricted uptake by the cell membrane. Zamecnik et al.,
Proc. Natl. Acad. Sci. USA 83: 4143-4146 [1986]). The
oligonucleotides can be modified to enhance their uptake, e.g., by
substituting their negatively charged phosphodiester groups by
uncharged groups.
[0184] There are a variety of techniques available for introducing
nucleic acids into viable cells. The techniques vary depending upon
whether the nucleic acid is transferred into cultured cell in
vitro, or in vivo in the cells of the intended host. Techniques
suitable for the transfer of nucleic acid into mammalian cells in
vitro include the use of liposomes, electroporation,
microinjection, cell fusion, DEAE-dextran, the calcium phosphate
precipitation method, etc. The currently preferred in vivo gene
transfer techniques include transfection with viral (typically
retroviral) vectors and viral coat protein-liposome mediated
transfection (Dzau et al., Trends in Biotechnology 11: 205-210
[1993]). In some situations it is desirable to provide the nucleic
acid source with an agent that targets the target cells, such as an
antibody specific for a cell surface membrane protein or the target
cell, a ligand for a receptor on the target cells, etc. Where
liposomes are employed, proteins which bind to a cell surface
membrane protein associated with endocytosis may by used for
targeting and/or to facilitate uptake, e.g., capsid proteins or
fragments thereof tropic for a particular cell type, antibodies for
proteins which undergo internalization in cycling, protein that
target intracellular localization and enhance intracellular
half-life. The technique of receptor-mediated endocytosis is
described, for example by Wu et al., J. Biol. Chem. 262: 4429-4432
(1987); and Wagner et al., Proc. Natl. Acad. Sci. USA 87: 3410-3414
(1990). For a review of gene marking and gene therapy protocols see
Anderson et al., Science 256: 808-813 (1992).
[0185] The PRO1031 or PRO1122 polypeptides described herein may
also be employed as molecular weight markers for protein
electrophoresis purposes.
[0186] The nucleic acid molecule encoding the PRO1031 or PRO1122
polypeptides or fragments thereof described herein are useful for
chromosome identification. In this regard, there exists an ongoing
need to identity new chromosome markers, since relatively few
chromosome marking reagents, based upon actual sequence data are
presently available. Each PRO1031 or PRO1122 nucleic acid molecule
of the present invention can be used as a chromosome marker.
[0187] The PRO1031 or PRO1122 polypeptides and nucleic acid
molecules of the present invention may also be used for tissue
typing, wherein the PRO1031 or PRO1122 polypeptides of the present
invention may be differentially expressed in one tissue as compared
to another. PRO1031 or PRO112 nucleic acid molecules will find use
for generating probes for PCR, Northern analysis, Southern analysis
and Western analysis.
[0188] PRO1031 or PRO1122 polypeptides of the present invention
which possess biological activity related to that of IL-17 may be
employed both in vivo for therapeutic purposes and in vitro. Those
of ordinary skill in the art will well know how to employ the
PRO1031 or PRO1122 polypeptides of the present invention for such
purposes.
[0189] PRO1031 or PRO1122 can be used in assays with the
polypeptides to which they have identity with to determine the
relative activities. The results can be applied accordingly.
[0190] An alignment of the predicted amino acid sequence of IL-17B
(e.g., UNQ516) (SEQ ID NO:1) and IL-17C (UNQ561) (SEQ ID NO:3) with
the known sequence of IL-17 (SEQ ID NO:11), show that this is a
family of related sequences with a 26-28% amino acid identity
between the three members (FIG. 7). All three polypeptides contain
a hydrophobic sequence at the N-terminus that is expected to
function as a secretion signal sequence of 18-20 amino acids,
giving a predicted size range for the members of this family 155 to
197 amino acids (mature MW.apprxeq.17 to .apprxeq.20 kDa). The
alignment of FIG. 7 shows several conserved amino acids, including
a tryptophan residue and 5 cysteines in the C-terminal half of the
proteins.
[0191] The PRO1031 or PRO1122 encoding nucleic acid or fragments
thereof can also be used for chromosomal localizations. For
example, the chromosome localization of IL-17B (UNQ516) (SEQ ID
NO:1) and IL-17C (UNQ561) (SEQ ID NO:3) was determined using Taqman
primers and probes designed in the 3'-untranslated regions of the
IL-17B and IL-17C, was performed by PCR with Stanford Radiation
Hybrid Panel G3 panel. IL-17B (UNQ516) (SEQ ID NO:1) mapped to
human chromosome 5q32-34, whereas IL-17C (UNQ561) (SEQ ID NO:3) was
localized to chromosome 16q24. Human IL-17 itself is found on
chromosome 2q31. Rouvier et al, M. Immunol. 150: 5445 (1993).
[0192] The isolation and characterization of the two new relatives
of IL-17, Applicants have established and expanded the potential
role of this family of cytokines may play in proinflammatory immune
and other responses. The three members of the family, IL-17 (SEQ ID
NO:1), IL-17B (SEQ ID NO:1) and IL-17C (SEQ ID NO:3), are modestly
related in primary structure with about 27% overall amino acid
identity including 5 conserved cysteine residues (FIG. 7). The
three family members share a number of features--they are 150-200
amino acid residues in length, they are secreted from cells via a
hydrophobic secretion signal sequence, and they are expressed as
disulfide-linked homodimers that in some cases appear to be
glycosylated.
[0193] While members of the same gene family based on amino acid
sequence similarity, the three proteins are expressed in different
tissues and are dispersed in the genome. IL-17 expression (SEQ ID
NO:11) has been reported only in activated T-cells, Fossiez et al.,
J. Exp. Med. 183: 2593 (1996), Yao et al., J. Immunol. 155: 5483
(1995)[Yao-3], while it is demonstrated herein that IL-17B
(DNA59294) (SEQ ID NO:2) is expressed in normal human adult
pancreas, small intestine, and stomach (FIG. 8). The expression
pattern of IL-17C (DNA62377) (SEQ ID NO:4), however, is much more
restricted, as confirmed expression in other tissues has not yet
been discovered.
[0194] The characterizations described herein demonstrate that the
biological activity of IL-17B (UNQ516) (SEQ ID NO:1) and IL-17C
(UNQ561) (SEQ ID NO:3) are considerably different from the
established activities for IL-17 (SEQ ID NO:11). IL-17B (UNQ516)
(SEQ ID NO:1) and IL-17C (UNQ561) (SEQ ID NO:3) each fail to induce
IL-6 production in human foreskin fibroblasts (Example 10) (FIG.
9A). This is in contrast to the marked induction known for IL-17
(SEQ ID NO:11). Yao et al., Immunity 3:811 (1995) [Yao-1], Yao et
al., J. Immunol. 155:5483 (1995)[Yao-3]. Conversely, IL-17B (SEQ ID
NO:1) and IL-17C (SEQ ID NO:3), each induce the release of
TNF-.alpha. from the monocytic cell line, THP1, while IL-17 has
only a very small effect (FIG. 9B). The stimulated release of
TNF-.alpha. in THP1 cells by IL-17B (SEQ ID NO:1) and IL-17C (SEQ
ID NO:3) is time and concentration dependent, (Example 10) (FIG.
10), with IL-17B (SEQ ID NO:1) being about 10-fold more potent than
IL-17C (SEQ ID NO:3) [EC.sub.50=2.4 nM for IL-17B vs. 25 nM for
IL-17C].
[0195] The different biological effects of IL-17 (SEQ ID NO:11) as
compared to IL-17B or C (SEQ ID NO:s 1 &3), suggests that they
may function via a different cell surface receptor (or some
differing receptor components) than the known IL-17 receptor. Yao
et al., Cytokine 9:794 (1997) [Yao-3]. In an effort to examine the
question of receptor specificity directly, Applicants have
demonstrated that both IL-17B (SEQ ID NO:1) and IL-17C (SEQ ID
NO:3) fail to bind to the IL-17 receptor ECD (SEQ ID NO:16) (FIG.
11A), and also fail to compete for the binding of IL-17 (SEQ ID
NO:11) to its receptor ECD (SEQ ID NO:16) (FIG. 11B). IL-17B (SEQ
ID NO:1) and IL-17C (SEQ ID NO:3) do bind to the surface of THP1
cells, where they have activity (FIG. 12). The interaction is
specific at least to the extent that a control Fc fusion protein
fails to bind to these cells. The results suggest that there could
be a set of receptors that bind and transduce the signal from the
family of IL-17 cytokines, a receptor/ligand model that has been
found for many cytokine and growth factor families.
[0196] The novel cytokines disclosed herein, PRO1031 (e.g., 516)
and PRO1122 (e.g., UNQ561), differ from IL-17 (SEQ ID NO:11) in
their patterns of expression and biological activities. The
differential expression coupled with the lack of interaction with
the known IL-17 receptor suggests and expanded role for the IL-17
family in the proinflammatory immune response.
[0197] F. Anti-PRO1031 and anti-PRO1122 Antibodies
[0198] The present invention further provides anti-PRO1031 and
anti-PRO1122 polypeptide antibodies. Exemplary antibodies include
polyclonal, monoclonal, humanized, bispecific, and heteroconjugate
antibodies.
[0199] 1. Polyclonal Antibodies
[0200] The anti-PRO1031 or anti-PRO1122 antibodies of the present
invention may comprise polyclonal antibodies. Methods of preparing
polyclonal antibodies are known to the skilled artisan. Polyclonal
antibodies can be raised in a mammal, for example, by one or more
injections of an immunizing agent and, if desired, an adjuvant.
Typically, the immunizing agent and/or adjuvant will be injected in
the mammal by multiple subcutaneous or intraperitoneal injections.
The immunizing agent may include the PRO1031 or PRO1122 polypeptide
or a fusion protein thereof. It may be useful to conjugate the
immunizing agent to a protein known to be immunogenic in the mammal
being immunized. Examples of such immunogenic proteins include but
are not limited to keyhole limpet hemocyanin, serum albumin, bovine
thyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants
which may be employed include Freund's complete adjuvant and
MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose
dicorynomycolate). The immunization protocol may be selected by one
skilled in the art without undue experimentation.
[0201] 2. Monoclonal Antibodies
[0202] The anti-PRO1031 or anti-PRO1122 antibodies may,
alternatively, be monoclonal antibodies. Monoclonal antibodies may
be prepared using hybridoma methods, such as those described by
Kohler and Milstein, Nature, 256:495 (1975). In a hybridoma method,
a mouse, hamster, or other appropriate host animal, is typically
immunized with an immunizing agent to elicit lymphocytes that
produce or are capable of producing antibodies that will
specifically bind to the immunizing agent. Alternatively, the
lymphocytes may be immunized in vitro.
[0203] The immunizing agent will typically include the PRO1031 or
PRO1122 polypeptide or a fusion protein thereof. Generally, either
peripheral blood lymphocytes ("PBLs") are used if cells of human
origin are desired, or spleen cells or lymph node cells are used if
non-human mammalian sources are desired. The lymphocytes are then
fused with an immortalized cell line using a suitable fusing agent,
such as polyethylene glycol, to form a hybridoma cell [Goding,
Monoclonal Antibodies. Principles and Practice, Academic Press,
(1986) pp. 59-103]. Immortalized cell lines are usually transformed
mammalian cells, particularly myeloma cells of rodent, bovine and
human origin. Usually, rat or mouse myeloma cell lines are
employed. The hybridoma cells may be cultured in a suitable culture
medium that preferably contains one or more substances that inhibit
the growth or survival of the unfused, immortalized cells. For
example, if the parental cells lack the enzyme hypoxanthine guanine
phosphoribosyl transferase (HGPRT or HPRT), the culture medium for
the hybridomas typically will include hypoxanthine, aminopterin,
and thymidine ("HAT medium"), which substances prevent the growth
of HGPRT-deficient cells.
[0204] Preferred immortalized cell lines are those that fuse
efficiently, support stable high level expression of antibody by
the selected antibody-producing cells, and are sensitive to a
medium such as HAT medium. More preferred immortalized cell lines
are murine myeloma lines, which can be obtained, for instance, from
the Salk Institute Cell Distribution Center, San Diego, Calif. and
the American Type Culture Collection, Rockville, Md. Human myeloma
and mouse-human heteromyeloma cell lines also have been described
for the production of human monoclonal antibodies [Kozbor, J.
Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody
Production Techniques and Applications, Marcel Dekker, Inc., New
York, (1987) pp. 51-63].
[0205] The culture medium in which the hybridoma cells are cultured
can then be assayed for the presence of monoclonal antibodies
directed against a PRO1031 or PRO1122 polypeptide. Preferably, the
binding specificity of monoclonal antibodies produced by the
hybridoma cells is determined by immunoprecipitation or by an in
vitro binding assay, such as radioimmunoassay (RIA) or
enzyme-linked immunoabsorbent assay (ELISA). Such techniques and
assays are known in the art. The binding affinity of the monoclonal
antibody can, for example, be determined by the Scatchard analysis
of Munson and Pollard, Anal. Biochem., 107:220 (1980).
[0206] After the desired hybridoma cells are identified, the clones
may be subcloned by limiting dilution procedures and grown by
standard methods [Goding, supra]. Suitable culture media for this
purpose include, for example, Dulbecco's Modified Eagle's Medium
and RPMI-1640 medium. Alternatively, the hybridoma cells may be
grown in vivo as ascites in a mammal.
[0207] The monoclonal antibodies secreted by the subclones may be
isolated or purified from the culture medium or ascites fluid by
conventional immunoglobulin purification procedures such as, for
example, protein A-Sepharose, hydroxylapatite chromatography, gel
electrophoresis, dialysis, or affinity chromatography.
[0208] The monoclonal antibodies may also be made by recombinant
DNA methods, such as those described in U.S. Pat. No. 4,816,567.
DNA encoding the monoclonal antibodies of the invention can be
readily isolated and sequenced using conventional procedures (e.g.,
by using oligonucleotide probes that are capable of binding
specifically to genes encoding the heavy and light chains of murine
antibodies). The hybridoma cells of the invention serve as a
preferred source of such DNA. Once isolated, the DNA may be placed
into expression vectors, which are then transfected into host cells
such as simian COS cells, Chinese hamster ovary (CHO) cells, or
myeloma cells that do not otherwise produce immunoglobulin protein,
to obtain the synthesis of monoclonal antibodies in the recombinant
host cells. The DNA also may be modified, for example, by
substituting the coding sequence for human heavy and light chain
constant domains in place of the homologous murine sequences [U.S.
Pat. No. 4,816,567; Morrison et al., Proc. Natl. Acad. Sci. USA 81,
6851-6855 (1984)] or by covalently joining to the immunoglobulin
coding sequence all or part of the coding sequence for a
non-immunoglobulin polypeptide. Such a non-immunoglobulin
polypeptide can be substituted for the constant domains of an
antibody of the invention, or can be substituted for the variable
domains of one antigen-combining site of an antibody of the
invention to create a chimeric bivalent antibody.
[0209] The antibodies may be monovalent antibodies. Methods for
preparing monovalent antibodies are well known in the art. For
example, one method involves recombinant expression of
immunoglobulin light chain and modified heavy chain. The heavy
chain is truncated generally at any point in the Fc region so as to
prevent heavy chain crosslinking. Alternatively, the relevant
cysteine residues are substituted with another amino acid residue
or are deleted so as to prevent crosslinking.
[0210] In vitro methods are also suitable for preparing monovalent
antibodies. Digestion of antibodies to produce fragments thereof,
particularly, Fab fragments, can be accomplished using routine
techniques known in the art.
[0211] 3. Humanized Antibodies
[0212] The anti-PRO1031 or anti-PRO1122 antibodies of the invention
may further comprise humanized antibodies or human antibodies.
Humanized forms of non-human (e.g., murine) antibodies are chimeric
immunoglobulins, immunoglobulin chains or fragments thereof (such
as Fv, Fab, Fab', F(ab').sub.2 or other antigen-binding
subsequences of antibodies) which contain minimal sequence derived
from non-human immunoglobulin. Humanized antibodies include human
immunoglobulins (recipient antibody) in which residues from a
complementary determining region (CDR) of the recipient are
replaced by residues from a CDR of a non-human species (donor
antibody) such as mouse, rat or rabbit having the desired
specificity, affinity and capacity. In some instances, Fv framework
residues of the human immunoglobulin are replaced by corresponding
non-human residues. Humanized antibodies may also comprise residues
which are found neither in the recipient antibody nor in the
imported CDR or framework sequences. In general, the humanized
antibody will comprise substantially all of at least one, and
typically two, variable domains, in which all or substantially all
of the CDR regions correspond to those of a non-human
immunoglobulin and all or substantially all of the FR regions are
those of a human immunoglobulin consensus sequence. The humanized
antibody optimally also will comprise at least a portion of an
immunoglobulin constant region (Fc), typically that of a human
immunoglobulin [Jones et al., Nature, 321:522-525 (1986); Riechmann
et al., Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct.
Biol., 2:593-596 (1992)].
[0213] Methods for humanizing non-human antibodies are well known
in the art. Generally, a humanized antibody has one or more amino
acid residues introduced into it from a source which is non-human.
These non-human amino acid residues are often referred to as
"import" residues, which are typically taken from an "import"
variable domain. Humanization can be essentially performed
following the method of Winter and co-workers [Jones et al.,
Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-327
(1988); Verhoeyen et al., Science, 239:1534-1536 (1988)], by
substituting rodent CDRs or CDR sequences for the corresponding
sequences of a human antibody. Accordingly, such "humanized"
antibodies are chimeric antibodies (U.S. Pat. No. 4,816,567),
wherein substantially less than an intact human variable domain has
been substituted by the corresponding sequence from a non-human
species. In practice, humanized antibodies are typically human
antibodies in which some CDR residues and possibly some FR residues
are substituted by residues from analogous sites in rodent
antibodies.
[0214] Human antibodies can also be produced using various
techniques known in the art, including phage display libraries
[Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et
al., J. Mol. Biol., 222:581 (1991)]. The techniques of Cole et al.
and Boerner et al. are also available for the preparation of human
monoclonal antibodies (Cole et al., Monoclonal Antibodies and
Cancer Therapy, Alan R. Liss, p. 77 (1985) and Boerner et al., J.
Immunol., 147(1):86-95 (1991)]. Similarly, human antibodies can be
made by introducing human immunoglobulin loci into transgenic
animals, e.g., mice in which the endogenous immunoglobulin genes
have been partially or complete inactivated. Upon challenge, human
antibody production is observed, which closely resembles that seen
in humans in all respects, including gene rearrangement, assembly
and antibody repertoire. This approach is described, for example,
in U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126;
5,633,425; 5,661,016, and in the following scientific publications:
Marks et al., Bio/Technology 10: 779-783 (1992); Lonberg et al.,
Nature 368: 856-859 (1994); Morrison, Nature 368: 812-13 (1994);
Fishwild et al., Nature Biotechnology 14: 845-51 (1996); Neuberger,
Nature Biotechnology 14: 826 (1996); Lonberg and Huszar, Intern.
Rev. Immunol. 13: 65-93 (1995).
[0215] 4. Antibody Dependent Enzyme Mediated Prodrug Therapy
(ADEPT)
[0216] The antibodies of the present invention may also be used in
ADEPT by conjugating the antibody to a prodrug-activating enzyme
which converts a prodrug (e.g. a peptidyl chemotherapeutic agent,
see WO 81/01145) to an active anti-cancer drug. See, for example,
WO 88/07378 and U.S. Pat. No. 4,975,278.
[0217] The enzyme component of the immunoconjugate useful for ADEPT
includes any enzyme capable of acting on a prodrug in such as way
so as to convert it into its more active, cytotoxic form.
[0218] Enzymes that are useful in the method of this invention
include, but are not limited to, glycosidase, glucose oxidase,
human lysosyme, human glucuronidase, alkaline phosphatase useful
for converting phosphate-containing prodrugs into free drugs;
arylsulfatase useful for converting sulfate-containing prodrugs
into free drugs; cytosine deaminase useful for converting non-toxic
5-fluorocytosine into the anti-cancer drug 5-fluorouracil;
proteases, such as serratia protease, thermolysin, subtilisin,
carboxypeptidases (e.g., carboxypeptidase G2 and carboxypeptidase
A) and cathepsins (such as cathepsins B and L), that are useful for
converting peptide-containing prodrugs into free drugs;
D-alanylcarboxypeptidases, useful for converting prodrugs that
contain D-amino acid substituents; carbohydrate-cleaving enzymes
such as .beta.-galactosidase and neuraminidase useful for
converting glycosylated prodrugs into free drugs; .beta.-lactamase
useful for converting drugs derivatized with .beta.-lactams into
free drugs; and penicillin amidases, such as penicillin Vamidase or
penicillin G amidase, useful for converting drugs derivatized at
their amine nitrogens with phenoxyacetyl or phenylacetyl groups,
respectively, into free drugs. Alternatively, antibodies with
enzymatic activity, also known in the art as Aabzymes@ can be used
to convert the prodrugs of the invention into free active drugs
(see, e.g., Massey, Nature 328: 457-458 (1987)). Antibody-abzyme
conjugates can be prepared as described herein for delivery of the
abzyme to a tumor cell population.
[0219] The enzymes of this invention can be covalently bound to the
anti-PRO1031 or anti-PRO1122 antibodies by techniques well known in
the art such as the use of the heterobifunctional cross-linking
agents discussed above. Alternatively, fusion proteins comprising
at least the antigen binding region of the antibody of the
invention linked to at least a functionally active portion of an
enzyme of the invention can be constructed using recombinant DNA
techniques well known in the art (see, e.g. Neuberger et al.,
Nature 312: 604-608 (1984)).
[0220] 5. Bispecific Antibodies
[0221] Bispecific antibodies are monoclonal, preferably human or
humanized, antibodies that have binding specificities for at least
two different antigens. In the present case, one of the binding
specificities is for a PRO1031 polypeptide, the other one is for
any other antigen, and preferably for a cell-surface protein or
receptor or receptor subunit.
[0222] Methods for making bispecific antibodies are known in the
art. Traditionally, the recombinant production of bispecific
antibodies is based on the co-expression of two immunoglobulin
heavy-chain/light-chain pairs, where the two heavy chains have
different specificities [Milstein and Cuello, Nature, 305:537-539
(1983)]. Because of the random assortment of immunoglobulin heavy
and light chains, these hybridomas (quadromas) produce a potential
mixture of ten different antibody molecules, of which only one has
the correct bispecific structure. The purification of the correct
molecule is usually accomplished by affinity chromatography steps.
Similar procedures are disclosed in WO 93/08829, published 13 May
1993, and in Traunecker et al., EMBO J., 10:3655-3659 (1991).
[0223] Antibody variable domains with the desired binding
specificities (antibody-antigen combining sites) can be fused to
immunoglobulin constant domain sequences. The fusion preferably is
with an immunoglobulin heavy-chain constant domain, comprising at
least part of the hinge, CH2, and CH3 regions. It is preferred to
have the first heavy-chain constant region (CH1) containing the
site necessary for light-chain binding present in at least one of
the fusions. DNAs encoding the immunoglobulin heavy-chain fusions
and, if desired, the immunoglobulin light chain, are inserted into
separate expression vectors, and are co-transfected into a suitable
host organism. For further details of generating bispecific
antibodies see, for example, Suresh et al. Methods in Enzymology,
121:210 (1986).
[0224] According to another approach described in WO 96/27011, the
interface between a pair of antibody molecules can be engineered to
maximize the percentage of heterodimers which are recovered from
recombinant cell culture. The preferred interface comprises at
least a part of the CH3 region of an antibody constant domain. In
this method, one or more small amino acid side chains from the
interface of the first antibody molecule are replaced with larger
side chains (e.g. tyrosine or tryptophan). Compensatory Acavities@
of identical or similar size to the large side chain(s) are created
on the interface of the second antibody molecule by replacing large
amino acid side chains with smaller ones (e.g. alanine or
threonine). This provides a mechanism for increasing the yield of
the heterodimer over other unwanted end-products such as
homodimers.
[0225] Bispecific antibodies can be prepared as full length
antibodies or antibody fragments (e.g. F(ab=).sub.2 bispecific
antibodies). Techniques for generating bispecific antibodies from
antibody fragments have been described in the literature. For
example, bispecific antibodies can be prepared can be prepared
using chemical linkage. Brennan et al., Science 229: 81 (1985)
describe a procedure wherein intact antibodies are proteolytically
cleaved to generate F(ab=).sub.2 fragments. These fragments are
reduced in the presence of the dithiol complexing agent sodium
arsenite to stabilize vicinal dithiols and prevent intermolecular
disulfide formation. The Fab=fragments generated are then converted
to thionitrobenzoate (TNB) derivatives. One of the Fab=-TNB
derivatives is then reconverted to the Fab=-thiol by reduction with
mercaptoethylamine and is mixed with an equimolar amount of the
other Fab=-TNB derivative to form the bispecific antibody. The
bispecific antibodies produced can be used as agents for the
selective immobilization of enzymes.
[0226] Fab=fragments may be directly recovered from E. coli and
chemically coupled to form bispecific antibodies. Shalaby et al.,
J. Exp. Med. 175: 217-225 (1992) describe the production of a fully
humanized bispecific antibody F(ab=).sub.2 molecule. Each
Fab=fragment was separately secreted from E. coli and subjected to
directed chemical coupling in vitro to form the bispecific
antibody. The bispecific antibody thus formed was able to bind to
cells overexpressing the ErbB2 receptor and normal human T cells,
as well as trigger the lytic activity of human cytotoxic
lymphocytes against human breast tumor targets.
[0227] Various technique for making and isolating bispecific
antibody fragments directly from recombinant cell culture have also
been described. For example, bispecific antibodies have been
produced using leucine zippers, Kostelny et al., J. Immunol.
148(5): 1547-1553 (1992), wherein the leucine zipper peptides from
the Fos and Jun proteins were linked to the Fab=portions of two
different antibodies by gene fusion. The antibody homodimers were
reduced at the hinge region to form monomers and then re-oxidized
to form the antibody heterodimers. This method can also be utilized
for the production of antibody homodimers. The Adiabody@ technology
described by Hollinger et al., Proc. Natl. Acad. Sci. USA 90:
6444-6448 (1993) has provided an alternative mechanism for making
bispecific antibody fragments. The fragments comprise a heavy-chain
variable domain (V.sub.H) connected to a light-chain variable
domain (V.sub.L) by a linker which is too short to allow pairing
between the two domains on the same chain. Accordingly, the V.sub.H
and V.sub.L domains of one fragment are forced to pair with the
complementary V.sub.L and V.sub.H domains of another fragment,
thereby forming two antigen-binding sites. Another strategy for
making bispecific antibody fragments by the use of single-chain Fv
(sFv) dimers has also been reported. See, Gruber et al., J.
Immunol. 152: 5368(1994).
[0228] Antibodies with more than two valencies are contemplated.
For example, trispecific antibodies can be prepared. Tutt et al.,
J. Immunol. 147: 60 (1991).
[0229] Exemplary bispecific antibodies may bind to two different
epitopes on a given APro@ protein herein. Alternatively, an
anti-@PRO@ protein arm may be combined with an arm which binds to a
triggering molecule on a leukocyte such as a T-cell receptor
molecule (e.g. CD2, CD3, CD28, or B7), or Fc receptors for IgG
(Fc.gamma.R), such as Fc.gamma.RI (CD64), Fc.gamma.RII (CD32) and
Fc.gamma.RIII (CD16) so as to focus cellular defense mechanisms to
the cell expressing the particular APRO@ protein. Bispecific
antibodies may also be used to localize cytotoxic agents to cells
which express a particular APRO@ polypeptide. These antibodies
possess a APRO@-binding arm and an arm which binds a cytotoxic
agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or
TETA. Another bispecific antibody of interest binds the APRO@
polypeptide and further binds tissue factor (TF).
[0230] 6. Heteroconjugate Antibodies
[0231] Heteroconjugate antibodies are also within the scope of the
present invention. Heteroconjugate antibodies are composed of two
covalently joined antibodies. Such antibodies have, for example,
been proposed to target immune system cells to unwanted cells [U.S.
Pat. No. 4,676,980], and for treatment of HIV infection [WO
91/00360; WO 92/200373; EP 03089]. It is contemplated that the
antibodies may be prepared in vitro using known methods in
synthetic protein chemistry, including those involving crosslinking
agents. For example, immunotoxins may be constructed using a
disulfide exchange reaction or by forming a thioether bond.
Examples of suitable reagents for this purpose include
iminothiolate and methyl-4-mercaptobutyrimidate and those
disclosed, for example, in U.S. Pat. No. 4,676,980.
[0232] 7. Effector Function Engineering
[0233] It may be desirable to modify the antibody of the invention
with respect to effector function, so as to enhance the
effectiveness of the antibody. For example cysteine residue(s) may
be introduced in the Fc region, thereby allowing interchain
disulfide bond formation in this region. The homodimeric antibody
thus generated may have improved internalization capability and/or
increased complement-mediated cell killing and antibody-dependent
cellular cytotoxicity (ADCC). See Caron et al., J. Exp Med.
176:1191-1195 (1992) and Shopes, B. J. Immunol. 148:2918-2922
(1992). Homodimeric antibodies with enhanced anti-tumor activity
may also be prepared using heterobifunctional cross-linkers as
described in Wolff et al. Cancer Research 53:2560-2565 (1993).
Alternatively, an antibody can be engineered which has dual Fc
regions and may thereby have enhanced complement lysis and ADCC
capabilities. See Stevenson et al., Anti-Cancer Drug Design 3:
219-230 (1989).
[0234] 8. Immunoconjugates
[0235] The invention also pertains to immunoconjugates comprising
an antibody conjugated to a cytotoxic agent such as a
chemotherapeutic agent, toxin (e.g. an enzymatically active toxin
of bacterial, fungal, plant or animal origin, or fragments thereof,
or a small molecule toxin), or a radioactive isotope (i.e., a
radioconjugate).
[0236] Chemotherapeutic agents useful in the generation of such
immunoconjugates have been described above. Enzymatically active
protein toxins and fragments thereof which can be used include
diphtheria A chain, nonbinding active fragments of diphtheria
toxin, cholera toxin, botulinus toxin, exotoxin A chain (from
Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A
chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins,
Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica
charantia inhibitor, curcin, crotin, sapaonaria officinalis
inhibitor, gelonin, saporin, mitogellin, restrictocin, phenomycin,
enomycin and the tricothecenes. Small molecule toxins include, for
example, calicheamicins, maytansinoids, palytoxin and CC1065. A
variety of radionuclides are available for the production of
radioconjugated antibodies. Examples include .sup.212Bi, .sup.131I,
.sup.131In, .sup.90Y and .sup.186Re.
[0237] Conjugates of the antibody and cytotoxic agent are made
using a variety of bifunctional protein coupling agents such as
N-succinimidyl-3-(2-pyridyldithiol)propionate (SPDP), iminothiolane
(IT), bifunctional derivatives of imidoesters (such as dimethyl
adipimidate HCL), active esters (such as disuccinimidyl suberate),
aldehydes (such as glutaraldehyde), bis-azido compounds (such as
bis(p-azidobenzoyl)hexanediamine), bis-diazonium derivatives (such
as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such
as tolyene 2,6-diisocyanate), and bis-active fluorine compounds
(such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin
immunotoxin can be prepared as described in Vitetta et al., Science
238: 1098 (1987). Carbon-14-labeled
1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid
(MX-DTPA) is an exemplary chelating agent for conjugation of
radionucleotide to the antibody. See WO94/11026.
[0238] In another embodiment, the antibody may be conjugated to a
"receptor" (such streptavidin) for utilization in tumor
pretargeting wherein the antibody-receptor conjugate is
administered to the patient, followed by removal of unbound
conjugate from the circulation using a clearing agent and then
administration of a "ligand" (e.g. avidin) which is conjugated to a
cytotoxic agent (e.g. a radionucleotide).
[0239] 9. Immunoliposomes
[0240] The antibodies disclosed herein may also be formulated as
immunoliposomes. Liposomes containing the antibody are prepared by
methods known in the art, such as described in Epstein et al.,
Proc. Natl. Acad. Sci. USA, 82:3688 (1985); Hwang et al., Proc.
Natl. Acad. Sci. USA, 77: 4030 (1980); and U.S. Pat. Nos. 4,485,045
and 4,544,545. Liposomes with enhanced circulation time are
disclosed in U.S. Pat. No. 5,013,556.
[0241] Particularly useful liposomes can be generated by the
reverse phase evaporation method with a lipid composition
comprising phosphatidylcholine, cholesterol and PEG-derivatized
phosphatidylethanolamine (PEG-PE). Liposomes are extruded through
filters of defined pore size to yield liposomes with the desired
diameter. Fab' fragments of the antibody of the present invention
can be conjugated to the liposomes as described in Martin et al.,
J. Biol. Chem. 257: 286-288 (1982) via a disulfide interchange
reaction. A chemotherapeutic agent (such as Doxorubicin) is
optionally contained within the liposome. See Gabizon et al., J.
National Cancer Inst. 81(19): 1484 (1989).
[0242] 10. Pharmaceutical Compositions of Antibodies
[0243] Antibodies specifically binding a PRO1031 or PRO1122
polypeptide identified herein, as well as other molecules
identified by the screening assays disclosed hereinbefore, can be
administered for the treatment of various disorders in the form of
pharmaceutical compositions.
[0244] If a PRO1031 or PRO1122 polypeptide is intracellular and
whole antibodies are used as inhibitors, internalizing antibodies
are preferred. However, lipofections or liposomes can also be used
to deliver the antibody, or an antibody fragment, into cells. Where
antibody fragments are used, the smallest inhibitory fragment that
specifically binds to the binding domain of the target protein is
preferred. For example, based upon the variable-region sequences of
an antibody, peptide molecules can be designed that retain the
ability to bind the target protein sequence. Such peptides can be
synthesized chemically and/or produced by recombinant DNA
technology. See, e.g., Marasco et al., Proc. Natl. Acad. Sci. USA
90: 7889-7893 (1993).
[0245] The formulation herein may also contain more than one active
compound as necessary for the particular indication being treated,
preferably those with complementary activities that do not
adversely affect each other. Alternatively, or in addition, the
composition may comprise an agent that enhances its function, such
as, for example, a cytotoxic agent, cytokines, chemotherapeutic
agent, or growth-inhibitory agent. Such molecules are suitable
present in combination in amounts that are effective for the
purpose intended.
[0246] The active ingredients may also be entrapped in
microcapsules prepared, for example, by coascervation techniques or
by interfacial polymerization, for example, hydroxymethylcellulose
or felatin-microcapsules and poly-(methylmethactylate)
microcapsules, respectively, in colloidal drug delivery systems
(for example, liposomes, albumin microspheres, microemulsions,
nano-particles, and nanocapsules) or in macroemulsions. Such
techniques are disclosed in Remington's Pharmaceutical Sciences,
supra.
[0247] The formulations to be used for in vivo administration must
be sterile. This is readily accomplished by filtration through
sterile filtration membranes.
[0248] Sustained-release preparations may be prepared. Suitable
examples of sustained-release preparations include semipermeable
matrices of solid hydrophobic polymers containing the antibody,
which matrices are in the form of shaped articles, e.g., films, or
microcapsules. Examples of sustained-release matrices include
polyesters, hydrogels (for example,
poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)),
polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic
acid .gamma.-ethyl-L-glutamate, non-degradable
ethylene-vinylacetate, degradable lactic acid-glycolic acid
copolymers such as the LUPRON DEPOT.TM. (injectable microspheres
composed of lactic acid-glycolic acid copolymer and leuprolide
acetate), and poly-D-(-).sub.3-hydroxylbutyric acid. While polymers
such as ethylene-vinyl acetate and lactic acid-glycolic acid enable
release of molecules for over 100 days, certain hydrogels release
proteins for shorter time periods. When encapsulated antibodies
remain in the body for a long time, they may denature or aggregate
as a result of exposure to moisture at 37.degree. C., resulting in
a loss of biological activity and possible changes in
immunogenicity. Rational strategies can be devised for
stabilization depending on the mechanisms involved. For example, if
the aggregation mechanism is discovered to be intermolecular S--S
bond formation through thiosulfide interchange, stabilization may
be achieved by modifying sulfhydryl residues, lyophilizing from
acidic solutions, controlling moisture content, using appropriate
additives, and developing specific polymer matrix compositions.
[0249] G. Uses for Anti-PRO1031 and Anti-PRO1122 Antibodies
[0250] The anti-PRO1031 and anti-PRO1122 antibodies of the present
invention have various utilities. For example, anti-PRO1031 or
anti-PRO1122 antibodies may be used in diagnostic assays for
PRO1031 or PRO1122 polypeptides, e.g., detecting expression in
specific cells, tissues, or serum. Various diagnostic assay
techniques known in the art may be used, such as competitive
binding assays, direct or indirect sandwich assays and
immunoprecipitation assays conducted in either heterogeneous or
homogeneous phases [Zola, Monoclonal Antibodies. A Manual of
Techniques, CRC Press, Inc. (1987) pp. 147-158]. The antibodies
used in the assays can be labeled with a detectable moiety. The
detectable moiety should be capable of producing, either directly
or indirectly, a detectable signal. For example, the detectable
moiety may be a radioisotope, such as .sup.3H, .sup.14C, .sup.32P,
.sup.35S, or .sup.125I, a fluorescent or chemiluminescent compound,
such as fluorescein isothiocyanate, rhodamine, or luciferin, or an
enzyme, such as alkaline phosphatase, beta-galactosidase or
horseradish peroxidase. Any method known in the art for conjugating
the antibody to the detectable moiety may be employed, including
those methods described by Hunter et al., Nature, 144:945 (1962);
David et al., Biochemistry, 13:1014 (1974); Pain et al., J.
Immunol. Meth., 40:219 (1981); and Nygren, J. Histochem. and
Cylochem., 30:407 (1982).
[0251] Anti-PRO1031 or anti-PRO1122 antibodies also are useful for
the affinity purification of PRO1031 or PRO1122 polypeptides,
respectively, from recombinant cell culture or natural sources. In
this process, the antibodies against a PRO1031 or PRO1122
polypeptide are immobilized on a suitable support, such a Sephadex
resin or filter paper, using methods well known in the art. The
immobilized antibody then is contacted with a sample containing the
PRO1031 or PRO1122 polypeptide to be purified, and thereafter the
support is washed with a suitable solvent that will remove
substantially all the material in the sample except the PRO1031 or
PRO1122 polypeptide, which is bound to the immobilized antibody.
Finally, the support is washed with another suitable solvent that
will release the PRO1031 or PRO1122 polypeptide from the
antibody.
[0252] H. PRO1031, PRO1122 and IL-17 Antagonists/Agonists
[0253] This invention encompasses methods of screening compounds to
identity those that mimic the PRO1031, PRO1122 or IL017 polypeptide
(agonists) or prevent the effect of the PRO1031, PRO1122 or IL-17
polypeptide (antagonists). Screening assays for antagonist drug
candidates are designed to identity compounds that bind or complex
with the PRO1031, PRO1122, IL-17 polypeptides encoded by the genes
identified herein, or otherwise interfere with the interaction of
the encoded polypeptides with other cellular proteins. Such
screening assays will include assays amenable to high-throughput
screening of chemical libraries, making them particularly suitable
for identifying small molecule drug candidates.
[0254] The assays can be performed in a variety of formats,
including protein-protein binding assays, biochemical screening
assays, immunoassays, and cell-based assays, which are well
characterized in the art. For example, to screen for antagonists
and/or agonists of PRO1031, PRO1122, IL-17 signaling, the assay
mixture is incubated under conditions whereby, but for the presence
of the candidate pharmacological agent, PRO1031, PRO1122 or IL-17
induces TNF-.alpha. release from THP-1 cells with a reference
activity. Alternatively, the tested activity can be the release of
nitric oxide (NO) and proteoglycans from IL17 and/or IL-1.alpha.
treated articular cartilage.
[0255] In binding assays, the interaction is binding and the
complex formed can be isolated or detected in the reaction mixture.
In a particular embodiment, the PRO1031, PRO1122 or IL-17
polypeptide encoded by the gene identified herein or the drug
candidate is immobilized on a solid phase, e.g., on a microtiter
plate, by covalent or non-covalent attachments. Non-covalent
attachment generally is accomplished by coating the solid surface
with a solution of the PRO1031, PRO1122 or IL-17 polypeptide and
drying. Alternatively, an immobilized antibody, e.g., a monoclonal
antibody, specific for the PRO1031, PRO1122 or IL-17 polypeptide to
be immobilized can be used to anchor it to solid surface. The assay
is performed by adding the non-immobilized component, which may be
labeled by a detectable label, to the immobilized component, which
may be labeled by a detectable label, to the immobilized component,
e.g., the coated surface containing the anchored component. When
the reaction is complete, the non-reacted components are removed,
e.g., by washing, and complexes anchored on the solid surface are
detected. When the originally non-immobilized component carries a
detectable label, the detection of label immobilized on the surface
indicates that complexing occurred. Where the originally
non-immobilized component does not carry a label, complexing can be
detected, for example, by using a labeled antibody specifically
binding the immobilized complex.
[0256] It the candidate compound interacts with but does not bind
to a particular PRO1031, PRO1132 or IL-17 polypeptide encoded by a
gene identified herein, its interaction with that polypeptide can
be assayed by methods well known for detecting protein-protein
interactions. Such assays include traditional approaches, such as,
e.g., cross-linking, co-immunoprecipitation, and co-purification
through gradients or chromatographic columns. In addition,
protein-protein interactions can be monitored through gradients or
chromatographic columns. In addition, protein-protein interactions
can be monitored by using a yeast-based genetic system described by
Fields and co-workers (Fields and Song, Nature 340: 245-246 (1989);
Chien et al., Proc. Natl. Acad. Sci. USA 88: 9578-9582 (1991) as
disclosed by Chevray and Nathans, Proc. Natl. Acad. Sci. USA 89:
5789-5791 (1991). Many transcriptional activators, such as yeast
GAL4, consist of two physically discrete modular domains, one
acting as the DNA-binding domain, while the other functions as the
transcription-activation domain. The yeast expression system
described in the foregoing publications (generally referred to as
the "two-hybrid system") takes advantage of this property, and
employs two hybrid proteins, one in which the target protein is
fused to the DNA-binding domain of GAL4, and another, in which
candidate activating proteins are fused to the activation domain.
The expression of GAL1-lacZ reporter gene under control of a
GAL4-activated promoter depends on reconstitution of GAL4 activity
via protein-protein interaction. Colonies containing interacting
polypeptide are detected with chromogenic substrate for
.beta.-galactosidase. A complete kit (MATCHMAKER.TM.) for
identifying protein-protein interactions between two specific
proteins using the two-hybrid technique is commercially available
from Clontech. This system can also be extended to map protein
domains involved in specific protein interactions as well as to
pinpoint amino acid residues that are crucial for these
interactions.
[0257] Compounds that interfere with the interaction of a gene
encoding a PRO1031, PRO1122 or IL-17 polypeptide identified herein
and other intra- or extracellular components can be tested as
follows: usually a reaction mixture is prepared containing the
product of the gene and the intra- or extracellular component under
conditions and for a time allowing for the interaction and binding
of the two products. To test the ability of a candidate compound to
inhibit binding, the reaction is run in the absence and in the
presence of the test compound. In addition, a placebo may be added
to a third reaction mixture, to serve as a positive control. The
binding (complex formation) between the test compound and the
intra- or extracellular component present in the mixture is
monitored as described hereinabove. The formation of a complex in
the control reaction(s) but not in the reaction mixture containing
the test compound indicates that the test compound interferes with
the interaction of the test compound and its reaction partner.
[0258] Antagonists may be detected by combining the PRO1031,
PRO1122 or IL-17 polypeptide and a potential antagonist with
membrane-bound PRO1031, PRO1122 or IL-17 polypeptide receptors or
recombinant receptors under appropriate conditions for a
competitive inhibition assay. The PRO1031, PRO1122 or IL-17
polypeptide can be labeled, such as by radioactivity, such that the
number of PRO1031, PRO1122 or IL-17 polypeptide molecules bound to
the receptor can be used to determine the effectiveness of the
potential antagonist. The gene encoding the receptor can be
identified by numerous methods known to those of skill in the art,
for example, ligand panning and FACS sorting. Coligan et al.,
Current Protocols in Immun. 1(2): Ch. 5 (1991). Preferably,
expression cloning is employed wherein polyadenylated RNA is
prepared from a cell responsive to the PRO1031 or PRO1122
polypeptide and a cDNA library created from this RNA is divided
into pools and used to transfect COS cells or other cells that are
not responsive to the PRO1031, PRO1122 or IL-17 polypeptide,
respectively. Transfected cells that are grown on glass slides are
exposed to labeled PRO1031, PRO1122 or IL-17 polypeptide. The
PRO1031, PRO1122 or IL-17 polypeptide can be labeled by a variety
of means including iodination or inclusion of a recognition site
for a site-specific protein kinase. Following fixation and
incubation, the slides are subjected to autoradiographic analysis.
Positive pools are identified and sub-pools are prepared and
re-transfected using an interactive sub-pooling and re-screening
process, eventually yielding a single clone that encodes the
putative receptor.
[0259] As an alternative approach for receptor identification,
labeled PRO1031, PRO1122 or IL-17 polypeptide can be
photoaffinity-linked with cell membrane or extract preparations
that express the receptor molecule. Cross-linked material is
resolved by PAGE and exposed to X-ray film. The labeled complex
containing containing the receptor can be excised, resolved into
peptide fragments, and subjected to protein micro-sequencing. The
amino acid sequence obtained from micro-sequencing would be used to
design a set of degenerate oligonucleotide probes to screen a cDNA
library to identity the gene encoding the putative receptor.
[0260] In another assay for antagonists, mammalian cells or a
membrane preparation expressing the receptor would be incubated
with labeled PRO1031, PRO1122 or IL-17 polypeptide in the presence
of the candidate compound. The ability of the compound to enhance
or block this interaction could then be removed.
[0261] More specific examples of potential antagonists include an
oligonucleotide that binds to the fusions of immunoglobulin with
PRO1031, PRO1122 or IL-17 polypeptide, and, in particular,
antibodies including, without limitation, poly- and monoclonal
antibodies and antibody fragments, single-chain antibodies,
anti-idiotypic antibodies, and chimeric or humanized versions of
such antibodies or fragments, as well as human antibodies and
antibody fragments. Alternatively, a potential antagonist may be a
closely related protein, for example, a mutated form of the
PRO1031, PRO1122 or IL-17 polypeptide that recognizes the receptor
but impart no effect, thereby competitively inhibiting the action
of the PRO1031, PRO1122 or IL-17 polypeptide.
[0262] Another potential PRO1031, PRO1122 or IL-17 polypeptide
antagonist is an antisense RNA or DNA construct prepared using
antisense technology, where, e.g., an antisense RNA or DNA molecule
acts to block directly the translation of mRNA by hybridizing to
targeted mRNA and preventing its translation into protein.
Antisense technology can be used to control gene expression through
triple-helix formation or antisense DNA or RNA, both of which
methods are based on binding of a polynucleotide to DNA or RNA. For
example, the 5' coding portion of the polynucleotide sequence,
which encodes the mature PRO1031, PRO1122 or IL-17 polypeptides
herein, is used to design an antisense RNA oligonucleotide
sequence, which encodes the mature PRO1031, PRO1122 or IL-17
polypeptides herein, is used to design an antisense RNA
oligonucleotide of about 10 to 40 base pairs in length. A DNA
oligonucleotide is designed to be complementary to a region of the
gene involved in transcription (triple helix--see Lee et al., Nucl.
Acids Res. 6: 3073 (1979); Cooney et al., Science 241: 456 (1988);
Dervan et al., Science 251: 1360 (1991)), thereby preventing
transcription and the production of the PRO1031 or PRO1122
polypeptide. The antisense RNA oligonucleotide hybridizes to the
mRNA in vivo and blocks translation of the mRNA molecule into the
PRO1031, PRO1122 or IL-17 polypeptide (antisense-Okano, Neurochem.
546: 560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of
Gene Expression (CRC Press: Boca Raton, Fla., 1988). The
oligonucleotides described above can also be delivered to cells
such that the antisense RNA or DNA may be expressed in vivo to
inhibit production of the PRO1031, PRO1122, IL-17 polypeptide. When
antisense DNA is used, oligodeoxyribonucleotides derived from the
translation-initiation site, e.g., between about -10 and +10
positions of the target gene nucleotide sequence, are
preferred.
[0263] Potential antagonists include small molecules that bind to
the active site, the receptor binding site, or growth factor or
other relevant binding site of the PRO1031 or PRO1122 polypeptide,
thereby blocking the normal biological activity of the PRO1031,
PRO1122 or IL-17 polypeptide. Examples of small molecules include,
but are not limited to, small peptides or peptide-like molecules,
preferably soluble peptides, and synthetic non-peptidyl organic or
inorganic compounds.
[0264] Ribozymes are enzymatic RNA molecules capable of catalyzing
the specific cleavage of RNA. Ribozymes act by sequence-specific
hybridization to the complementary target RNA, followed by
endonuclytic cleavage. Specific ribozyme cleavage sites within a
potential RNA target can be identified by known techniques. For
further details, see e.g., Rossi, Current Biology 4: 469-471 (1994)
and PCT publication No. WO 97/33551 (published Sep. 18, 1997).
[0265] Nucleic acid molecules in triple-helix formation used to
inhibit transcription should be single-stranded and composed of
deoxynucleotides. The base composition of these oligonucleotides is
designed such that it promotes triple-helix formation via Hoogsteen
base-pairing rules, which generally require sizeable stretches of
purines or pyrimidines on one strand of a duplex. For further
details see, e.g., PCR publication No. WO 97/33551, supra.
[0266] I. Diagnostic Uses
[0267] Another use of the compounds of the invention (e.g.,
PRO1031- or PRO1122-variants and anti-PRO1031 or anti-PRO1122
antibodies) described herein is to help diagnose whether a disorder
is driven, to some extent, by PRO1031 or PRO1122 modulated
signaling.
[0268] A diagnostic assay to determine whether a particular
disorder (e.g., degenerative cartilaginous disorder) is driven by
PRO1031 or PRO1122 signaling, can be carried out using the
following steps: (1) culturing test cells or tissues expressing
PRO1031 or PRO1122; (2) administering a compound which can inhibit
PRO1031 or PRO1122 modulated signaling; and (3) measuring the
PRO1031 or PRO1122 mediated phenotypic effects in the test cells.
The steps can be carried out using standard techniques in light of
the present disclosure. For example, standard techniques can be
used to isolate cells or tissues and culturing or in vivo.
[0269] Compounds of varying degree of selectivity are useful for
diagnosing the role of PRO1031 or PRO1122. For example, compounds
which PRO1031 or PRO1122 in addition to another form of adaptor
molecule can be used as an initial test compound to determine if
one of several adaptor molecules drive the disorder. The selective
compounds can then be used to further eliminate the possible role
of the other adaptor proteins in driving the disorder. Test
compounds should be more potent in inhibiting intracellular
signaling activity than in exerting a cytotoxic effect (e.g., an
IC.sub.50/LD.sub.50 of greater than one). The IC.sub.50 and
LD.sub.50 can be measured by standard techniques, such as an MTT
assay, or by measuring the amount of LDH released. The degree of
IC.sub.50/LD.sub.50 of a compound should be taken into account in
evaluating the diagnostic assay. Generally, the larger the ratio
the more relative the information. Appropriate controls take into
account the possible cytotoxic effect of a compound of a compound,
such as treating cells not associated with a cell proliferative
disorder (e.g., control cells) with a test compound, can also be
used as part of the diagnostic assay. The diagnostic methods of the
invention involve the screening for agents that modulate the
effects of PRO1031 or PRO1122 upon degenerative cartilagenous
disorders. Exemplary detection techniques include radioactive
labeling and immunoprecipitating (U.S. Pat. No. 5,385,915).
[0270] For example, antibodies, including antibody fragments, can
be used to qualitatively or quantitatively detect the expression of
proteins encoded by the disease-related genes (Amarker gene
products@). The antibody preferably is equipped with a detectable,
e.g. fluorescent label, and binding can be monitored by light
microscopy, flow cytometry, fluorimetry, or other techniques known
in the art.
[0271] In situ detection of antibody binding to the marker gene
products can be performed, for example, by immunofluorescence or
immunoelectron microscopy. For this purpose, a histological
specimen is removed from the patient, and a labeled antibody is
applied to it, preferably by overlaying the antibody on a
biological sample. This procedure also allows for determining the
distribution of the marker gene product in the tissue examined. It
will be apparent for those skilled in the art that a wide variety
of histological methods are readily available for in situ
detection.
[0272] J. Pharmaceutical Compositions
[0273] The PRO1031 or PRO1122, antagonists or agonists thereof
(e.g., antibodies), as well as other molecules identified by the
screening assays disclosed hereinbefore, can be employed as
therapeutic agents. Such therapeutic agents are formulated
according to known methods to prepare pharmaceutically useful
compositions, whereby the PRO1031 or PRO1122, antagonist or agonist
thereof is combined in admixture with a pharmaceutically acceptable
carrier.
[0274] In the case of PRO1031 or PRO1122 antagonist or agonist
antibodies, if the protein encoded by the amplified gene is
intracellular and whole antibodies are used as inhibitors,
internalizing antibodies are preferred. However, lipofections or
liposomes can also be used to deliver the antibody, or an antibody
fragment, into cells. Where antibody fragments are used, the
smallest inhibitory fragment which specifically binds to the
binding domain of the target protein is preferred. For example,
based upon the variable region sequences of an antibody, peptide
molecules can be designed which retain the ability to bind the
target protein sequence. Such peptides can be synthesized
chemically and/or produced by recombinant DNA technology (see, e.g.
Marasco et al., Proc. Natl. Acad. Sci. USA 90: 7889-7893
[1993]).
[0275] Therapeutic formulations are prepared for storage by mixing
the active ingredient having the desired degree of purity with
optional pharmaceutically acceptable carriers, excipients or
stabilizers (Remington's Pharmaceutical Sciences 16th edition,
Osol, A. Ed. [1980]), in the form of lyophilized formulations or
aqueous solutions. Acceptable carriers, excipients, or stabilizers
are nontoxic to recipients at the dosages and concentrations
employed, and include buffers such as phosphate, citrate, and other
organic acids; antioxidants including ascorbic acid and methionine;
preservatives (such as octadecyldimethylbenzyl ammonium chloride;
hexamethonium chloride; benzalkonium chloride, benzethonium
chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as
methyl or propyl paraben; catechol; resorcinol; cyclohexanol;
3-pentanol; and m-cresol); low molecular weight (less than about 10
residues) polypeptides; proteins, such as serum albumin, gelatin,
or immunoglobulins; hydrophilic polymers such as
polyvinylpyrrolidone; amino acids such as glycine, glutamine,
asparagine, histidine, arginine, or lysine; monosaccharides,
disaccharides, and other carbohydrates including glucose, mannose,
or dextrins; chelating agents such as EDTA; sugars such as sucrose,
mannitol, trehalose or sorbitol; salt-forming counter-ions such as
sodium; metal complexes (e.g. Zn-protein complexes); and/or
non-ionic surfactants such as TWEEN.TM., PLURONICS.TM. or
polyethylene glycol (PEG).
[0276] The formulation herein may also contain more than one active
compound as necessary for the particular indication being treated,
preferably those with complementary activities that do not
adversely affect each other. Alternatively, or in addition, the
composition may comprise a cytotoxic agent, cytokine or growth
inhibitory agent. Such molecules are suitably present in
combination in amounts that are effective for the purpose
intended.
[0277] The active ingredients may also be entrapped in
microcapsules prepared, for example, by coacervation techniques or
by interfacial polymerization, for example, hydroxymethylcellulose
or gelatin-microcapsules and poly-(methylmethacylate)
microcapsules, respectively, in colloidal drug delivery systems
(for example, liposomes, albumin microspheres, microemulsions,
nano-particles and nanocapsules) or in macroemulsions. Such
techniques are disclosed in Remington's Pharmaceutical Sciences
16th edition, Osol, A. Ed. (1980).
[0278] The formulations to be used for in vivo administration must
be sterile. This is readily accomplished by filtration through
sterile filtration membranes.
[0279] Therapeutic compositions herein generally are placed into a
container having a sterile access port, for example, and
intravenous solution bag or vial having a stopper pierceable by a
hypodermic injection needle.
[0280] Sustained-release preparations may be prepared. Suitable
examples of sustained-release preparations include semipermeable
matrices of solid hydrophobic polymers containing the antibody,
which matrices are in the form of shaped articles, e.g. films, or
microcapsules. Examples of sustained-release matrices include
polyesters, hydrogels (for example,
poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)),
polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic
acid and .gamma.-ethyl-L-glutamate, non-degradable ethylene-vinyl
acetate, degradable lactic acid-glycolic acid copolymers such as
the LUPRON DEPOT.TM. (injectable microspheres composed of lactic
acid-glycolic acid copolymer and leuprolide acetate), and
poly-D-(-)-3-hydroxybutyric acid. Microencapsulation of recombinant
proteins for sustained release has been successfully performed with
human growth hormone (rhGH), interferon-(rhlFN-), interleukin-2,
and MN rpg 120. Johnson et al., Nat. Med. 2: 795-799 (1996); Yasuda
et al., Biomed. Ther. 27: 1221-1223 (1993); Hora et al.,
Bio/Technology 8: 755-758 (1990); Cleland, "Design and Production
of Single Immunization Vaccines Using Polylactide Polyglycolide
Microsphere Systems," in Vaccine Design: The Subunit and Adjuvant
Approach, Powell and Newman, eds., (Penum Press: New York, 1995),
pp. 439-462; WO 97/03692; WO 96/40072; WO 96/07399; and U.S. Pat.
No. 5,654,010.
[0281] The sustained-release formulations of these proteins may be
developed using poly lactic-coglycolic acid (PLGA) polymer due to
its biocompatibility and wide range of biodegradable properties.
The degradation products of PLGA, lactic and glycolic acids, can be
cleared quickly within the human body. Moreover, the degradability
of this polymer can be adjusted from months to years depending on
its molecular weight and composition. Lewis, "Controlled release of
bioactive agents from lactide/glycolide polymer", in Biodegradable
Polymers as Drug Delivery Systems (Marcel Dekker; New York, 1990),
M. Chasin and R. Langer (Eds.) pp. 1-41.
[0282] While polymers such as ethylene-vinyl acetate and lactic
acid-glycolic acid enable release of molecules for over 100 days,
certain hydrogels release proteins for shorter time periods. When
encapsulated antibodies remain in the body for a long time, they
may denature or aggregate as a result of exposure to moisture at
37.degree. C., resulting in a loss of biological activity and
possible changes in immunogenicity. Rational strategies can be
devised for stabilization depending on the mechanism involved. For
example, if the aggregation mechanism is discovered to be
intermolecular S--S bond formation through thio-disulfide
interchange, stabilization may be achieved by modifying sulfhydryl
residues, lyophilizing from acidic solutions, controlling moisture
content, using appropriate additives, and developing specific
polymer matrix compositions.
[0283] K. Methods of Treatment
[0284] It is contemplated that the compounds of the present
invention may be used to treat various conditions, including those
characterized by overexpression and/or activation of the
disease-associated genes identified herein. Exemplary conditions or
disorders to be treated with such antibodies and other compounds,
including, but not limited to, small organic and inorganic
molecules, peptides, antisense molecules, etc. include inflammatory
and immunologic disorders, especially those characterized by
cartilage matrix breakdown such as arthritis, (e.g.,
osteoarthritis, psoriatic arthritis, rheumatoid arthritis) or other
degenerative inflammatory diseases.
[0285] The active agents of the present invention, e.g. antibodies,
are administered to a mammal, preferably a human, in accord with
known methods, such as intravenous administration as a bolus or by
continuous infusion over a period of time, by intramuscular,
intraperitoneal, intracerebral, intracerobrospinal, subcutaneous,
intra-articular, intrasynovial, intrathecal, intraoccular,
intralesional, oral, topical, inhalation or through sustained
release.
[0286] Other therapeutic regimens may be combined with the
administration of the PRO1031, PRO1122, antagonists or antagonists,
anti-cancer agents, e.g. antibodies of the instant invention.
[0287] For the prevention or treatment of disease, the appropriate
dosage of an active agent, (e.g. an antibody) will depend on the
type of disease to be treated, as defined above, the severity and
course of the disease, whether the agent is administered for
preventive or therapeutic purposes, previous therapy, the patient's
clinical history and response to the agent, and the discretion of
the attending physician. The agent is suitably administered to the
patient at one time or over a series of treatments.
[0288] Dosages and desired drug concentration of pharmaceutical
compositions of the present invention may vary depending on the
particular use envisioned. The determination of the appropriate
dosage or route of administration is well within the skill of an
ordinary artisan. Animal experiments provide reliable guidance for
the determination of effective does for human therapy. Interspecies
scaling of effective doses can be performed following the
principles laid down by Mordenti, J. and Chappell, W. "The Use of
Interspecies Scaling in Toxicokinetics," In Toxicokinetics and New
Drug Development, Yacobi et al., Eds, Pergamon Press, New York
1989, pp. 42-46.
[0289] When in vivo administration of a PRO1031 or PRO1122
polypeptide or agonist or antagonist thereof is employed, normal
dosage amounts may vary from about 10 .mu.g/kg up to 100 mg/kg of
mammal body weight or more per day, preferably about 1 .mu.g/kg/day
up to 100 mg/kg of mammal body weight or more pre day, depending
upon the route of administration. Guidance as to particular dosages
and methods of delivery is provided in the literature; see, for
example, U.S. Pat. Nos. 4,657,760, 5,206,344 or 5,255,212. It is
within the scope of the invention that different formulations will
be effective for different treatment compounds and different
disorders, that administration targeting one organ or tissue, for
example, may necessitate delivery in a manner different from that
to another organ or tissue. Moreover, dosages may be administered
by one or more separate administrations, or by continuous infusion.
For repeated administrations over several days or longer, depending
on the condition, the treatment is sustained until a desired
suppression of disease symptoms occurs. However, other dosage
regimens may be useful. The progress of this therapy is easily
monitored by conventional techniques and assays.
[0290] L. Articles of Manufacture
[0291] In another embodiment of the invention, an article of
manufacture containing materials useful for the diagnosis or
treatment of the disorders described above is provided. The article
of manufacture comprises a container and a label. Suitable
containers include, for example, bottles, vials, syringes, and test
tubes. The containers may be formed from a variety of materials
such as glass or plastic. The container holds a composition which
is effective for diagnosing or treating the condition and may have
a sterile access port (for example the container may be an
intravenous solution bag or a vial having a stopper pierceable by a
hypodermic injection needle). The active agent in the composition
is typically a PRO1031, PRO1122 polypeptide, antagonist, or agonist
thereof. The label on, or associated with, the container indicates
that the composition is used for diagnosing or treating the
condition of choice. The article of manufacture may further
comprise a second container comprising a
pharmaceutically-acceptable buffer, such as phosphate-buffered
saline, Ringer's solution and dextrose solution. It may further
include other materials desirable from a commercial and user
standpoint, including other buffers, diluents, filters, needles,
syringes, and package inserts with instructions for use.
[0292] The following examples are offered for illustrative purposes
only, and are not intended to limit the scope of the present
invention in any way.
[0293] All patent and literature references cited in the present
specification are hereby incorporated by reference in their
entirety.
EXAMPLES
[0294] Commercially available reagents referred to in the examples
were used according to manufacturer's instructions unless otherwise
indicated. The source of those cells identified in the following
examples, and throughout the specification, by ATCC accession
numbers is the American Type Culture Collection, Rockville, Md.
Example 1
Isolation of cDNA Clones Encoding Human PRO1031
[0295] The extracellular domain (ECD) sequences (including the
secretion signal, if any) of from about 950 known secreted proteins
from the Swiss-Prot public protein database were used to search
expressed sequence tag (EST) databases. The EST databases included
public EST databases (e.g., GenBank, Merck/Wash U.) and a
proprietary EST DNA database (LIFESEQ.RTM., Incyte Pharmaceuticals,
Palo Alto, Calif.). The search was performed using the computer
program BLAST or BLAST2 (Altshul et al., Methods in Enzymology
266:460-480 (1996)) as a comparison of the ECD protein sequences to
a 6 frame translation of the EST sequence. Those comparisons
resulting in a BLAST score of 70 (or in some cases 90) or greater
that did not encode known proteins were clustered and assembled
into consensus DNA sequences with the program "phrap" (Phil Green,
University of Washington, Seattle, Wash.).
[0296] An initial virtual sequence fragment (consensus assembly)
was assembled relative to other EST sequences using phrap. The
initial consensus DNA sequence was extended using repeated cycles
of BLAST and phrap to extend the consensus sequence as far as
possible using the sources of EST sequences discussed above. The
results of this assembly is shown in FIG. 5 (SEQ ID NO:5), also
referred to as DNA47332.
[0297] One sequence comprising the consensus assembly, W74558
(clone 344649) (SEQ ID NO:6) was further examined. The sequence was
obtained from the IMAGE consortium and analyzed. Lennon et al.,
Genomics 33: 151 (1996). DNA sequencing gave the full-length DNA
sequence for PRO1031 [herein designated as DNA59294-1381] (SEQ ID
NO:2) and the derived PRO1031 protein sequence (UNQ516) (SEQ ID
NO:1).
[0298] The entire nucleotide sequence of DNA59294-1381 is shown in
FIG. 2 (SEQ ID NO:2). Clone DNA59294-1381 contains a single open
reading frame with an apparent translational initiation site at
nucleotide positions 42-44 and ending at the stop codon at
nucleotide positions 582-584 (FIG. 2) (SEQ ID NO:2). The predicted
polypeptide precursor is 180 amino acids long (FIG. 1) (SEQ ID
NO:1). The full-length PRO1031 (UNQ516) protein shown in FIG. 2
(SEQ ID NO:1) has an estimated molecular weight of about 20437 and
a pI of about 9.58. Clone DNA59294-1381 (SEQ ID NO:2) has been
deposited with the ATCC, and have been assigned deposit number
209866. In the event of any sequencing irregularities or errors
with the sequences provided herein, it is understood that the
deposited clone contains the correct sequence for DNA59624 (SEQ ID
NO:2). Furthermore, the sequences provided herein are the result of
known sequencing techniques.
[0299] Analysis of the amino acid sequence of the full-length
PRO1031 polypeptide (UNQ516) (SEQ ID NO:1) suggests that it is a
novel cytokine.
[0300] Further analysis of the amino acid sequence of SEQ ID NO:2
reveals that the putative signal peptide is at about amino acids
1-20 of SEQ ID NO:2. An N-glycosylation site is at about amino
acids 75-78 of SEQ ID NO:2. A region having sequence identity with
IL-17 is at about amino acids 96-180. The corresponding nucleotides
can be routinely determined given the sequences provided
herein.
Example 2
Isolation of cDNA Clones Encoding Human PRO1122
[0301] An expressed sequence tag (EST) DNA database (LIFESEQ.RTM.,
Incyte Pharmaceuticals, Palo Alto, Calif.) was searched and an EST
was identified. The EST was Incyte 1347523 (SEQ ID NO:7) also
called DNA49665. Based on DNA49665 (SEQ ID NO:7), oligonucleotides
were synthesized: 1) to identify by PCR a cDNA library that
contained the sequence of interest, and 2) for use as probes to
isolated a clone of the full-length coding sequence for the
PRO1122. [e.g., Sambrook et al., Molecular Cloning. A Laboratory
Manual (New York: Cold Spring Harbor Laboratory Press, 1989);
Dieffenbach et al., PCR Primer: A Laboratory Manual (Cold Spring
Harbor Laboratory Press, 1995)].
[0302] Forward and reverse PCR primers generally range from 20 to
30 nucleotides and are often designed to give a PCR product of
about 100-1000 bp in length. The probes sequences are typically
40-55 bp in length. In some cases, additional oligonucleotides are
synthesized when the consensus sequence is greater than about 1-1.5
kpb. In order to screen several libraries for a full-length clone,
DNA from the libraries was screened by PCR amplification, as per
Ausuble et al., Current Protocols in Molecular Biology, with the
PCR primer pair. A positive library was then used to isolate clones
encoding the gene of interest using the probe oligonucleotide and
one of the primer pairs.
[0303] PCR primers (forward, reverse and hybridization) were
synthesized: TABLE-US-00002 forward PCR primer:
5'-ATCCACAGAAGCTGGCCTTCGCCG-3' (SEQ ID NO:8) reverse PCR primer:
5'-GGGACGTGGATGAACTCGGTGTGG-3' (SEQ ID NO:9)
[0304] hybridization probe: TABLE-US-00003 (SEQ ID NO:10)
5'-TATCCACAGAAGCTGGCCTTCGCCGAGTGCCTGTGCAGAG-3'.
[0305] In order to screen several libraries for a source of a
full-length clone, DNA from the libraries was screened by PCR
amplification with the PCR primer pair identified above. A positive
library was then used to isolate clones encoding the PRO1122 gene
using the probe oligonucleotide and one of the PCR primers.
[0306] RNA for construction of the cDNA libraries was isolated from
human fetal kidney tissue. The cDNA libraries used to isolate the
cDNA clones were constructed using standard methods using
commercially available reagents such as those from Invitrogen, San
Diego, Calif. The cDNA was primed with oligo dT containing a NotI
site, linked with blunt to SalI hemikinased adaptors, cleaved with
NotI, sized appropriately by gel electrophoresis, and cloned in a
defined orientation into a suitable cloning vector (such as pRKB or
pRKD; pRK5B is a precursor of pRK5D that does not contain the SfiI
site; see, Holmes et al., Science 235: 1278-1280 (1991)) in the
unique XhoI and NotI sites.
[0307] DNA sequencing of the clones isolated as described above
gave the full-length DNA sequence for PRO1122 [herein designated as
DNA62377-1381-1] (SEQ ID NO:4) and the derived protein PRO1122
sequence (UNQ561) (SEQ ID NO:3).
[0308] The entire nucleotide sequence of DNA62377-1381-1 (SEQ ID
NO:4) is shown in FIGS. 4A-4B (SEQ ID NO:4). Clone DNA62377-1381-1
(SEQ ID NO:4) contains a single open reading frame with an apparent
translational initiation site at nucleotide positions 50-52 and
ending at the stop codon at nucleotide positions 641-643 of SEQ ID
NO:4 (FIGS. 4A-4B). The predicted polypeptide precursor is 197
amino acids long (FIG. 3) (SEQ ID NO:3). The full-length PRO1122
protein shown in FIG. 3 (UNQ561) (SEQ ID NO:3) has an estimated
molecular weight of about 21765 daltons and a pI of about 8.53.
Clone DNA62377-1381-1 has been deposited with the ATCC on Dec. 22,
1998 and has been assigned deposit number 203552. It is understood
that in the event or a sequencing irregularity or error in the
sequences provided herein, the correct sequence is the sequence
deposited. Futhermore, all sequences provided herein are the result
of known sequencing techniques.
[0309] Analysis of the amino acid sequence of the isolated
full-length PRO1122 (UNQ561) suggests that it possesses similarity
with IL-17, thereby indicating that PRO1122 (UNQ561) may be a novel
cytokine. FIG. 3 (SEQ ID NO:3) also shows the approximate locations
of the signal peptide, leucine zipper pattern, and a region having
sequence identity with IL-17. The corresponding nucleotides can be
routinely determined, e.g., by reference to FIGS. 4A-4B.
Example 3
Use of PRO1031- or PRO1122-Encoding DNA as a Hybridization
Probe
[0310] The following method describes use of a nucleotide sequence
encoding PRO1031 as a hybridization probe.
[0311] DNA comprising the coding sequence of full-length PRO1031
(as shown in FIG. 2, SEQ ID NO:2), PRO1122 (as shown in FIG. 4, SEQ
ID NO:4) or a fragment thereof is employed as a probe to screen for
homologous DNAs (such as those encoding naturally-occurring
variants of PRO1031 or PRO1122 in human tissue cDNA libraries or
human tissue genomic libraries.
[0312] Hybridization and washing of filters containing either
library DNAs is performed under the following high stringency
conditions. Hybridization of radiolabeled PRO1031 or PRO1122
polypeptide-derived probe to the filters is performed in a solution
of 50% formamide, 5.times.SSC, 0.1% SDS, 0.1% sodium pyrophosphate,
50 mM sodium phosphate, pH 6.8, 2.times. Denhardt's solution, and
10% dextran sulfate at 42.degree. C. for 20 hours. Washing of the
filters is performed in an aqueous solution of 0.1.times.SSC and
0.1% SDS at 42.degree. C.
[0313] DNAs having a desired sequence identity with the DNA
encoding full-length native sequence PRO1031 or PRO1122 polypeptide
can then be identified using standard techniques known in the
art.
Example 4
Expression of PRO1031 or PRO1122 Polypeptides in E. coli
[0314] This example illustrates the preparation of unglycosylated
forms of PRO1031 or PRO1122 polypeptides by recombinant expression
in E. coli.
[0315] The DNA sequence encoding the full-length PRO1031, PRO1122
or a fragment or variant thereof is initially amplified using
selected PCR primers. The primers should contain restriction enzyme
sites which correspond to the restriction enzyme sites on the
selected expression vector. A variety of expression vectors may be
employed. An example of a suitable vector is pBR322 (derived from
E. coli; see Bolivar et al., Gene, 2:95 (1977)) which contains
genes for ampicillin and tetracycline resistance. The vector is
digested with restriction enzyme and dephosphorylated. The PCR
amplified sequences are then ligated into the vector. The vector
will preferably include sequences which encode for an antibiotic
resistance gene, a trp promoter, a polyhis leader (including the
first six STII codons, polyhis sequence, and enterokinase cleavage
site), the PRO1031 or PRO1122 coding region, lambda transcriptional
terminator, and an argU gene.
[0316] The ligation mixture is then used to transform a selected E.
coli strain using the methods described in Sambrook et al., supra.
Transformants are identified by their ability to grow on LB plates
and antibiotic resistant colonies are then selected. Plasmid DNA
can be isolated and confirmed by restriction analysis and DNA
sequencing.
[0317] Selected clones can be grown overnight in liquid culture
medium such as LB broth supplemented with antibiotics. The
overnight culture may subsequently be used to inoculate a larger
scale culture. The cells are then grown to a desired optical
density, during which the expression promoter is turned on.
[0318] After culturing the cells for several more hours, the cells
can be harvested by centrifugation. The cell pellet obtained by the
centrifugation can be solubilized using various agents known in the
art, and the solubilized PRO1031 or PRO1122 polypeptide can then be
purified using a metal chelating column under conditions that allow
tight binding of the polypeptide.
Example 5
Expression of PRO1031 or PRO1122 Polypeptides in Mammalian
Cells
[0319] This example illustrates preparation of glycosylated forms
of PRO1031 or PRO1122 polypeptides by recombinant expression in
mammalian cells.
[0320] The vector, pRK5 (see EP 307,247, published Mar. 15, 1989),
is employed as the expression vector. Optionally, the PRO1031- or
PRO1122-encoding DNA is ligated into pRK5 with selected restriction
enzymes to allow insertion of the PRO1031- or PRO1122-encoding DNA
using ligation methods such as described in Sambrook et al., supra.
The resulting vector is called pRK5-PRO1031 or pRK5-PRO1122,
respectively.
[0321] In one embodiment, the selected host cells may be 293 cells.
Human 293 cells (ATCC CCL 1573) are grown to confluence in tissue
culture plates in medium such as DMEM supplemented with fetal calf
serum and optionally, nutrient components and/or antibiotics. About
10 .mu.g pRK5-PRO1031 or pRK5-PRO1122 DNA is mixed with about 1
.mu.g DNA encoding the VA RNA gene [Thimmappaya et al., Cell,
31:543 (1982)] and dissolved in 500 .mu.l of 1 mM Tris-HCl, 0.1 mM
EDTA, 0.227 M CaCl.sub.2. To this mixture is added, dropwise, 500
.mu.l of 50 mM HEPES (pH 7.35), 280 mM NaCl, 1.5 mM NaPO.sub.4, and
a precipitate is allowed to form for 10 minutes at 25.degree. C.
The precipitate is suspended and added to the 293 cells and allowed
to settle for about four hours at 37.degree. C. The culture medium
is aspirated off and 2 ml of 20% glycerol in PBS is added for 30
seconds. The 293 cells are then washed with serum free medium,
fresh medium is added and the cells are incubated for about 5
days.
[0322] Approximately 24 hours after the transfections, the culture
medium is removed and replaced with culture medium (alone) or
culture medium containing 200 .mu.Ci/ml .sup.35S-cysteine and 200
.mu.Ci/ml .sup.35S-methionine. After a 12 hour incubation, the
conditioned medium is collected, concentrated on a spin filter, and
loaded onto a 15% SDS gel. The processed gel may be dried and
exposed to film for a selected period of time to reveal the
presence of PRO1031 or PRO1122 polypeptide. The cultures containing
transfected cells may undergo further incubation (in serum free
medium) and the medium is tested in selected bioassays.
[0323] In an alternative technique, PRO1031- or PRO1122-encoding
DNA may be introduced into 293 cells transiently using the dextran
sulfate method described by Somparyrac et al., Proc. Nail. Acad.
Sci., 12:7575 (1981). 293 cells are grown to maximal density in a
spinner flask and 700 .mu.g pRK5-PRO1031 or pRK5-PRO1122 DNA is
added. The cells are first concentrated from the spinner flask by
centrifugation and washed with PBS. The DNA-dextran precipitate is
incubated on the cell pellet for four hours. The cells are treated
with 20% glycerol for 90 seconds, washed with tissue culture
medium, and re-introduced into the spinner flask containing tissue
culture medium, 5 .mu.g/ml bovine insulin and 0.1 .mu.g/ml bovine
transferrin. After about four days, the conditioned media is
centrifuged and filtered to remove cells and debris. The sample
containing expressed PRO1031 or PRO1122 polypeptide can then be
concentrated and purified by any selected method, such as dialysis
and/or column chromatography.
[0324] In another embodiment, PRO1031 or PRO1122 polypeptide can be
expressed in CHO cells. The pRK5-PRO1031 or pRK5-PRO1122 vector can
be transfected into CHO cells using known reagents such as
CaPO.sub.4 or DEAE-dextran. As described above, the cell cultures
can be incubated, and the medium replaced with culture medium
(alone) or medium containing a radiolabel such as
.sup.35S-methionine. After determining the presence of PRO1031 or
PRO1122 polypeptide, the culture medium may be replaced with serum
free medium. Preferably, the cultures are incubated for about 6
days, and then the conditioned medium is harvested. The medium
containing the expressed PRO1031 or PRO1122 polypeptide can then be
concentrated and purified by any selected method.
[0325] Epitope-tagged PRO1031 or PRO1122 polypeptide may also be
expressed in host CHO cells. The PRO1031- or PRO1122-encoding DNA
may be subcloned out of the pRK5 vector. The subclone insert can
undergo PCR to fuse in frame with a selected epitope tag such as a
poly-his tag into a Baculovirus expression vector. The poly-his
tagged PRO1031- or PRO1122-encoding DNA insert can then be
subcloned into a SV40 driven vector containing a selection marker
such as DHFR for selection of stable clones. Finally, the CHO cells
can be transfected (as described above) with the SV40 driven
vector. Labeling may be performed, as described above, to verify
expression. The culture medium containing the expressed poly-His
tagged PRO1031 or PRO1122 polypeptide can then be concentrated and
purified by any selected method, such as by Ni.sup.2+-chelate
affinity chromatography.
Example 6
Expression of a PRO1031 Polypeptide in Yeast
[0326] The following method describes recombinant expression of
PRO1031 or PRO1122 polypeptides in yeast.
[0327] First, yeast expression vectors are constructed for
intracellular production or secretion of PRO1031 or PRO1122
polypeptide from the ADH2/GAPDH promoter. DNA encoding the PRO1031
or PRO1122 polypeptide of interest, a selected signal peptide and
the promoter is inserted into suitable restriction enzyme sites in
the selected plasmid to direct intracellular expression of the
PRO1031 or PRO1122 polypeptide. For secretion, DNA encoding the
PRO1031 or PRO1122 polypeptide can be cloned into the selected
plasmid, together with DNA encoding the ADH2/GAPDH promoter, the
yeast alpha-factor secretory signal/leader sequence, and linker
sequences (if needed) for expression of the PRO1031 or PRO1122
polypeptide.
[0328] Yeast cells, such as yeast strain AB110, can then be
transformed with the expression plasmids described above and
cultured in selected fermentation media. The transformed yeast
supernatants can be analyzed by precipitation with 10%
trichloroacetic acid and separation by SDS-PAGE, followed by
staining of the gels with Coomassie Blue stain.
[0329] Recombinant PRO1031 or PRO1122 polypeptide can subsequently
be isolated and purified by removing the yeast cells from the
fermentation medium by centrifugation and then concentrating the
medium using selected cartridge filters. The concentrate containing
the PRO1031 or PRO1122 polypeptide may further be purified using
selected column chromatography resins.
Example 6
Expression of PRO1031 or PRO1122 Polypeptides in
Baculovirus-Infected Insect Cells
[0330] The following method describes recombinant expression of
PRO1031 or PRO1122 polypeptides in Baculovirus-infected insect
cells.
[0331] The PRO1031- or PRO1122-encoding DNA is fused upstream of an
epitope tag contained within a baculovirus expression vector. Such
epitope tags include poly-his tags and immunoglobulin tags (like Fc
regions of IgG). A variety of plasmids may be employed, including
plasmids derived from commercially available plasmids such as
pVL1393 (Novagen). Briefly, the PRO1031- or PRO1122-encoding DNA or
the desired portion of the PRO1031- or PRO1122-encoding DNA (such
as the sequence encoding the extracellular domain of a
transmembrane protein) is amplified by PCR with primers
complementary to the 5' and 3' regions. The 5' primer may
incorporate flanking (selected) restriction enzyme sites. The
product is then digested with those selected restriction enzymes
and subcloned into the expression vector.
[0332] Recombinant baculovirus is generated by co-transfecting the
above plasmid and BaculoGold.TM. virus DNA (Pharmingen) into
Spodoptera frugiperda ("Sf9") cells (ATCC CRL 1711) using
lipofectin (commercially available from GIBCO-BRL). After 4 to 5
days of incubation at 28.degree. C., the released viruses are
harvested and used for further amplifications. Viral infection and
protein expression is performed as described by O'Reilley et al.,
Baculovirus Expression vectors: A Laboratory Manual, Oxford:Oxford
University Press (1994).
[0333] Expressed poly-his tagged PRO1031 or PRO1122 polypeptide can
then be purified, for example, by Ni.sup.2+-chelate affinity
chromatography as follows. Extracts are prepared from recombinant
virus-infected Sf9 cells as described by Rupert et al., Nature,
362:175-179 (1993). Briefly, Sf9 cells are washed, resuspended in
sonication buffer (25 mL Hepes, pH 7.9; 12.5 mM MgCl.sub.2; 0.1 mM
EDTA; 10% Glycerol; 0.1% NP-40; 0.4 M KCl), and sonicated twice for
20 seconds on ice. The sonicates are cleared by centrifugation, and
the supernatant is diluted 50-fold in loading buffer (50 mM
phosphate, 300 mM NaCl, 10% Glycerol, pH 7.8) and filtered through
a 0.45 .mu.m filter. A Ni.sup.2+-NTA agarose column (commercially
available from Qiagen) is prepared with a bed volume of 5 mL,
washed with 25 mL of water and equilibrated with 25 mL of loading
buffer. The filtered cell extract is loaded onto the column at 0.5
mL per minute. The column is washed to baseline A.sub.280 with
loading buffer, at which point fraction collection is started.
Next, the column is washed with a secondary wash buffer (50 mM
phosphate; 300 mM NaCl, 10% Glycerol, pH 6.0), which elutes
nonspecifically bound protein. After reaching A.sub.280 baseline
again, the column is developed with a 0 to 500 mM Imidazole
gradient in the secondary wash buffer. One mL fractions are
collected and analyzed by SDS-PAGE and silver staining or western
blot with Ni.sup.2+-NTA-conjugated to alkaline phosphatase
(Qiagen). Fractions containing the eluted His.sub.10-tagged PRO1031
polypeptide are pooled and dialyzed against loading buffer.
[0334] Alternatively, purification of the IgG tagged (or Fc tagged)
PRO1031 polypeptide can be performed using known chromatography
techniques, including for instance, Protein A or protein G column
chromatography.
Example 7
Preparation of Antibodies that Bind PRO1031 or PRO1122
Polypeptides
[0335] This example illustrates the preparation of monoclonal
antibodies which can specifically bind to PRO1031 or PRO1122
polypeptides.
[0336] Techniques for producing the monoclonal antibodies are known
in the art and are described, for instance, in Goding, supra.
Immunogens that may be employed include purified PRO1031 or PRO1122
polypeptide, fusion proteins containing a PRO1031 or PRO1122
polypeptide, and cells expressing recombinant PRO1031 or PRO1122
polypeptide on the cell surface. Selection of the immunogen can be
made by the skilled artisan without undue experimentation.
[0337] Mice, such as Balb/c, are immunized with the PRO1031 or
PRO1122 immunogen emulsified in complete Freund's adjuvant and
injected subcutaneously or intraperitoneally in an amount from
1-100 micrograms. Alternatively, the immunogen is emulsified in
MPL-TDM adjuvant (Ribi Immunochemical Research, Hamilton, Mont.)
and injected into the animal's hind foot pads. The immunized mice
are then boosted 10 to 12 days later with additional immunogen
emulsified in the selected adjuvant. Thereafter, for several weeks,
the mice may also be boosted with additional immunization
injections. Serum samples may be periodically obtained from the
mice by retro-orbital bleeding for testing in ELISA assays to
detect anti-PRO1031 or anti-PRO1122 polypeptide antibodies.
[0338] After a suitable antibody titer has been detected, the
animals "positive" for antibodies can be injected with a final
intravenous injection of PRO1031 or PRO1122 polypeptide. Three to
four days later, the mice are sacrificed and the spleen cells are
harvested. The spleen cells are then fused (using 35% polyethylene
glycol) to a selected murine myeloma cell line such as P3X63AgU.1,
available from ATCC, No. CRL 1597. The fusions generate hybridoma
cells which can then be plated in 96 well tissue culture plates
containing HAT (hypoxanthine, aminopterin, and thymidine) medium to
inhibit proliferation of non-fused cells, myeloma hybrids, and
spleen cell hybrids.
[0339] The hybridoma cells will be screened in an ELISA for
reactivity against PRO1031 or PRO1122 polypeptide. Determination of
"positive" hybridoma cells secreting the desired monoclonal
antibodies against a PRO1031 or PRO1122 polypeptide is within the
skill in the art.
[0340] The positive hybridoma cells can be injected
intraperitoneally into syngeneic Balb/c mice to produce ascites
containing the anti-PRO1031 or anti-PRO1122 polypeptide monoclonal
antibodies. Alternatively, the hybridoma cells can be grown in
tissue culture flasks or roller bottles. Purification of the
monoclonal antibodies produced in the ascites can be accomplished
using ammonium sulfate precipitation, followed by gel exclusion
chromatography. Alternatively, affinity chromatography based upon
binding of antibody to protein A or protein G can be employed.
Example 8
RNA Expression
[0341] Multi-tissue blots containing poly A.sup.+ RNA (2 .mu.g per
lane) from various human tissues were purchased from Clontech (Palo
Alto, Calif.). The entire coding regions of human IL-17B (UNQ516)
(700 bp) (SEQ ID NO:17) and IL-17C (UNQ561) (1.1 kbp) (SEQ ID
NO:18) were used as hybridization probes. DNA probes were labeled
with [.alpha.-.sup.32P]-dCTP by random priming DNA labeling beads
(Pharmacia Biotech). Hybridization was performed using Expresshyb
(Clontech) containing the radiolabeled probes at 68.degree. C. for
1 hour. The blots were then washed with 2.times.SSC/0.05% SDS
solution at room temperature for 40 minutes, followed by washes in
0.1.times.SSC/0.05% SDS solution at 55.degree. C. for 40 minutes
with one change of fresh solution. The blots were exposed in a
phosphorimager and the resulting image is reported herein as FIG.
8.
[0342] For IL-17B (SEQ ID NO:1), an 800 bp mRNA transcript was
found in pancreas, small intestine, and stomach of adult human
tissues; a weaker band was detected in testis. (FIG. 8). IL-17C
(SEQ ID NO:2) expression was examined in the same set of adult
human tissues, but no detectable signals were observed.
Example 9
Generating Fc/His Fusion Proteins
[0343] The coding sequences of IL17B (SEQ ID NO:17) and IL17C (SEQ
ID NO:18) were amplified by PCR and subcloned into the EcoRI and
SmaI sites of pBPH.His.c to generate a C-terminal GHHHHHHHH tag
(SEQ ID NO:19) or the EcoRI and Stu sites of pBPH.IgG to generate a
C-terminal fusion with the Fc region of human IgG1. Vectors
pBPH.His.c and pBPH.IgG are derivatives of the baculovirus
expression vector pVL1393 (Pharmingen). A control Fc or his-tagged
protein was constructed in a similar way be C-terminally linking
pancreatitis-associated protein (175 amino acid) to the Fc portion
of the human IgG1 or a his8 tag.
[0344] The fusion proteins were expressed in H5 cells using the
manufacturer's recommended procedure (Invitrogen). In brief, the
DNA constructs were co-transfected with BaculoGold Baculovirus DNA
(Pharmingen) in a 7:1 ratio into adherent Sf9 cells. Cells were
incubated at 28.degree. C. for 4 days and the supernatent was
harvested. The transfection supernatant was amplified and was
subject to affinity purification by either protein A-sepharose
beads (Pharmacia) for Fc fusion proteins or Ni--NTA agarose beads
(QIAGEN) for His-tagged proteins.
[0345] To examine the protein expression, SDS-PAGE analysis was
performed on the affinity purified recombinant proteins under
non-reducing and reducing conditions, followed by silver
staining.
Example 10
Induction of IL-6 and TNF-.alpha. Release
[0346] Using the procedure outlined in Yao et al., J. Immunol. 155:
5483 (1995) (Yao-2) for IL-6 (SEQ ID NO:14) release, human foreskin
fibroblast cells (ATCC CRL-2091) were cultured in MEM media (10%
FBS) with the test cytokine. After incubation for 18 hours at
37.degree. C. and 5% CO.sub.2, conditioned media were assayed for
IL-6 using an ELISA kit (R&D Systems). For TNF-.alpha.
secretion, human leukemia monocytic THP-1 cells were cultured in
RPMI media (10% FBS) with test cytokine. After incubation for 18
hour at 37.degree. C. and 5% CO.sub.2, conditioned media were
quantitated for TNF-.alpha. (SEQ ID NO:20) using and ELISA assay
kit (R&D Systems).
[0347] Human foreskin fibroblast cells (ATCC) were separately
cultured in MEM media (10% FBS) in the presence of IL-17B (UNQ516)
(SEQ ID NO:1) and IL-17C (UNQ561) (SEQ ID NO:3). After incubation
for 18 hours at 37.degree. C. and 5% CO.sub.2, conditioned media
were assayed for IL-6 (SEQ ID NO:14) using an ELISA kit (R&D
Systems). In contrast to the high level of IL-6 (SEQ ID NO:14)
induced by IL-17 (SEQ ID NO:11), both IL-17B (SEQ ID NO:1) and
IL17C (SEQ ID NO:3) failed to stimulate IL-6 (SEQ ID NO:14)
secretion in fibroblast cells (FIG. 9A).
[0348] Using the procedure outlined in Yao et al, Cytokine 9: 794
(1997) [Yao-3], a human leukemic monocytic cell line, THP-1, was
used to assay for the stimulation of TNF-.alpha. (SEQ ID NO:20)
release by IL-17 (SEQ ID NO:11), UNQ516 (SEQ ID NO:1) and UNQ561
(SEQ ID NO:3) by culturing in RPMI media (10% FBS). After
incubation for 18 hour at 37.degree. C. and 5% CO.sub.2,
conditioned media were quantitated for TNF-.alpha. (SEQ ID NO:19)
using and ELISA assay kit (R&D Systems). While IL-17 (SEQ ID
NO:11) induced only a low level of TNF-.alpha. (SEQ ID NO:19) in
THP-1 cells, both IL-17B and IL-17C (as Fc fusion proteins)
stimulated TNF-.alpha. production in THP-1 cells (FIG. 9B). A
control Fc fusion protein had no effect.
[0349] In order to further characterize the stimulation of
TNF-.alpha. release by Il-17B and IL-17C, the time course and
concentration dependence of the response were assayed in THP-1
cells. FIG. 10 illustrates that IL-17B (UNQ516) (SEQ ID NO:1) and
IL-17C (UNQ561) (SEQ ID NO:3) stimulate the release of TNF-.alpha.
(SEQ ID NO:19) in a time- and concentration-dependent manner. The
EC.sub.50 for IL-17B (UNQ516) (SEQ ID NO:1) stimulation is 2.4 nM,
while for IL-17C (UNQ561) (SEQ ID NO:3), 25 nM.
[0350] While the IL-17B (UNQ516) (SEQ ID NO:1) and IL-17C (UNQ561)
(SEQ ID NO:3) preparations used in these experiments contained
undetectable level of endotoxin (less than 1 EU/ml), additional
control experiments were performed to confirm that the TNF-.alpha.
(SEQ ID NO:19) release from THP-1 cells was real and not
artifactual. The IL-17B (UNQ516) (SEQ ID NO:1) and IL-17C (UNQ561)
(SEQ ID NO:3) activities were unaffected by polymyxin B treatment
and were abolished by heat treatment, further supporting the notion
that the proteins themselves were responsible for the activities
and not any contaminating endotoxin.
Example 11
IL-17 Receptor Binding
Cloning of the ECD of hIL-17 Receptor:
[0351] In order to clone the ECD of the human IL-17 receptor, two
oligonucleotide primers were designed at the 5' and 3' ends of
IL-17R ECD (SEQ ID NO:15) based on the published sequence. Yao et
al., supra (Yao-3). The two probes had the following sequences:
TABLE-US-00004 primer 1: 5'-CTG TAC CTC GAG GGT GCA GAG-3' (SEQ ID
NO:20) primer 2: 5'-CCC AAG CTT GGG TCA ATG ATG ATG (SEQ ID NO:21)
ATG ATG ATG ATG ATG CCA CAG GGG CAT GTA GTC C-3'
[0352] The above primers were used in PCR reactions to amplify the
full-length cDNA from a human testis cDNA library with Pfu Turbo
DNA polymerase (Promega). A C-terminal his tag was introduced by
PCR through the addition of nucleotides encoding eight histidines
to the 3' end primer. The PCR product was then subcloned into an
expression plasmid vector pRK5B. Sequence analysis confirmed that
the insert contains a DNA fragment encoding the extracellular
domain (1-320 amino acids) of the published hIL-17 receptor. (SEQ
ID NO:15).
Immunoprecipitation of the IL-17R ECD:
[0353] The differential activity of IL-17 when compared to IL-17B
(UNQ516) (SEQ ID NO:1) and IL-17C (UNQ561) (SEQ ID NO:3) suggested
that they might bind and activate different cell surface receptors.
In order to test whether IL-17B (UNQ516) (SEQ ID NO:1) or IL-17C
(UNQ561) (SEQ ID NO:3) directly bind to the receptor, an expression
plasmid containing the IL-17R(C-terminal his-tagged) (SEQ ID NO:22)
was transfected into 293 cells using SuperFect transfection reagent
(Quiagen). Metabolic labeling of 293 cells was performed 16 hours
after transfection using 50 .mu.Ci/ml [.sup.35S]-Cys/Met mixture
for 6 hours. Conditioned medium was collected and concentrated
(Centricon-10, Amicon). To examine the expression of the IL-17R ECD
(SEQ ID NO:15), Ni--NTA beads (Quiagen) were used to affinity
precipitate the his-tagged IL-17R ECD (SEQ ID NO:22) from the
conditioned medium.
[0354] The conditioned medium was diluted in RIPA buffer (1% NP40,
0.5% sodium deoxycholate, 0.1% SDS in PBS) was incubated with IL-17
(SEQ ID NO:11) and the Fc fusion proteins overnight at 4.degree. C.
Protein A-agarose beads (Pierce) were added to precipitate the Fc
fusion proteins. The precipitates were washed three times to
precipitate the Fc fusion proteins. The precipitates were washed
three times in RIPA buffer, denatured in SDS sample buffer, and
electrophoresed on NuPAGE 4-12% Bis-Tris gels (Novex). For IL-17
(SEQ ID NO: 11) immunoprecipitation, anti-IL-17 antibody (R&D
Systems) was added. In a competitive binding experiment,
immunoprecipitation of IL-17R ECD (SEQ ID NO:15) by IL-17 (SEQ ID
NO:11) is performed in the presence of a 5-fold molar excess of
IL-17B.his (SEQ ID NO:23, IL-17C.his (SEQ ID NO:24 and control his
tagged protein.
[0355] The IL-17R ECD (SEQ ID NO:15 migrated as a 60 kDa band when
purified via its histidine tag (FIG. 11A, lane 1). Furthermore, the
IL-17R ECD (SEQ ID NO:15 also precipitated in combination with
IL-17 (SEQ ID NO:11) (lane 3). However, both IL-17B (SEQ ID NO:1)
and IL-17C (SEQ ID NO:3) failed to compete for the binding of IL-17
(SEQ ID NO:11) for the labeled IL-17 receptor ECD (SEQ ID NO:15
(FIG. 11B, lane 15 and 16).
Example 12
Fluorescence-Activated Cell Sorter (FACS) Analysis of Binding to
THP-1 Cells
[0356] THP-1 cells (5.times.105) were pre-incubated in PBS
containing 5% horse serum at 4.degree. C. for 30 minutes to block
non-specific binding. IL-17 (SEQ ID NO:11), IL-17B.fc (SEQ ID
NO:12), IL-17C.Fc (SEQ ID NO:13), or control Fc (1 .mu.g each) were
added and incubated with the THP-1 cells in a volume of 0.25 ml on
ice for 1 hour. For the IL-17 binding experiment, primary anti
hIL-17 antibody (1:100 dilution) and secondary goat anti-mouse
antibody conjugated to FITC (Jackson Immunology Lab, 1:100
dilution) were added sequentially with 30-60 minutes incubation and
extensive washes before each addition. For the Fc fusion proteins,
the cells were stained with FITC conjugated goat anti-human IgG (Fc
specific, Jackson Immunology Lab, 1:100 dilution). After thorough
washes, a minimum of 5,000 cells were analyzed using a FACScan
(Becton Dickinson).
[0357] The resulting of the above procedure was that both IL-17B
(SEQ ID NO:12) and IL-17C (SEQ ID NO:13) Fc fusion proteins
displayed binding to THP-1 cells compared with a control Fc fusion
protein (FIG. 13).
Example 13
Purification of PRO1031 or PRO1122 Polypeptides Using Specific
Antibodies
[0358] Native or recombinant PRO1031 or PRO1122 polypeptides may be
purified by a variety of standard techniques in the art of protein
purification. For example, pro-PRO1031 or pro-PRO1122 polypeptide,
mature PRO1031 or PRO1122 polypeptide, or pre-PRO1031 or
pre-PRO1122 polypeptide is purified by immunoaffinity
chromatography using antibodies specific for the PRO1031 or PRO1122
polypeptide of interest. In general, an immunoaffinity column is
constructed by covalently coupling the anti-PRO1031 or anti-PRO1122
antibody to an activated chromatographic resin.
[0359] Polyclonal immunoglobulins are prepared from immune sera
either by precipitation with ammonium sulfate or by purification on
immobilized Protein A (Pharmacia LKB Biotechnology, Piscataway,
N.J.). Likewise, monoclonal antibodies are prepared from mouse
ascites fluid by ammonium sulfate precipitation or chromatography
on immobilized Protein A. Partially purified immunoglobulin is
covalently attached to a chromatographic resin such as
CnBr-activated SEPHAROSE.RTM. (Pharacia LKB Biotechnology). The
antibody is coupled to the resin, the resin is blocked, and the
derivative resin is washed according to the manufacturer's
instructions.
[0360] Such an immunoaffinity column is utilized in the
purification of PRO1031 or PRO1122 polypeptide by preparing a
fraction of cells containing PRO1031 or PRO1122 polypeptide in a
soluble form. This preparation is derived by solubilization of the
whole cell or of a subcellular fraction obtained via differential
centrifugation by the addition of detergent or by other methods
well known in the art. Alternatively, soluble PRO1031 or PRO1122
polypeptide containing a signal sequence may be secreted in useful
quantity into the medium in which the cells are grown.
[0361] A soluble PRO1031 or PRO1122 polypeptide-containing
preparation is passed over the immunoaffinity column, the and
column is washed under conditions that allow the preferential
absorbance of PRO1031 or PRO1122 polypeptide (e.g., high ionic
strength buffers in the presence of detergent). Then, the column is
eluted under conditions that disrupt antibody-PRO1031 or -PRO1122
polypeptide binding (e.g., a low pH buffer such as approximately pH
2-3, or a high concentration of a chaotrope such as urea or
thiocyanate ion), and PRO1031 or PRO1122 polypeptide is
collected.
Example 14
Drug Screening
[0362] This invention is particularly useful for screening
compounds by using PRO1031 or PRO1122 polypeptides or binding
fragments thereof in any of a variety of drug screening techniques.
The PRO1031 or PRO1122 polypeptide or fragment employed in such a
test may either bye free in solution, affixed to a solid support,
borne on a cell surface, or located intracellularly. One method of
drug screening utilized eukaryotic or prokaryotic host cells which
are stably transformed with recombinant nucleic acids expressing
the PRO1031 or PRO1122 polypeptide or fragment. Drugs are screened
against such transformed cells in competitive binding assays. Such
cells, either in viable or fixed form, can be used for standard
binding assays. On may measure, for example, the formation of
complexes between PRO1031 or PRO1122 polypeptide or a fragment and
the agent being tested. Alternatively, one can examine the
diminution in complex formation between the PRO1031 or PRO1122
polypeptide and its target cell or target receptors caused by the
agent being tested.
[0363] Thus, the present invention provides methods of screening
for drugs or any other agents which can affect a PRO1031 or PRO1122
polypeptide-associated disease or disorder. These methods comprise
contacting such an agent with a PRO1031 or PRO1122 polypeptide or
fragment thereof and assaying (i) for the presence of a complex
between the agent and the PRO1031 or PRO1122 polypeptide or
fragment, or (ii) for the presence of a complex between the PRO1031
or PRO1122 polypeptide or fragment and the cell, by methods well
known in the art. In such competitive binding assays, the PRO1031
or PRO1122 polypeptide or fragment is typically labeled. After
suitable incubation, free PRO1031 or PRO1122 polypeptide or
fragment is separated from that present in bound form, and the
amount of free or uncomplexed label is a measure of the ability of
the particular agent to bind to PRO1031 or PRO1122 or to interfere
with the PRO1031 or PRO1122 polypeptide/cell complex.
[0364] Another technique for drug screening provide high throughput
screening for compounds having suitable binding affinity to a
polypeptide and is described in detail in WO 84/03564, published on
Sep. 13, 1984. Briefly stated, large numbers of different small
peptide test compounds are synthesized on a solid substrate, such
as plastic pins or some other surface. As applied to a PRO1031 or
PRO1122 polypeptide, the peptide test compounds are reacted with
PRO1031 or PRO1122 polypeptide and washed. Bound PRO1031 or PRO1122
is detected by methods well known in the art. Purified PRO1031 or
PRO1122 polypeptide can also be coated directly onto plates for use
in the aforementioned drug screening techniques. In addition,
non-neutralizing antibodies can by used to capture the peptide and
immobilize it on the solid support.
[0365] This invention also contemplates the use of competitive drug
screening assays in which neutralizing antibodies capable of
binding PRO1031 or PRO1122 polypeptide specifically compete with a
test compound for binding to PRO1031 or PRO1122 polypeptide or
fragments thereof. In this manner, the antibodies can be used to
detect the presence of any peptide which shares one or more
antigenic determinants with PRO1031 or PRO1122 polypeptide.
Example 15
Rational Drug Design
[0366] The goal of rational drug design is to produce structural
analogs of biologically active polypeptide of interest (i.e., a
PRO1031 or PRO1122 polypeptide) or of small molecules with which
they interact, e.g., agonists, antagonists, or inhibitors. Any of
these examples can be used to fashion drugs which are more active
or stable forms of the PRO1031 or PRO1122 polypeptide or which
enhance or interfere with the function of the PRO1031 or PRO1122
polypeptide in vivo. (c.f., Hodgson, Bio/Technology 2: 19-21
(1991)).
[0367] In one approach, the three-dimensional structure of the
PRO1031 or PRO1122 polypeptide, or of a PRO1031 or PRO1122
polypeptide-inhibitor complex, is determined by x-ray
cystallography, by computer modeling or, most typically, by a
combination of the two approaches. Both the shape and charges of
the PRO1031 or PRO1122 must be ascertained to elucidate the
structure and to determine active sties(s) of the molecule. Less
often, useful information regarding the structure of the PRO1031 or
PRO1122 may be gained by modeling based on the structure of
homologous proteins. In both cases, relevant structural information
is used to design analogous PRO1031 or PRO1122 polypeptide-like
molecules or to identity efficient inhibitors. Useful examples of
rational drug design may include molecules which have improved
activity or stability as shown by Braxton and Wells, Biochemistry
31: 7796-7801 (1992) or which act as inhibitors, agonists, or
antagonists of native peptides as shown by Athauda et al., J.
Biochem. 113: 742-746 (1993).
[0368] It is also possible to isolate a target-specific antibody,
selected by functional assay, as described above, and then to solve
its crystal structure. This approach, in principle, yields a
pharmacore upon which subsequent drug design can be based. It is
possible to bypass protein cystallography altogether by generating
anti-idiotypic antibodies (anti-ids) to a functional,
pharmacologically active antibody. As a mirror image of a mirror
image, the binding site of anti anti-ids would be expected to be an
analog of the original receptor. The anti-id could then by used to
identify and isolate peptides from banks of chemically or
biologically produced peptides. The isolated peptides would then
act as the pharmacore.
[0369] By virtue of the present invention, sufficient amounts of
the PRO1031 or PRO1122 polypeptide may be made available to perform
such analytical studies as X-ray crystallography. In addition,
knowledge of the PRO1031 or PRO1122 polypeptide amino acid sequence
provided herein will provide guidance to those employing computer
modeling techniques in place or in addition to x-ray
crystallography.
Example 16
Articular cartilage Explant Assay
Introduction:
[0370] As mentioned previously, IL-17 is likely to play a role in
the initiation or maintenance of the proinflammatory response.
IL-17 is a cytokine expressed by CD4.sup.+ T.sub.h cells and
induces the secretion of proinflammatory and hematopoietic
cytokines (e.g., IL-1.beta., TNF-.alpha., IL-6, IL-8, GM-CSF.
Aarvak et al., J. Immunol 162: 1246-1251 (1999); Fossiez et al., J.
Exp. Med. 183: 2593-2603 (1996); Jovanovic et al, J. Immunol. 160:
3513-3521 (1998) in a number of cell types including synoviocytes
and macrophages. In the presence of IL-17, fibroblasts sustain
sustain the proliferation of CD34+ hematopoietic progenitors and
induce their preferential maturation into neutrophils. As a result,
Il-17 may constitute an early initiator of the T cell-dependent
inflammatory reaction and be part of the cytokine network which
bridges the immune system to hematopoiesis.
[0371] Expression of IL-17 has been found in the synovium of
patients with rheumatoid arthritis, psoriatic arthritis, or
osteoarthritis, but not in normal joint tissues. IL-17 can
synergize with the monocyte-derived, proinflammatory cytokines
IL-1.beta. or TNF-.alpha. to induce IL-6 and GM-CSF. By acting
directly on synoviocytes, IL-17 could enhance secretion of
proinflammatory cytokines in vivo and thus exacerbate joint
inflammation and destruction.
[0372] To further understand the possible role of IL-17, Applicants
have tested the effects of IL-17 on cartilage matrix metabolism. In
light of the known catabolic effects of nitric oxide (NO) on
cartilage, and the existence of high levels of NO in arthritic
joints, NO production was also measured.
Methods:
[0373] Articular cartilage explants: The metacarpophalangeal joint
of a 4-6 month old female pigs was aseptically dissected, and
articular cartilage is removed by free-hand slicing in a careful
manner so as to avoid the underlying bone. The cartilage was minced
and cultured in bulk for at least 24 hours in a humidified
atmosphere of 95% air 5% CO.sub.2 in serum free (SF) media
(DME/F121:1) with 0.1% BSA and antibiotics. After washing three
times, approximately 80 mg of articular cartilage was aliquoted
into micronics tubes and incubated for at least 24 hours in the
above SF media. Test proteins were then added at 1% either alone or
in combination with IL-1.alpha. (10 ng/ml) (SEQ ID NO:25). Media
was harvested and changed at various timepoints (0, 24, 48, 72
hours) and assayed for proteoglycan content using the
1,9-dimethyl-methylene blue (DMB) colorimetric assay described in
Farndale and Buttle, Biochem. Biophys. Acta 883: 173-177 (1985).
After labeling (overnight) with .sup.35S-sulfur, the tubes were
weighed to determine the amount of tissue. Following an overnight
digestion, the amount of proteoglycan remaining in the tissue as
well as proteoglycan synthesis (.sup.35S-incorporation) is
determined.
[0374] Measurement of NO production: The assay is based on the
principle that 2,3-diaminonapthalene (DAN) reacts with nitrite
under acidic conditions to form 1-(H)-naphthotriazole, a
flourescent product. As NO is quickly metabolized into nitrite
(NO.sub.2.sup.-1) and nitrate (NO.sub.3.sup.-1), detection of
nitrite, is one means of detecting (albeit undercounting) the
actual NO produced. 10 .mu.L of DAN (0.05 mg. mL in 0.62M HCl) is
added to 100 .mu.L of sample (cell culture supernatant), mixed, and
incubated at room temperature for 10-20 minutes. Reaction is
terminated with 5 mL of 2.8N NaOH. Formation of
2,3-diaminonaphthotriazole was measured using a Cytoflor
flourescent plate reader with excitation at 360 nm and emission
read at 450 nm. For optimal measurement of flourescent intensity,
black plates with clear bottoms were used.
Results and Discussion:
[0375] IL-17 (SEQ ID NO:11) was observed to both increase the
release of and decrease the synthesis of proteoglycans (FIG. 13).
Moreover, this effect was additive to the effect observed from
IL-1.alpha.. (FIG. 13) (SEQ ID NO:25). The effects of IL-17 are not
mediated by the production of nitric oxide, nor does inhibition of
nitric oxide release augment matrix breakdown. UNQ561 (SEQ ID NO:3)
increases matrix breakdown and inhibits matrix synthesis. Thus,
expression of PRO1122 is likely to be associated with degenerative
cartilagenous disorders. On the other hand, UNQ516 (SEQ ID NO:1)
increases matrix synthesis and inhibits nitric oxide release by
articular cartilage explants.
[0376] In conclusion, IL-17 likely contributes to loss of articular
cartilage in arthritic joints, and thus inhibition of its activity
might limit inflammation and cartilage destruction. IL-1 and IL-17
have similar yet distinct activities due to their use of different
receptors and overlapping downstream signaling mechanisms.
[0377] Given the findings of the potent catabolic effects of IL-17
on articular cartilage explants and the homology of UNQ516 and
UNQ561 to IL-17, antagonists to any or all of these proteins may be
useful for the treatment of inflammatory conditions and cartilage
defects such as arthritis. However, our finding that UNQ516
inhibits NO production and enhances matrix synthesis suggests that
this protein and agonists thereof could have beneficial effects
within the joint and may thus, in and of itself, be useful for the
treatment of the above mentioned disorders.
[0378] Finally, it is well known that growth factors can have
biphasic effects and that diseased tissue can respond differently
than normal tissue to a given factor in vivo. For these reasons,
antagonists or agonists (e.g. the proteins themselves) of UNQ 516,
UNQ 561, or IL-17, may be useful for the treatment of inflammatory
conditions and joint disorders such as arthritis.
Deposit of Material
[0379] The following materials have been deposited with the
American Type Culture Collection, 10801 University Boulevard,
Manassas, Va. USA 20110-2209 (ATCC): TABLE-US-00005 Material ATCC
Dep. No. Deposit Date DNA59294-1381 209866 14 May 1998
DNA62377-1381-1 203546 22 Dec. 1998
[0380] This deposit was made under the provisions of the Budapest
Treaty on the International Recognition of the Deposit of
Microorganisms for the Purpose of Patent Procedure and the
Regulations thereunder (Budapest Treaty). This assures maintenance
of a viable culture of the deposit for 30 years from the date of
deposit. The deposit will be made available by ATCC under the terms
of the Budapest Treaty, and subject to an agreement between
Genentech, Inc. and ATCC, which assures permanent and unrestricted
availability of the progeny of the culture of the deposit to the
public upon issuance of the pertinent U.S. patent or upon laying
open to the public of any U.S. or foreign patent application,
whichever comes first, and assures availability of the progeny to
one determined by the U.S. Commissioner of Patents and Trademarks
to be entitled thereto according to 35 USC .sctn.122 and the
Commissioner's rules pursuant thereto (including 37 CFR .sctn.1.14
with particular reference to 886 OG 638).
[0381] The assignee of the present application has agreed that if a
culture of the materials on deposit should die or be lost or
destroyed when cultivated under suitable conditions, the materials
will be promptly replaced on notification with another of the same.
Availability of the deposited material is not to be construed as a
license to practice the invention in contravention of the rights
granted under the authority of any government in accordance with
its patent laws.
[0382] The foregoing written specification is considered to be
sufficient to enable one skilled in the art to practice the
invention. The present invention is not to be limited in scope by
the construct deposited, since the deposited embodiment is intended
as a single illustration of certain aspects of the invention and
any constructs that are functionally equivalent are within the
scope of this invention. The deposit of material herein does not
constitute an admission that the written description herein
contained is inadequate to enable the practice of any aspect of the
invention, including the best mode thereof, nor is it to be
construed as limiting the scope of the claims to the specific
illustrations that it represents. Indeed, various modifications of
the invention in addition to those shown and described herein will
become apparent to those skilled in the art from the foregoing
description and fall within the scope of the appended claims.
Sequence CWU 1
1
26 1 180 PRT Homo sapiens 1 Met Asp Trp Pro His Asn Leu Leu Phe Leu
Leu Thr Ile Ser Ile 1 5 10 15 Phe Leu Gly Leu Gly Gln Pro Arg Ser
Pro Lys Ser Lys Arg Lys 20 25 30 Gly Gln Gly Arg Pro Gly Pro Leu
Ala Pro Gly Pro His Gln Val 35 40 45 Pro Leu Asp Leu Val Ser Arg
Met Lys Pro Tyr Ala Arg Met Glu 50 55 60 Glu Tyr Glu Arg Asn Ile
Glu Glu Met Val Ala Gln Leu Arg Asn 65 70 75 Ser Ser Glu Leu Ala
Gln Arg Lys Cys Glu Val Asn Leu Gln Leu 80 85 90 Trp Met Ser Asn
Lys Arg Ser Leu Ser Pro Trp Gly Tyr Ser Ile 95 100 105 Asn His Asp
Pro Ser Arg Ile Pro Val Asp Leu Pro Glu Ala Arg 110 115 120 Cys Leu
Cys Leu Gly Cys Val Asn Pro Phe Thr Met Gln Glu Asp 125 130 135 Arg
Ser Met Val Ser Val Pro Val Phe Ser Gln Val Pro Val Arg 140 145 150
Arg Arg Leu Cys Pro Pro Pro Pro Arg Thr Gly Pro Cys Arg Gln 155 160
165 Arg Ala Val Met Glu Thr Ile Ala Val Gly Cys Thr Cys Ile Phe 170
175 180 2 687 DNA Homo sapiens 2 aggcgggcag cagctgcagg ctgaccttgc
agcttggcgg aatggactgg 50 cctcacaacc tgctgtttct tcttaccatt
tccatcttcc tggggctggg 100 ccagcccagg agccccaaaa gcaagaggaa
ggggcaaggg cggcctgggc 150 ccctggcccc tggccctcac caggtgccac
tggacctggt gtcacggatg 200 aaaccgtatg cccgcatgga ggagtatgag
aggaacatcg aggagatggt 250 ggcccagctg aggaacagct cagagctggc
ccagagaaag tgtgaggtca 300 acttgcagct gtggatgtcc aacaagagga
gcctgtctcc ctggggctac 350 agcatcaacc acgaccccag ccgtatcccc
gtggacctgc cggaggcacg 400 gtgcctgtgt ctgggctgtg tgaacccctt
caccatgcag gaggaccgca 450 gcatggtgag cgtgccggtg ttcagccagg
ttcctgtgcg ccgccgcctc 500 tgcccgccac cgccccgcac agggccttgc
cgccagcgcg cagtcatgga 550 gaccatcgct gtgggctgca cctgcatctt
ctgaatcacc tggcccagaa 600 gccaggccag cagcccgaga ccatcctcct
tgcacctttg tgccaagaaa 650 ggcctatgaa aagtaaacac tgacttttga aagcaag
687 3 197 PRT Homo sapiens 3 Met Thr Leu Leu Pro Gly Leu Leu Phe
Leu Thr Trp Leu His Thr 1 5 10 15 Cys Leu Ala His His Asp Pro Ser
Leu Arg Gly His Pro His Ser 20 25 30 His Gly Thr Pro His Cys Tyr
Ser Ala Glu Glu Leu Pro Leu Gly 35 40 45 Gln Ala Pro Pro His Leu
Leu Ala Arg Gly Ala Lys Trp Gly Gln 50 55 60 Ala Leu Pro Val Ala
Leu Val Ser Ser Leu Glu Ala Ala Ser His 65 70 75 Arg Gly Arg His
Glu Arg Pro Ser Ala Thr Thr Gln Cys Pro Val 80 85 90 Leu Arg Pro
Glu Glu Val Leu Glu Ala Asp Thr His Gln Arg Ser 95 100 105 Ile Ser
Pro Trp Arg Tyr Arg Val Asp Thr Asp Glu Asp Arg Tyr 110 115 120 Pro
Gln Lys Leu Ala Phe Ala Glu Cys Leu Cys Arg Gly Cys Ile 125 130 135
Asp Ala Arg Thr Gly Arg Glu Thr Ala Ala Leu Asn Ser Val Arg 140 145
150 Leu Leu Gln Ser Leu Leu Val Leu Arg Arg Arg Pro Cys Ser Arg 155
160 165 Asp Gly Ser Gly Leu Pro Thr Pro Gly Ala Phe Ala Phe His Thr
170 175 180 Glu Phe Ile His Val Pro Val Gly Cys Thr Cys Val Leu Pro
Arg 185 190 195 Ser Val 4 1047 DNA Homo sapiens 4 gccaggtgtg
caggccgctc caagcccagc ctgccccgct gccgccacca 50 tgacgctcct
ccccggcctc ctgtttctga cctggctgca cacatgcctg 100 gcccaccatg
acccctccct cagggggcac ccccacagtc acggtacccc 150 acactgctac
tcggctgagg aactgcccct cggccaggcc cccccacacc 200 tgctggctcg
aggtgccaag tgggggcagg ctttgcctgt agccctggtg 250 tccagcctgg
aggcagcaag ccacaggggg aggcacgaga ggccctcagc 300 tacgacccag
tgcccggtgc tgcggccgga ggaggtgttg gaggcagaca 350 cccaccagcg
ctccatctca ccctggagat accgtgtgga cacggatgag 400 gaccgctatc
cacagaagct ggccttcgcc gagtgcctgt gcagaggctg 450 tatcgatgca
cggacgggcc gcgagacagc tgcgctcaac tccgtgcggc 500 tgctccagag
cctgctggtg ctgcgccgcc ggccctgctc ccgcgacggc 550 tcggggctcc
ccacacctgg ggcctttgcc ttccacaccg agttcatcca 600 cgtccccgtc
ggctgcacct gcgtgctgcc ccgttcagtg tgaccgccga 650 ggccgtgggg
cccctagact ggacacgtgt gctccccaga gggcaccccc 700 tatttatgtg
tatttattgt tatttatatg cctcccccaa cactaccctt 750 ggggtctggg
cattccccgt gtctggagga cagcccccca ctgttctcct 800 catctccagc
ctcagtagtt gggggtagaa ggagctcagc acctcttcca 850 gcccttaaag
ctgcagaaaa ggtgtcacac ggctgcctgt accttggctc 900 cctgtcctgc
tcccggcttc ccttacccta tcactggcct caggccccgc 950 aggctgcctc
ttcccaacct ccttggaagt acccctgttt cttaaacaat 1000 tatttaagtg
tacgtgtatt attaaactga tgaacacatc cccaaaa 1047 5 830 DNA Homo
sapiens unsure 105-115 unknown base 5 ggcagcaggg accaagagag
gcacgcttgc ccttttatga catcagagct 50 cctggttctt gctccttggg
actctgggac ttacaccagt ggcacccctg 100 gctcnnnnnn nnnnnaattc
ggtacgaggc tggggttcag gcgggcagca 150 gctgcaggct gaccttgcag
cttggcggaa tggactggcc tcacaacctg 200 ctgtttcttc ttaccatttc
catcttcctg gggctgggcc agcccaggag 250 ccccaaaagc aagaggaagg
ggcaagggcg gcctgggccc ctggtccctg 300 gccctcacca ggtgccactg
gacctggtgt cacggatgaa accgtatgcc 350 cgcatggagg agtatgagag
gaacatcgag gagatgttgg cccagctgag 400 gaacagttca gagctggccc
agagaaagtg tgaggtcaac ttgcagctgt 450 ggatgtccaa caagaggagc
ctgtctccct ggggctacag catcaaccac 500 gaccccagcc gtatccccgt
ggacctccgg aggcacggtg cctgtgtctg 550 ggcttgtgtg aaccccttca
ccatgcagga ggaccgcagc atggtgagcg 600 tgccggtgtt cagccaggtt
cctgtgcgcc gccgcctctg cccgccaccg 650 ccccgcacag ggccttgccg
ccagcgcgca gtcatggaga ccatcgctgt 700 gggctgcacc tgcatcttct
gaatcgacct ggcccagaag ccaggccagc 750 agcccgagac catcctcctt
gcacctttgt gccaagaaag gcctatgaaa 800 agtaaacact gacttttgaa
agcaaaaaaa 830 6 397 DNA Homo sapiens unsure 10, 150, 267 unknown
base 6 aggcgggcan agctgcaggc tgaccttgca gcttggcgga atggactggc 50
ctcacaacct gctgtttctt cttaccattt ccatcttcct ggggctgggc 100
agccaggagc cccaaaagca agaggaaggg gcaagggcgg cctgggcccn 150
tggcctggcc tcaccaggtg ccactggacc tggtgtcacg gatgaaaccg 200
tatgcccgca tggaggagta tgagaggaac atcgaggaga tggtggccca 250
gctgaggaac agctcanaag ctggcccaga gaaagtgtga ggtcaacttg 300
cagctgtgga tgtccaacaa gaaggagcct gtctcccttg gggctacaag 350
catcaaccac cgaccccagc cgtatccccg tgggaccttg ccgggac 397 7 230 DNA
Homo sapiens 7 cacggatgag gaccgctatc cacagaagct ggccttcgcc
gagtgcctgt 50 gcagaggctg tatcgatgca cggacgggcc gcgagacagc
tgcgctcaac 100 tccgtgcggc tgctccagag cctgctggtg ctgcgccgcc
ggccctgctc 150 ccgcgacggc tcggggctcc ccacacctgg ggcctttgcc
ttccacaccg 200 agttcatcca cgtccccgtc ggctgcacct 230 8 24 DNA
Artificial sequence Forward PCR primer 8 atccacagaa gctggccttc gccg
24 9 24 DNA Artificial sequence reverse PCR primer 9 gggacgtgga
tgaactcggt gtgg 24 10 40 DNA Artificial sequence hybridization
probe 10 tatccacaga agctggcctt cgccgagtgc ctgtgcagag 40 11 155 PRT
Homo sapiens 11 Met Thr Pro Gly Lys Thr Ser Leu Val Ser Leu Leu Leu
Leu Leu 1 5 10 15 Ser Leu Glu Ala Ile Val Lys Ala Gly Ile Thr Ile
Pro Arg Asn 20 25 30 Pro Gly Cys Pro Asn Ser Glu Asp Lys Asn Phe
Pro Arg Thr Val 35 40 45 Met Val Asn Leu Asn Ile His Asn Arg Asn
Thr Asn Thr Asn Pro 50 55 60 Lys Arg Ser Ser Asp Tyr Tyr Asn Arg
Ser Thr Ser Pro Trp Asn 65 70 75 Leu His Arg Asn Glu Asp Pro Glu
Arg Tyr Pro Ser Val Ile Trp 80 85 90 Glu Ala Lys Cys Arg His Leu
Gly Cys Ile Asn Ala Asp Gly Asn 95 100 105 Val Asp Tyr His Met Asn
Ser Val Pro Ile Gln Gln Glu Ile Leu 110 115 120 Val Leu Arg Arg Glu
Pro Pro His Cys Pro Asn Ser Phe Arg Leu 125 130 135 Glu Lys Ile Leu
Val Ser Val Gly Cys Thr Cys Val Thr Pro Ile 140 145 150 Val His His
Val Ala 155 12 408 PRT Artificial Sequence IL17B-Fc fusion 12 Met
Asp Trp Pro His Asn Leu Leu Phe Leu Leu Thr Ile Ser Ile 1 5 10 15
Phe Leu Gly Leu Gly Gln Pro Arg Ser Pro Lys Ser Lys Arg Lys 20 25
30 Gly Gln Gly Arg Pro Gly Pro Leu Ala Pro Gly Pro His Gln Val 35
40 45 Pro Leu Asp Leu Val Ser Arg Met Lys Pro Tyr Ala Arg Met Glu
50 55 60 Glu Tyr Glu Arg Asn Ile Glu Glu Met Val Ala Gln Leu Arg
Asn 65 70 75 Ser Ser Glu Leu Ala Gln Arg Lys Cys Glu Val Asn Leu
Gln Leu 80 85 90 Trp Met Ser Asn Lys Arg Ser Leu Ser Pro Trp Gly
Tyr Ser Ile 95 100 105 Asn His Asp Pro Ser Arg Ile Pro Val Asp Leu
Pro Glu Ala Arg 110 115 120 Cys Leu Cys Leu Gly Cys Val Asn Pro Phe
Thr Met Gln Glu Asp 125 130 135 Arg Ser Met Val Ser Val Pro Val Phe
Ser Gln Val Pro Val Arg 140 145 150 Arg Arg Leu Cys Pro Pro Pro Pro
Arg Thr Gly Pro Cys Arg Gln 155 160 165 Arg Ala Val Met Glu Thr Ile
Ala Val Gly Cys Thr Cys Ile Phe 170 175 180 Pro Asp Lys Thr His Thr
Cys Pro Pro Cys Pro Ala Pro Glu Leu 185 190 195 Leu Gly Gly Pro Ser
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 200 205 210 Thr Leu Met Ile
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 215 220 225 Asp Val Ser
His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 230 235 240 Asp Gly
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 245 250 255 Gln
Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 260 265 270
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser 275 280
285 Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala 290
295 300 Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
305 310 315 Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
Val 320 325 330 Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
Ser Asn 335 340 345 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
Val Leu Asp 350 355 360 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
Thr Val Asp Lys 365 370 375 Ser Arg Trp Gln Gln Gly Asn Val Phe Ser
Cys Ser Val Met His 380 385 390 Glu Ala Leu His Asn His Tyr Thr Gln
Lys Ser Leu Ser Leu Ser 395 400 405 Pro Gly Lys 13 425 PRT
Artificial Sequence IL-17C-Fc fusion 13 Met Thr Leu Leu Pro Gly Leu
Leu Phe Leu Thr Trp Leu His Thr 1 5 10 15 Cys Leu Ala His His Asp
Pro Ser Leu Arg Gly His Pro His Ser 20 25 30 His Gly Thr Pro His
Cys Tyr Ser Ala Glu Glu Leu Pro Leu Gly 35 40 45 Gln Ala Pro Pro
His Leu Leu Ala Arg Gly Ala Lys Trp Gly Gln 50 55 60 Ala Leu Pro
Val Ala Leu Val Ser Ser Leu Glu Ala Ala Ser His 65 70 75 Arg Gly
Arg His Glu Arg Pro Ser Ala Thr Thr Gln Cys Pro Val 80 85 90 Leu
Arg Pro Glu Glu Val Leu Glu Ala Asp Thr His Gln Arg Ser 95 100 105
Ile Ser Pro Trp Arg Tyr Arg Val Asp Thr Asp Glu Asp Arg Tyr 110 115
120 Pro Gln Lys Leu Ala Phe Ala Glu Cys Leu Cys Arg Gly Cys Ile 125
130 135 Asp Ala Arg Thr Gly Arg Glu Thr Ala Ala Leu Asn Ser Val Arg
140 145 150 Leu Leu Gln Ser Leu Leu Val Leu Arg Arg Arg Pro Cys Ser
Arg 155 160 165 Asp Gly Ser Gly Leu Pro Thr Pro Gly Ala Phe Ala Phe
His Thr 170 175 180 Glu Phe Ile His Val Pro Val Gly Cys Thr Cys Val
Leu Pro Arg 185 190 195 Ser Val Pro Asp Lys Thr His Thr Cys Pro Pro
Cys Pro Ala Pro 200 205 210 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu
Phe Pro Pro Lys Pro 215 220 225 Lys Asp Thr Leu Met Ile Ser Arg Thr
Pro Glu Val Thr Cys Val 230 235 240 Val Val Asp Val Ser His Glu Asp
Pro Glu Val Lys Phe Asn Trp 245 250 255 Tyr Val Asp Gly Val Glu Val
His Asn Ala Lys Thr Lys Pro Arg 260 265 270 Glu Glu Gln Tyr Asn Ser
Thr Tyr Arg Val Val Ser Val Leu Thr 275 280 285 Val Leu His Gln Asp
Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 290 295 300 Val Ser Asn Lys
Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser 305 310 315 Lys Ala Lys
Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 320 325 330 Pro Ser
Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 335 340 345 Leu
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 350 355 360
Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 365 370
375 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 380
385 390 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val
395 400 405 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
Ser 410 415 420 Leu Ser Pro Gly Lys 425 14 212 PRT Homo sapiens 14
Met Asn Ser Phe Ser Thr Ser Ala Phe Gly Pro Val Ala Phe Ser 1 5 10
15 Leu Gly Leu Leu Leu Val Leu Pro Ala Ala Phe Pro Ala Pro Val 20
25 30 Pro Pro Gly Glu Asp Ser Lys Asp Val Ala Ala Pro His Arg Gln
35 40 45 Pro Leu Thr Ser Ser Glu Arg Ile Asp Lys Gln Ile Arg Tyr
Ile 50 55 60 Leu Asp Gly Ile Ser Ala Leu Arg Lys Glu Thr Cys Asn
Lys Ser 65 70 75 Asn Met Cys Glu Ser Ser Lys Glu Ala Leu Ala Glu
Asn Asn Leu 80 85 90 Asn Leu Pro Lys Met Ala Glu Lys Asp Gly Cys
Phe Gln Ser Gly 95 100 105 Phe Asn Glu Glu Thr Cys Leu Val Lys Ile
Ile Thr Gly Leu Leu 110 115 120 Glu Phe Glu Val Tyr Leu Glu Tyr Leu
Gln Asn Arg Phe Glu Ser 125 130 135 Ser Glu Glu Gln Ala Arg Ala Val
Gln Met Ser Thr Lys Val Leu 140 145 150 Ile Gln Phe Leu Gln Lys Lys
Ala Lys Asn Leu Asp Ala Ile Thr 155 160 165 Thr Pro Asp Pro Thr Thr
Asn Ala Ser Leu Leu Thr Lys Leu Gln 170 175 180 Ala Gln Asn Gln Trp
Leu Gln Asp Met Thr Thr His Leu Ile Leu 185 190 195 Arg Ser Phe Lys
Glu Phe Leu Gln Ser Ser Leu Arg Ala Leu Arg 200 205 210 Gln Met 15
320 PRT Homo sapiens 15 Met Gly Ala Ala Arg Ser Pro Pro Ser Ala Val
Pro Gly Pro Leu 1 5 10 15 Leu Gly Leu Leu Leu Leu Leu Leu Gly Val
Leu Ala Pro Gly Gly 20 25
30 Ala Ser Leu Arg Leu Leu Asp His Arg Ala Leu Val Cys Ser Gln 35
40 45 Pro Gly Leu Asn Cys Thr Val Lys Asn Ser Thr Cys Leu Asp Asp
50 55 60 Ser Trp Ile His Pro Arg Asn Leu Thr Pro Ser Ser Pro Lys
Asp 65 70 75 Leu Gln Ile Gln Leu His Phe Ala His Thr Gln Gln Gly
Asp Leu 80 85 90 Phe Pro Val Ala His Ile Glu Trp Thr Leu Gln Thr
Asp Ala Ser 95 100 105 Ile Leu Tyr Leu Glu Gly Ala Glu Leu Ser Val
Leu Gln Leu Asn 110 115 120 Thr Asn Glu Arg Leu Cys Val Arg Phe Glu
Phe Leu Ser Lys Leu 125 130 135 Arg His His His Arg Arg Trp Arg Phe
Thr Phe Ser His Phe Val 140 145 150 Val Asp Pro Asp Gln Glu Tyr Glu
Val Thr Val His His Leu Pro 155 160 165 Lys Pro Ile Pro Asp Gly Asp
Pro Asn His Gln Ser Lys Asn Phe 170 175 180 Leu Val Pro Asp Cys Glu
His Ala Arg Met Lys Val Thr Thr Pro 185 190 195 Cys Met Ser Ser Gly
Ser Leu Trp Asp Pro Asn Ile Thr Val Glu 200 205 210 Thr Leu Glu Ala
His Gln Leu Arg Val Ser Phe Thr Leu Trp Asn 215 220 225 Glu Ser Thr
His Tyr Gln Ile Leu Leu Thr Ser Phe Pro His Met 230 235 240 Glu Asn
His Ser Cys Phe Glu His Met His His Ile Pro Ala Pro 245 250 255 Arg
Pro Glu Glu Phe His Gln Arg Ser Asn Val Thr Leu Thr Leu 260 265 270
Arg Asn Leu Lys Gly Cys Cys Arg His Gln Val Gln Ile Gln Pro 275 280
285 Phe Phe Ser Ser Cys Leu Asn Asp Cys Leu Arg His Ser Ala Thr 290
295 300 Val Ser Cys Pro Glu Met Pro Asp Thr Pro Glu Pro Ile Pro Asp
305 310 315 Tyr Met Pro Leu Trp 320 16 543 DNA Homo sapiens 16
atggactggc ctcacaacct gctgtttctt cttaccattt ccatcttcct 50
ggggctgggc cagcccagga gccccaaaag caagaggaag gggcaagggc 100
ggcctgggcc cctggcccct ggccctcacc aggtgccact ggacctggtg 150
tcacggatga aaccgtatgc ccgcatggag gagtatgaga ggaacatcga 200
ggagatggtg gcccagctga ggaacagctc agagctggcc cagagaaagt 250
gtgaggtcaa cttgcagctg tggatgtcca acaagaggag cctgtctccc 300
tggggctaca gcatcaacca cgaccccagc cgtatccccg tggacctgcc 350
ggaggcacgg tgcctgtgtc tgggctgtgt gaaccccttc accatgcagg 400
aggaccgcag catggtgagc gtgccggtgt tcagccaggt tcctgtgcgc 450
cgccgcctct gcccgccacc gccccgcaca gggccttgcc gccagcgcgc 500
agtcatggag accatcgctg tgggctgcac ctgcatcttc tga 543 17 594 DNA Homo
sapiens 17 atgacgctcc tccccggcct cctgtttctg acctggctgc acacatgcct
50 ggcccaccat gacccctccc tcagggggca cccccacagt cacggtaccc 100
cacactgcta ctcggctgag gaactgcccc tcggccaggc ccccccacac 150
ctgctggctc gaggtgccaa gtgggggcag gctttgcctg tagccctggt 200
gtccagcctg gaggcagcaa gccacagggg gaggcacgag aggccctcag 250
ctacgaccca gtgcccggtg ctgcggccgg aggaggtgtt ggaggcagac 300
acccaccagc gctccatctc accctggaga taccgtgtgg acacggatga 350
ggaccgctat ccacagaagc tggccttcgc cgagtgcctg tgcagaggct 400
gtatcgatgc acggacgggc cgcgagacag ctgcgctcaa ctccgtgcgg 450
ctgctccaga gcctgctggt gctgcgccgc cggccctgct cccgcgacgg 500
ctcggggctc cccacacctg gggcctttgc cttccacacc gagttcatcc 550
acgtccccgt cggctgcacc tgcgtgctgc cccgttcagt gtga 594 18 9 PRT
Artificial Sequence HIS tag 18 Gly His His His His His His His His
1 5 19 157 PRT Homo sapiens 19 Val Arg Ser Ser Ser Arg Thr Pro Ser
Asp Lys Pro Val Ala His 1 5 10 15 Val Val Ala Asn Pro Gln Ala Glu
Gly Gln Leu Gln Trp Leu Asn 20 25 30 Arg Arg Ala Asn Ala Leu Leu
Ala Asn Gly Val Glu Leu Arg Asp 35 40 45 Asn Gln Leu Val Val Pro
Ser Glu Gly Leu Tyr Leu Ile Tyr Ser 50 55 60 Gln Val Leu Phe Lys
Gly Gln Gly Cys Pro Ser Thr His Val Leu 65 70 75 Leu Thr His Thr
Ile Ser Arg Ile Ala Val Ser Tyr Gln Thr Lys 80 85 90 Val Asn Leu
Leu Ser Ala Ile Lys Ser Pro Cys Gln Arg Glu Thr 95 100 105 Pro Glu
Gly Ala Glu Ala Lys Pro Trp Tyr Glu Pro Ile Tyr Leu 110 115 120 Gly
Gly Val Phe Gln Leu Glu Lys Gly Asp Arg Leu Ser Ala Glu 125 130 135
Ile Asn Arg Pro Asp Tyr Leu Asp Phe Ala Glu Ser Gly Gln Val 140 145
150 Tyr Phe Gly Ile Ile Ala Leu 155 20 21 DNA Artificial Sequence
IL-17R PCR Primer 20 ctgtacctcg agggtgcaga g 21 21 58 DNA
Artificial Sequence IL-17R PCR Primer 21 cccaagcttg ggtcaatgat
gatgatgatg atgatgatgc cacaggggca 50 tgtagtcc 58 22 328 PRT Homo
sapiens 22 Met Gly Ala Ala Arg Ser Pro Pro Ser Ala Val Pro Gly Pro
Leu 1 5 10 15 Leu Gly Leu Leu Leu Leu Leu Leu Gly Val Leu Ala Pro
Gly Gly 20 25 30 Ala Ser Leu Arg Leu Leu Asp His Arg Ala Leu Val
Cys Ser Gln 35 40 45 Pro Gly Leu Asn Cys Thr Val Lys Asn Ser Thr
Cys Leu Asp Asp 50 55 60 Ser Trp Ile His Pro Arg Asn Leu Thr Pro
Ser Ser Pro Lys Asp 65 70 75 Leu Gln Ile Gln Leu His Phe Ala His
Thr Gln Gln Gly Asp Leu 80 85 90 Phe Pro Val Ala His Ile Glu Trp
Thr Leu Gln Thr Asp Ala Ser 95 100 105 Ile Leu Tyr Leu Glu Gly Ala
Glu Leu Ser Val Leu Gln Leu Asn 110 115 120 Thr Asn Glu Arg Leu Cys
Val Arg Phe Glu Phe Leu Ser Lys Leu 125 130 135 Arg His His His Arg
Arg Trp Arg Phe Thr Phe Ser His Phe Val 140 145 150 Val Asp Pro Asp
Gln Glu Tyr Glu Val Thr Val His His Leu Pro 155 160 165 Lys Pro Ile
Pro Asp Gly Asp Pro Asn His Gln Ser Lys Asn Phe 170 175 180 Leu Val
Pro Asp Cys Glu His Ala Arg Met Lys Val Thr Thr Pro 185 190 195 Cys
Met Ser Ser Gly Ser Leu Trp Asp Pro Asn Ile Thr Val Glu 200 205 210
Thr Leu Glu Ala His Gln Leu Arg Val Ser Phe Thr Leu Trp Asn 215 220
225 Glu Ser Thr His Tyr Gln Ile Leu Leu Thr Ser Phe Pro His Met 230
235 240 Glu Asn His Ser Cys Phe Glu His Met His His Ile Pro Ala Pro
245 250 255 Arg Pro Glu Glu Phe His Gln Arg Ser Asn Val Thr Leu Thr
Leu 260 265 270 Arg Asn Leu Lys Gly Cys Cys Arg His Gln Val Gln Ile
Gln Pro 275 280 285 Phe Phe Ser Ser Cys Leu Asn Asp Cys Leu Arg His
Ser Ala Thr 290 295 300 Val Ser Cys Pro Glu Met Pro Asp Thr Pro Glu
Pro Ile Pro Asp 305 310 315 Tyr Met Pro Leu Trp His His His His His
His His His 320 325 23 175 PRT Artificial Sequence IL-17B His tag
23 Ile Phe Leu Gly Leu Gly Gln Pro Arg Ser Pro Lys Ser Lys Arg 1 5
10 15 Lys Gly Gln Gly Arg Pro Gly Pro Leu Ala Pro Gly Pro His Gln
20 25 30 Val Pro Leu Asp Leu Val Ser Arg Met Lys Pro Tyr Ala Arg
Met 35 40 45 Glu Glu Tyr Glu Arg Asn Ile Glu Glu Met Val Ala Gln
Leu Arg 50 55 60 Asn Ser Ser Glu Leu Ala Gln Arg Lys Cys Glu Val
Asn Leu Gln 65 70 75 Leu Trp Met Ser Asn Lys Arg Ser Leu Ser Pro
Trp Gly Tyr Ser 80 85 90 Ile Asn His Asp Pro Ser Arg Ile Pro Val
Asp Leu Pro Glu Ala 95 100 105 Arg Cys Leu Cys Leu Gly Cys Val Asn
Pro Phe Thr Met Gln Glu 110 115 120 Asp Arg Ser Met Val Ser Val Pro
Val Phe Ser Gln Val Pro Val 125 130 135 Arg Arg Arg Leu Cys Pro Pro
Pro Pro Arg Thr Gly Pro Cys Arg 140 145 150 Gln Arg Ala Val Met Glu
Thr Ile Ala Val Gly Cys Thr Cys Ile 155 160 165 Phe Gly His His His
His His His His His 170 175 24 206 PRT Artificial Sequence
IL-17C-His tag 24 Met Thr Leu Leu Pro Gly Leu Leu Phe Leu Thr Trp
Leu His Thr 1 5 10 15 Cys Leu Ala His His Asp Pro Ser Leu Arg Gly
His Pro His Ser 20 25 30 His Gly Thr Pro His Cys Tyr Ser Ala Glu
Glu Leu Pro Leu Gly 35 40 45 Gln Ala Pro Pro His Leu Leu Ala Arg
Gly Ala Lys Trp Gly Gln 50 55 60 Ala Leu Pro Val Ala Leu Val Ser
Ser Leu Glu Ala Ala Ser His 65 70 75 Arg Gly Arg His Glu Arg Pro
Ser Ala Thr Thr Gln Cys Pro Val 80 85 90 Leu Arg Pro Glu Glu Val
Leu Glu Ala Asp Thr His Gln Arg Ser 95 100 105 Ile Ser Pro Trp Arg
Tyr Arg Val Asp Thr Asp Glu Asp Arg Tyr 110 115 120 Pro Gln Lys Leu
Ala Phe Ala Glu Cys Leu Cys Arg Gly Cys Ile 125 130 135 Asp Ala Arg
Thr Gly Arg Glu Thr Ala Ala Leu Asn Ser Val Arg 140 145 150 Leu Leu
Gln Ser Leu Leu Val Leu Arg Arg Arg Pro Cys Ser Arg 155 160 165 Asp
Gly Ser Gly Leu Pro Thr Pro Gly Ala Phe Ala Phe His Thr 170 175 180
Glu Phe Ile His Val Pro Val Gly Cys Thr Cys Val Leu Pro Arg 185 190
195 Ser Val Gly His His His His His His His His 200 205 25 271 PRT
Homo sapiens 25 Met Ala Lys Val Pro Asp Met Phe Glu Asp Leu Lys Asn
Cys Tyr 1 5 10 15 Ser Glu Asn Glu Glu Asp Ser Ser Ser Ile Asp His
Leu Ser Leu 20 25 30 Asn Gln Lys Ser Phe Tyr His Val Ser Tyr Gly
Pro Leu His Glu 35 40 45 Gly Cys Met Asp Gln Ser Val Ser Leu Ser
Ile Ser Glu Thr Ser 50 55 60 Lys Thr Ser Lys Leu Thr Phe Lys Glu
Ser Met Val Val Val Ala 65 70 75 Thr Asn Gly Lys Val Leu Lys Lys
Arg Arg Leu Ser Leu Ser Gln 80 85 90 Ser Ile Thr Asp Asp Asp Leu
Glu Ala Ile Ala Asn Asp Ser Glu 95 100 105 Glu Glu Ile Ile Lys Pro
Arg Ser Ala Pro Phe Ser Phe Leu Ser 110 115 120 Asn Val Lys Tyr Asn
Phe Met Arg Ile Ile Lys Tyr Glu Phe Ile 125 130 135 Leu Asn Asp Ala
Leu Asn Gln Ser Ile Ile Arg Ala Asn Asp Gln 140 145 150 Tyr Leu Thr
Ala Ala Ala Leu His Asn Leu Asp Glu Ala Val Lys 155 160 165 Phe Asp
Met Gly Ala Tyr Lys Ser Ser Lys Asp Asp Ala Lys Ile 170 175 180 Thr
Val Ile Leu Arg Ile Ser Lys Thr Gln Leu Tyr Val Thr Ala 185 190 195
Gln Asp Glu Asp Gln Pro Val Leu Leu Lys Glu Met Pro Glu Ile 200 205
210 Pro Lys Thr Ile Thr Gly Ser Glu Thr Asn Leu Leu Phe Phe Trp 215
220 225 Glu Thr His Gly Thr Lys Asn Tyr Phe Thr Ser Val Ala His Pro
230 235 240 Asn Leu Phe Ile Ala Thr Lys Gln Asp Tyr Trp Val Cys Leu
Ala 245 250 255 Gly Gly Pro Pro Ser Ile Thr Asp Phe Gln Ile Leu Glu
Asn Gln 260 265 270 Ala 26 177 PRT Homo sapiens 26 Met Glu Ile Cys
Arg Gly Leu Arg Ser His Leu Ile Thr Leu Leu 1 5 10 15 Leu Phe Leu
Phe His Ser Glu Thr Ile Cys Arg Pro Ser Gly Arg 20 25 30 Lys Ser
Ser Lys Met Gln Ala Phe Arg Ile Trp Asp Val Asn Gln 35 40 45 Lys
Thr Phe Tyr Leu Arg Asn Asn Gln Leu Val Ala Gly Tyr Leu 50 55 60
Gln Gly Pro Asn Val Asn Leu Glu Glu Lys Ile Asp Val Val Pro 65 70
75 Ile Glu Pro His Ala Leu Phe Leu Gly Ile His Gly Gly Lys Met 80
85 90 Cys Leu Ser Cys Val Lys Ser Gly Asp Glu Thr Arg Leu Gln Leu
95 100 105 Glu Ala Val Asn Ile Thr Asp Leu Ser Glu Asn Arg Lys Gln
Asp 110 115 120 Lys Arg Phe Ala Phe Ile Arg Ser Asp Ser Gly Pro Thr
Thr Ser 125 130 135 Phe Glu Ser Ala Ala Cys Pro Gly Trp Phe Leu Cys
Thr Ala Met 140 145 150 Glu Ala Asp Gln Pro Val Ser Leu Thr Asn Met
Pro Asp Glu Gly 155 160 165 Val Met Val Thr Leu Phe Tyr Phe Gln Glu
Asp Glu 170 175
* * * * *